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Chapter 1 : Physiology and pathology of the hematopoietic system 
 
I. Hematopoiesis 
 
Hematopoiesis is a physiological process resulting in the production and perpetual 
replacement of various blood elements. Human hematopoietic tissue is highly prolific, as 
about 1013 blood cells are produced every day in adult man under normal physiological 
conditions.1 This permanent production activity is provided by a small cell fraction located in 
bone marrow called hematopoietic stem cell (HSC). Hence, all blood cells are derived from a 
common pluripotent HSC capable of both self-renewal and further differentiation into 
committed cells. Hematopoiesis is a complex and tightly regulated cellular system that allows 
fine adjustments to blood cell production to fit with the needs of the organism in physiological 
conditions or in response to external aggressions (bleeding, diseases...). 
In the embryo, hematopoiesis begins within the yolk sac and then gradually migrates 
to the liver and spleen in the early stages of human embryonic development. It only becomes 
medullar after the 15th week.2 In the fetus, hematopoietic activity is found in the liver, spleen, 
thymus, lymph nodes and bone marrow. In human adults, hematopoiesis is limited to short 
and flat bones like the hip bone, pelvis, sternum, ribs or vertebrae while in rodents, spleen 
also keep a hematopoietic activity during adulthood. However, maturation, activation, and in 
some cases proliferation of lymphoid cells occur in secondary lymphoid organs (spleen, 
thymus and lymph nodes). In adults, hematopoiesis can sometimes also occur outside the 
bone marrow in pathological processes, it is then referred to as extramedullary 
hematopoiesis. For example, it can be caused by myelofibrosis, after fibrotic changes within 
the bone marrow "crowd out" hematopoietic cells, causing them to migrate to other sites such 
as the liver and spleen.3 
II. Hematopoietic compartments 
 
In the hematopoietic system, four cellular compartments are generally defined: 
hematopoietic stem cells (HSCs), progenitors, precursors and mature cells.1 These cells 
undergo sequential divisions as they mature and mature cells have limited life spans. HSCs 
are able to produce multipotent progenitors (MPPs), that can in turn differentiate into 
common myeloid progenitors (CMPs) or common lymphoid progenitors (CLPs), thus giving 
rise to myeloid or lymphoid lineage, respectively. Progenitors will further proliferate and 
differentiate into precursors, finally leading to the production of mature cells. HSCs, 
progenitors and precursors are localized in the bone marrow whereas mature cells circulate 
in the peripheral blood. 
? ??
Mature cells provide specialized functions and have a limited lifespan. They are easily 
identifiable on the basis of morphological criteria, phenotypic markers but also functional 
properties. In the myeloid hematopoietic lineage, erythrocytes, platelets and different white 
blood cell types, such as monocytes and granulocytes are formed. In the lymphoid lineage, T 
cells, B cells and NK cells are generated. The hierarchical model of hematopoiesis is shown 
in Figure 1. 
 
Figure 1 : From hematopoietic stem cells to mature and functional hematopoietic cells. 
Diagram showing the development of the different blood cells from hematopoietic stem cell to 
mature cells. HSC gives rise to multipotent progenitors that in turn will give rise to common 
myeloid progenitors (CMP) and common lymphoid progenitors (CLP). CLP progeny include B 
cells, T cells and NK cells while CMP generates different types of precursors that will 
eventually give rise to erythrocytes, platelets, neutrophils, eosinophils, basophils and 
macrophages. 
 
Erythrocytes are primarily involved in gas exchange between the organism and the 
external environment and represent more than 95% of the total blood cell population. The 
cytoplasm of erythrocytes is rich in hemoglobin, an iron-containing protein that can bind 
oxygen and is responsible for the red color of the cells. Erythrocytes are flexible and oval 
biconcave disks ranging from 6 µm to 8 µm of diameter, lacking cell nucleus and most 
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organelles, in order to accommodate maximum space for hemoglobin. They possess a half-
life of about 120 days. Leukocytes (neutrophils, eosinophils, basophils, monocytes and 
lymphocytes) are major players in the immune system. They represent only a small 
proportion of the total blood cell population (less than 0.1%) and have a very variable lifetime 
ranging from 8h for some polynuclear cells to up to several months for some lymphocytes. 
Finally, the platelets also called thrombocytes are mainly involved in the clotting process and 
account for about 3% of the total blood cell population. Their half-life ranges from about 7 
days to 10 days. Platelets have no nucleus: they are fragments of cytoplasm that are derived 
from the megakaryocytes of the bone marrow, and then enter the peripheral blood 
circulation. Platelets are biconvex discoid structures shaped like a lens ranging from 2 µm to 
3 µm of diameter and only found in mammals.4 
Precursors are derived from the differentiation of the progenitors. They have lost all 
self-renewal potential, are engaged towards differentiation in a unique hematopoietic lineage 
and are fated to proliferation and cell maturation. The precursors do not generate colonies in 
semi-solid medium (CFC assay), but are morphologically identifiable (microscopic 
observations, staining...). Each precursor type will undergo amplification in cell number (3 to 
5 cell divisions), with morphological criteria specific to each stage of maturation, 
corresponding to the gradual acquisition of specific components of terminally differentiated 
cells, such as hemoglobin in erythrocytes (oxygen transport) or granules in neutrophils 
(phagocytosis). Precursors ultimately give rise to mature and functional cells released into 
the bloodstream. 
Progenitors are derived from HSCs that are committed to differentiation towards 
myeloid or lymphoid lineages. Unlike HSCs, they are no longer able to self-renew but have 
acquired a strong proliferative capability while remaining able to differentiate. However, self-
renewal was recently observed in differentiated macrophage populations, suggesting that it 
may not be a specific HSC attribute.5 Like HSCs, progenitors cannot be morphologically 
identifiable, but can be detected by functional testing. The CFC assay (Colony Forming Cell) 
allows the identification of multipotent and committed myeloid progenitors. Inspired from 
previous work,6 this test is based on their ability to form colonies in a semi-solid medium 
containing methylcellulose, supplemented with cytokines and growth factors (Methods). A 
CFC colony will be obtained after 2 weeks of culture from the proliferation and the 
differentiation of a single hematopoietic progenitor. Different types of myeloid colonies can be 
observed and identified under a microscope: CFU-Mix (colony forming unit-granulocyte, 
erythroids, macrophages, megakaryocytes), CFU-GM (colony forming unit-granulocyte, 
macrophages), CFU-E (colony forming unit-Erythroids), CFU-Eo (Colony Forming Unit-
Eosinophils) and CFU-Baso (Colony Forming Unit-Basophils). The size of a given colony 
informs about the degree of maturity of the progenitor at the origin of the colony, the most 
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immature progenitors having a higher proliferation potential in methylcellulose compared to 
more mature progenitors. The most immature colonies are characterized by "early CFU" and 
more mature colonies "late CFU." However, megakaryocytic progenitors cannot be detected 
by the CFC assay described above because of the presence of TGF-β in the semi-solid 
medium used, which inhibits their growth. To circumvent this problem, the CFU-MK assay 
(Colony Forming Unit - megakaryocytes) was developed from a semi-solid medium 
containing collagen supplemented with horse serum. Moreover, human lymphoid progenitors 
seem to require stromal support for growth and therefore cannot be detected by CFC assay. 
Since most mature blood cells are terminally differentiated and short-lived in blood 
circulation, it is essential to generate functional blood cells to maintain the hematopoietic 
system in a steady state through the proliferation and differentiation of HSCs. In adults, 
HSCs are principally located in the bone marrow and represent less than 0.01% of the total 
bone marrow cell population. They can also be found in umbilical cord blood and, in small 
numbers, in peripheral blood. With regard to morphology, hematopoietic stem cells resemble 
lymphocytes. They are round cells with a rounded nucleus and low cytoplasm-to-nucleus 
ratio. HSCs have an extensive self-renewal and proliferative potential as well as the 
capability to differentiate into progenitors of all blood cell lineages. Self-renewal refers to the 
ability to produce daughter cells with identical characteristics and is necessary to ensure that 
the HSC pool is sustained throughout adult life. The balance between self-renewal and 
differentiation is regulated to maintain the HSC pool while generating sufficient progeny. This 
can be achieved by asymmetric cell division where one HSC gives rise to an identical 
daughter cell and a differentiated progeny (Figure 2). In addition, HSC can also divide 
symmetrically to generate two identical daughter cells or two differentiated progenies (Figure 
2). This self-renewal ensures that the HSC pool is protected from exhaustion. However, the 
frequency of these cell divisions varies amongst the HSCs. In this respect, the most primitive 
HSCs only rarely divide, whereas other HSCs divide more frequently. The formation of 
mature and functional blood cells by the HSCs occurs via several consecutive cell divisions 
and maturation stages. The initial asymmetrical cell division is followed by several 
symmetrical cell divisions, during which two identical daughter cells are generated. These 
newly formed cells are more differentiated than their parental cells and become increasingly 
committed to either the myeloid or the lymphoid lineage. 
 
 
? ??
 
Figure 2 : Stem cell self-renewal, proliferation and differentiation. Stem cells are able to 
divide through symmetric or asymmetric divisions. (A) Symmetric division produces two 
identical daughter cells that can either be identical to the parent cell or different, with a more 
restricted potential compared to the parent cell. The production of two SC identical to the 
parent SC allows the maintenance of the SC population, while the production of two engaged 
daughter cells will lead to their progressive proliferation and differentiation until the formation 
of terminally differentiated and functional cells. (B) Asymmetric division leads to the formation 
of a daughter cell identical to the parent cell and of a second cell with more restricted 
potential. 
 
III. Hematopoietic Stem Cells 
 
?
Continuous production of mature blood cells is allowed by the existence of a small 
cell fraction in the bone marrow called hematopoietic stem cell (HSC). The existence of a 
multipotent HSC has first been proved in 1961.7 It has been demonstrated that irradiation of 
mice destroys their hematopoietic tissue and induces a fatal medullar aplasia in the absence 
bone marrow transplantation. On the contrary, if a transplant is performed after irradiation 
(injection of bone marrow from syngenic mice) the animals do not die of myelosuppression. 
Ten days after transplantation, the spleen of the recipient mice were filled with macroscopic 
cell clusters. These colonies called “Colony Forming Unit-Spleen” (CFU-S) were mixed 
colonies, as they were constituted of cells belonging to different lineages. This experiment 
was repeated after introduction of various chromosomal abnormalities in the transplanted 
cells. It was then observed that all the cells of a unique colony displayed the same 
chromosomal abnormality, thus demonstrating that all cells of a colony originated from the 
same multipotent hematopoietic stem cell.7 Finally, the self-renewal capability of these cells 
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has also been evidenced as the injection of a splenic colony into a new irradiated mouse 
allowed the reconstitution of hematopoiesis in this mouse 
HSCs are mostly found in the bone marrow where they still represent a small cell 
population. Their presence in the blood is not excluded but they remain extremely rare under 
normal physiological conditions. It is estimated that one out of 104 bone marrow cells could 
be a HSC against one out of 105 in the circulating blood. HSC can be obtained by bone 
marrow aspiration (usually from the pelvis, at the iliac crest) for stem cell transplantations 
(SCT). The cells can be removed as liquid to perform a smear and to look at their 
morphology or they can be removed via core biopsy to maintain the bone marrow 
architecture. In order to obtain HSCs from the circulating peripheral blood, donors are 
injected with a cytokine, such as granulocyte-colony stimulating factor (G-CSF), that induces 
the detachment of HSC from their bone marrow stroma and their circulation in the blood 
vessels where they can easily be harvested. However, the percentage of HSCs among bone 
marrow cells is still very low. Thus, it is very important to be able to identify these cells to 
characterize their functional properties. 
HSC function is usually assessed in-vitro by long-term culture initiating-cell (LTC-IC)8,9 
assay and in-vivo by bone marrow engraftment of non-obese diabetic/severe combined 
immunodeficient (NOD/SCID) mice.10 LTC-IC assays detect primitive progenitors that are 
able to form CFC colonies after 5 weeks culture on a stromal feeder layer (Methods).8 
NOD/SCID-repopulating cells are capable of reconstituting lethally irradiated NOD/SCID 
mice with a singe cell and are more primitive than most LTC-IC.10 Based on their ability to 
reconstitute the hematopoietic system of lethally irradiated mice, mouse HSCs can be 
separated into three distinct groups: long-term HSCs (LT-HSCs) which are able to generate 
all types of blood cells for the lifetime of the animals and reconstitute secondary hosts; short-
term HSCs (ST-HSCs) which derive from LT-HSCs but can only reconstitute myeloid and/or 
lymphoid lineages for a limited period of time and multipotent progenitors (MPPs), which are 
generated by ST-HSCs, have no detectable self-renewal capability and only transiently 
reconstitute lethally irradiated mice (Figure 3). HSCs are also characterized by their ability to 
reject some vital dyes such as Hoechst 33342 or Rhodamine 123 via the presence of efflux 
pumps on their surface.11 The expression of these transporters such as MDR1 (Multi-drug 
resistance 1) and ABCG2 (ATP-binding cassette subfamily G member 2) is correlated with 
the immature status of hematopoietic cells.12 In addition, it has been suggested that the 
frequency of HSCs division is smaller compared to hematopoietic progenitors and 
precursors.13,14 This property can be demonstrated by conventional methods such as cell-
cycle analysis, flow cytometry or immunohistochemistry but also by cell staining with BrdU 
(bromodeoxyuridine) or GFP (Green Fluorescent Protein), thus allowing a spatial and 
temporal monitoring of HSCs in-vivo. During their successive divisions, cells gradually lose 
? ??
their staining, until the signal is no longer detectable. In contrast, cells that have completed 
few divisions retain their staining and are easily detectable. Finally, in-vivo experiments 
helped to highlight the existence of two different HSCs subpopulations: a population of cells 
called "dormant" or quiescent (about 30%) that divide every 145 to 193 days and a 
population of more active cells (about 70%) which divide every 28 to 36 days.15,16 While the 
two subpopulations are capable of reconstituting normal hematopoiesis after transplantation 
in a first previously irradiated animal, only the population of quiescent cells possesses long-
term recovery capabilities as demonstrated by serial transplantation assays.15,16 
 
 
Figure 3 : Hematopoietic compartments. Diagram showing the different stages of 
hematopoietic stem cell differentiation, their location, the functional assays used to identify 
these cells, and the associated expression of CD34 and CD38. 
 
In addition to morphological analysis, identification of the different hematopoietic 
compartments may be supplemented by surface antigens analysis. Indeed, all the cells in the 
body carry on their surface specific proteins, that can be used as markers to detect cell 
lineage and maturity. These surface antigenic markers are readily detectable by flow 
cytometry with the use of specific monoclonal antibodies coupled to fluorochromes. At 
present, there is still no specific and exclusive marker for HSCs. However, some markers are 
expressed during early stages of hematopoiesis and have been used in this regard. This is 
the case of CD34, which is very frequently used for human HSCs identification. However, its 
use is highly controversial because its expression has also been observed on the surface of 
endothelial cells17 and stromal cells precursors.18 Consequently, it is often combined with 
other markers of positive or negative selection such as CD38.19 It is generally accepted that 
the most immature human hematopoietic cells express CD34 but not CD38. During 
differentiation, the human hematopoietic cells progressively lose the expression of CD34,20
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and gradually acquire the expression of CD38 (until precursor compartment) as well as other 
lineage specific markers. If we only refer to the expression of CD34 and CD38 markers, it is 
generally accepted that HSCs express CD34 but not CD38 (CD34+, CD38-), the progenitors 
express CD34 and CD38 (CD34+, CD38+), the precursors have lost the expression of CD34 
but keep that of CD38 (CD34-, CD38+) and finally, the mature cells have lost the expression 
of these two markers (CD34-, CD38-) (Figure 3). In the early 1990s, a combination of surface 
antigenic markers was first proposed to refine identification and isolation of HSCs.21 In mice, 
this population expresses Sca-1 (stem cell antigen 1) but not the differentiation markers 
associated with B, T, and myeloid lineages, grouped under the abbreviation Lin (Lineage). In 
addition, these cells express low levels of Thy-1 (Thymocyte Antigen 1). This population was 
called Thy-1low, Sca-1+, Lin-.21 In humans, the closest cell population to HSCs was described 
as Thy-1+, CD34+, Lin-.22 LT-HSC are currently described as the Lin-, Sca1+, c-Kit+, CD45+, 
Thy1.1low, Flk2-, CD34+, Slamf1+ cell population in the murine hematopoietic system, and as 
the Lin-, CD34+, CD38-, CD45RA-, CD90+, CD123+, CD133+ cells population in the human 
hematopoietic system.21,23–26 In humans, the Lin-, CD34+, CD38-, CD90+, CD123+, CD133+ 
fraction is enriched in HSCs, but probably still contains one or more mature sub-populations. 
However, this remains technically difficult to demonstrate. This area of research is very 
dynamic, and research groups regularly propose new antigenic surface markers to refine the 
characterization of HSC population. For example, CD49f was recently proposed, as the loss 
of its expression is associated with a decrease in hematopoietic repopulating capability of a 
CD34+, CD38-, CD45RA-, Thy+/- cell population.27 
HSC fate is tightly controlled through many signals provided by their bone marrow 
microenvironment, the so-called stem cell niche. The niche allows contacts between stem 
cells and all the necessary factors to maintain their immaturity, such as extracellular matrix or 
cytokines. 
 
IV. Hematopoietic niche 	  
1. Concept 
 
The niche is the environment in which stem cells reside. It is responsible for the 
maintenance of unique stem cell properties such as self-renewal, quiescence and stemness. 
The concept of "niche" emerged in 1978 from a work that demonstrated the existence of 
spatially defined zones capable of providing all the necessary factors for the survival and 
development of cells involved in tissue maintenance and regeneration in adult organisms.28 
This was further supported by the crucial role of bone marrow stromal cells for in-vitro 
cultivation of LTC-IC.9 In bone marrow, HSCs are located in hematopoietic niches that are 
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complex three-dimensional structures containing extracellular matrix (ECM) proteins, soluble 
factors such as cytokines or growth factors, as well as stromal, endothelial and 
hematopoietic cells responsible of their synthesis. 
2. Composition 
 
The bone marrow stroma usually refers to tissue not directly involved in the marrow's 
primary function of hematopoiesis. This stroma is mainly composed of fibroblasts, 
myofibroblast, adipocytes, osteoblasts, chondrocytes, endothelial cells, osteoclasts and 
macrophages dispersed in ECM.29 However, these different cell types do not have the same 
origin. Indeed, fibroblasts, myofibroblasts, adipocytes, chondrocytes, osteoblasts and 
reticular cells are derived from the differentiation of mesenchymal stem cells (MSCs) while 
endothelial cells originate from endothelial stem cells and macrophages are part of the 
hematopoietic lineage. Interestingly, nestin+ MSCs are spatially associated with HSCs and 
adrenergic nerve fibers in the bone marrow.30 It has been demonstrated that adrenergic 
signals are able to induce MSCs differentiation toward osteoblastic lineage, thus leading to 
an increase in HSC content. Osteoclasts result from the fusion of macrophages in the 
presence of RANKL (receptor activator of nuclear factor κβ ligand) and M-CSF (Macrophage 
colony-stimulating factor).31 Stromal cells have the potential to control hematopoiesis via 
soluble molecules or ECM synthesis, and through direct interactions with HSCs. Moreover, 
these factors are also produced by hematopoietic cells themselves, which are part of the 
bone marrow microenvironment. 
3. HSCs regulation 
 
HSC fate has been demonstrated to be dependant on many different factors, such as 
cytokines, ECM composition, interactions with other cells, glucose and oxygen levels or 
physical factors (Figure 4). Thus, hematopoiesis control is a very complex system because of 
the interplay between the different parameters. 
To date, numerous cytokines and growth factors are known to regulate 
hematopoiesis.32 Due to the large number of these factors and their multiple implications in 
hematopoiesis, it is difficult to make an exhaustive list. That is why only the main factors 
identified to date will be developed here. IL-6 (interleukin 6), SCF (stem cell factor), Flt3-
ligand (Fms-like tyrosine kinase receptor-3) and LIF (Leukemia Inhibitory Factor) have been 
described as the principle factors affecting the most immature hematopoietic cells fate. They 
are able to increase the number of HSCs in cell cycle and to sensitize them to the action of 
other growth factors. IL-3 and GM-CSF (Granulocyte Macrophage-Colony Stimulating 
Factor) have been involved in survival and differentiation of hematopoietic progenitor cells. 
	   28	  
Among these cytokines, GM-CSF is produced by several cell types such as T lymphocytes, 
monocytes, endothelial cells, fibroblasts or osteoblasts. GM-CSF primarily acts on 
proliferation and differentiation of granulocytic and macrophage lineages, but is also capable 
to induce differentiation of megakaryocytes, eosinophils, or erythrocytes in presence of 
erythropoietin. G-CSF (Granulocyte-Colony Stimulating Factor), M-CSF (Macrophage-Colony 
Stimulating Factor), IL-4, IL-5, IL-6, EPO (Erythropoietin) and TPO (Thrombopoietin) target 
more committed cells and promote proliferation and terminal maturation of these cells. 
Although TPO was initially considered as a factor influencing the cells engaged towards 
megakaryocytic differentiation, it was recently demonstrated that it could also induce HSCs 
proliferation. EPO is mainly produced by interstitial cells of the kidney and is specifically 
involved in erythroid precursors stimulation and globin synthesis. Finally, stromal cells also 
produce factors able to inhibit hematopoiesis, by regulating self-renewal, proliferation and 
differentiation of HSCs. Among them, there are particular types of prostaglandins E and 
some cytokines such as IL-8, MIP-1α (Macrophage Inflammatory Protein-1α), TNF-α (tumor 
necrosis factor α) and IFNs (Interferons).33 Several key signaling pathways including 
Hedgehog, Notch, Wnt, TGF-β (Tumor Growth Factor β) and others play key roles in HSC 
biology. The TGF-β superfamily is composed of a multitude of molecules that include Bone 
Morphogenetic Proteins (BMPs), family particularly involved in HSC regulation and whose 
effects on these cells will be described in chapter 4. 
ECM contains fibers of collagen, fibronectin, laminin, or proteoglycans that contribute 
to the hematopoietic niche structure and regulation. Hematopoietic stem cells have direct 
and relatively specific interactions with ECM and stromal cells in the bone marrow. These 
interactions are primarily responsible for adhesion and thus the maintenance of HSCs in the 
bone marrow. However, they also allow the transmission of signals that modulate the 
survival, proliferation and cell differentiation. Primary hematopoietic cells express over 20 
different adhesion receptors.34,35 Among these molecules, the best known belong to the 
integrin family. Integrins are transmembrane glycoproteins consisting of two subunits α and 
β, which, after binding with their ligand, stimulate different intracellular signaling pathways. 
Integrins are responsible for cell adhesion to ECM proteins such as fibronectin, laminin or 
collagen, or to stromal cells through cell adhesion molecules (CAM) such as ICAM and 
VCAM,36 selectins, molecules of the "immunoglobulin-like" family such as that PECAM-1 or 
sialomucins such as CD34, CD43, CD45RA, PSGL 1 (P-selectin glycoprotein ligand-1) and 
CD164. HSCs mainly express α4β1 (VLA-4) α5β1 (VLA-5) integrins, the expression of which 
decreases with HSCs differentiation and is necessary for their progressive detachment from 
the bone marrow stroma.37 Many studies have described the importance of these two 
integrins in regulating HSCs fate. Indeed, α4β1 integrin has been involved in the control of 
myelopoiesis, erythropoiesis and lymphopoiesis B.38 This same integrin also controls HSCs 
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quiescence by maintaining its adhesion to the bone marrow stroma.39 
While many different biological parameters governing HSC control have already been 
identified, some of them seem more complex and may not be as well understood. For 
example, in zebra-fish embryo, it was demonstrated that HSCs production depends on 
glucose levels in a dose-dependant response.40 Moreover, a very interesting study also 
demonstrated that sympathetic nervous system regulates the attraction of HSCs to their 
niche.41 This was revealed by the use of mice deficient in UDP-galactose ceramide 
galactosyltransferase, an enzyme required for normal peripheral nerve myelination and 
conduction, that failed to mobilize hematopoietic progenitors in response to G-CSF. 
Other than biological factors, chemical composition or physical parameters have also 
been identified for their role in SC and HSC fate control. For example, hypoxia (low oxygen 
levels) has been shown to favor the self-renewal of both murine and human HSCs.42–44 The 
primordial role of hypoxia in HSC control was further supported by demonstration that HSC 
are predominantly located in hypoxic regions of the bone marrow. This was evidenced by in-
vivo perfusion of a Hoechst 33342 dye gradient simulating the level of oxygenation in the 
bone marrow.45 
Biomechanical forces are critical regulators of embryogenesis. However, little is 
known about the role of mechanical forces in the regulation of adult SC. Interestingly, recent 
studies have demonstrated that these signals could be involved in HSC regulation.46 Indeed, 
the application of shear stress on mouse embryonic stem cells led to the hematopoietic 
commitment of these cells. It was further evidenced that fluid shear stress increases the 
expression of Runx1 in hematopoietic progenitor cells, leading to an increase of their colony-
forming potential in-vitro.46 The consequences of mechanical stress on HSC fate will be 
further described in chapter 3. 
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Figure 4 : Hematopoietic stem cell fate control by their microenvironment. HSC fate is 
tightly controlled through interactions with their bone marrow microenvironment, the so-called 
hematopoietic niche. This dialogue is mediated by different factors such as soluble factors, 
extra-cellular matrix, cell-cell interactions as well as physical parameters. In a physiological 
context, all those parameters allow a fine control of hematopoiesis. 
 
Interestingly, the different components of the microenvironment seem to respect a 
precise distribution within the bone marrow, suggesting that their interactions with 
hematopoietic cells may dictate the location of the latter.47 Indeed, it has been demonstrated 
that interactions between HSCs and their microenvironment depend on the hematopoietic 
cell lineage and its degree of maturation.48 According to the current hypothesis, the 
specialized region within BM that houses and controls HSCs fate has been classified into two 
morphologically different niches: osteoblastic niche (or endosteal niche) and vascular niche 
(or endothelial niche). HSCs are mainly maintained by the osteoblastic niche, which provides 
a quiescent HSC microenvironment, while the vascular niche is thought to regulate HSCs 
proliferation, differentiation, and mobilization. 
4. Osteoblastic niche 
 
Osteoblastic niche is precisely located at the interface between the bone and the 
bone marrow, where new trabecular bone is formed by osteoblasts (Figure 5).49 By definition, 
this niche mainly consists in osteoblasts that are involved in the control of HSC fate (Figure 
6). Unlike osteoclasts that resorb bone matrix, osteoblasts synthesize it, thus ensuring a 
constant remodeling of bone tissue. The tightly regulated balance between these two cell 
populations maintains bone tissue homeostasis. In 2003, Zhang's group developed a mouse 
model invalidated for the BMP type Ia receptor (BMPRIa), a receptor usually expressed at 
the membrane of osteoblasts.50 Using this model, they demonstrated that BMPRIa loss 
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increased the number of osteoblasts in the mice bone marrow, and that it was correlated with 
an increased number of HSCs. Further analysis allowed them to demonstrate a real 
interaction between osteoblasts and HSCs through adherent junctions involving N-cadherin. 
The same year, these observations were supported by the development of a transgenic 
mouse model producing osteoblast-specific, activated PTH/PTHrP receptors, constitutively 
active for parathyroid hormone signaling.51 This induced the production of high levels of 
Notch and Jagged1 ligands and the proliferation of osteoblasts, thus leading to an increase 
in the number of HSCs. In 2004, the importance of Tie-2/Angiopoietin1 interaction in HSCs 
regulation was also demonstrated. Tie-2 is expressed by quiescent murine HSCs, localized 
near the bone surface, at the location described by Zhang’s group as the osteoblastic 
niche.50 By using an in-vitro co-culture system with OP9 murine stromal cells, the authors 
demonstrated that Tie-2/Angiopoietin1 interaction increases HSCs adhesion to the stroma 
and maintains their immature phenotype by inhibition of cell division and induction of 
quiescence.52 This leads to the maintenance of HSCs’ repopulation capabilities in-vivo. 
Osteoblasts are involved in the production of numerous ECM proteins such as type I 
collagen fibers and fibronectin. Nevertheless, in 2005, two studies based on the use of a 
mouse model deleted for osteopontin, an ECM protein highly expressed in bone, have 
demonstrated the importance of this glycoprotein in the regulation of HSC, with whom it 
interacts via CD44, VLA-4 and VLA-5 (Very Late Antigen-4/5) molecules.53 It was 
demonstrated that an osteopontin-free environment is able by itself to increase the number of 
HSCs and to reduce their apoptosis, suggesting that osteopontin is able to control the size of 
HSCs population in-vivo. A second study reported that osteopontin is mainly localized close 
to the bone surface and that it plays an important role in the localization of murine HSCs after 
transplantation.54 These studies also demonstrated that osteopontin physically interacts with 
HSCs in this particular area, thus regulating their proliferation. In-vitro, osteopontin 
decreases the proliferation and differentiation of murine and human hematopoietic 
progenitors but does not induce apoptosis of CD34+, CD38- cord blood cells.54 
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Figure 5 : Location of osteoblastic and vascular niches. Hematopoietic 
microenvironment is composed of two structurally distinct niches. Osteoblastic niche is 
precisely located at the interface between the bone and the bone marrow, where new 
trabecular bone is formed by osteoblasts. Vascular niche is located in the axial part of the 
bone at the center of the bone marrow, a heavily vascularized surface with endothelial cells 
lining the sinusoid vessels and reticular cells. 
 
5. Vascular niche 
 
The existence of vascular HSC niche has been demonstrated in 2005.55 It is located 
in the axial part of the bone at the center of the bone marrow (Figure 5). Since the endosteal 
surface is heavily vascularized, vascular and perivascular cells, such as reticular cells, 
adipocytes, and mesenchymal cells might contribute to the formation of HSC niches at or 
near the endosteum. In the vascular niche, HSCs are located near reticular cells and 
endothelial cells lining the sinusoid vessels, allowing exchanges with the venous circulation 
(Figure 6).55 However, HSCs regulation by the vascular niche has been less documented 
compared to their regulation by osteoblastic niche. Nevertheless, it has been reported that 
sinusoids near which are located HSCs are surrounded by reticular cells that secrete 
abnormally high levels of SDF1 (Stromal cell-Derived Factor-1), a molecule involved in the 
maintenance and mobilization of HSCs.56 More recently, co-culture of mouse HSCs with 
bone marrow endothelial cells showed that by direct cell contacts, endothelial cells were able 
to maintain LT-HSCs in culture and to stimulate their expansion while retaining their self-
renewal capabilities.57 In-vivo studies using a murine model deleted for Notch1/Notch also 
showed that bone marrow endothelial cells are responsible for the proliferation of LT-HSCs 
through Notch signaling.57 Furthermore, in adult mice, conditional deletion of VEGF receptor 
type R2 (VEGFR2), which prevents the regeneration of reticular cells surrounding the 
? ??
vascular niche, also prevents hematopoietic reconstitution of irradiated mice.58 Moreover, the 
selective activation of Akt1 (c-akt murine thymoma viral oncogene homolog 1) in bone 
marrow endothelial cells led to an increase in the number of HSCs and to an acceleration of 
the hematopoietic repopulation after myeloablation (severe or complete depletion of bone 
marrow cells) in adult mice.59 These observations demonstrate that bone marrow endothelial 
cells as well as neighboring reticular cells play an important role in the regulation of HSC, 
particularly for HSCs maintenance and localization. 
 
 
Figure 6 : Regulation of HSCs by osteoblastic and vascular niches. In the vascular 
niche, HSCs interact with endothelial cells that form the blood vessels via the Notch signaling 
pathway or proteins such as Akt1. HSCs also interact with reticular cells via SDF1/CXCR4 
signaling. In the osteoblastic niche, a large number of different cell types coexist. However, 
osteoblasts have been described as the main regulators of HSCs. HSCs and osteoblasts 
interact through N-cadherin, Jagged/Notch1, Angiopoïétin-1/Tie-2 and osteopontin signaling. 
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The intricate process of hematopoiesis is tightly regulated by the BM 
microenvironment to ensure the proper generation of sufficient blood cells. Therefore, 
defects in self-renewal and differentiation can severely hamper normal hematopoiesis, 
leading to hematopoietic insufficiency or leukemic processes. In the case of leukemia, these 
aberrations are often the result of inherited or acquired genetic alterations. 
 
V. Leukemia 
 
Leukemia is a hematologic disorder characterized by the abnormal increase in the 
number of white blood cells in the tissues. It is responsible for an estimated 4% of all cancer-
related deaths. This cancer of the blood tissue is classified according to the phenotype of 
dominant proliferating cells and to the speed of disease progression. Acute leukemias are 
characterized by the rapid increase of large numbers of immature blood cells. This huge 
production of immature blood cells impairs the production of normal cells. Due to their 
immaturity, these cells are unable to function properly to prevent or fight infection. 
Inadequate numbers of red blood cells and platelets being made by the bone marrow cause 
anemia, as well as easy bleeding and bruising. Furthermore, due to overcrowding of the 
bone marrow, these immature blood cells, called blasts, can enter the circulation and spread 
throughout the body. Chronic leukemias are characterized by a slower accumulation of more 
mature blood cells as compared to acute leukemias. Since acute and chronic leukemias can 
affect cells belonging to the myeloid or lymphoid lineages, leukemias are divided into four 
main categories: Chronic Myeloid Leukemia (CML), Acute Myeloid Leukemia (AML), Acute 
Lymphoblastic Leukemia (ALL) and Chronic Lymphocytic Leukemia (CLL). Leukemia can be 
further classified based on the cell type involved such as B cell Chronic Lymphocytic 
Leukemia (B-CLL) or T cell Acute Lymphoblastic Leukemia (T-ALL). In addition, lymphomas 
are also cancers derived from the lymphocytic lineage. However, the main difference 
between leukemias and lymphomas is that in leukemia, cancer cells are mainly present in 
the bone marrow and blood, while in lymphoma it tends to be in lymph nodes and other 
tissues. As the focus of this project, CML biology will be detailed in Chapter 2. 
ALL is the most common form of cancers in children and represents approximately 
25% of cancer diagnoses among children younger than 15 years. Nevertheless, it can also 
appear in adults. It is characterized by an over-production of cancerous immature cells called 
lymphoblasts. Based on the expression of lineage-specific antigens and the presence of 
lineage-specific gene rearrangements, ALL cells has been identified to be derived from either 
B- or T-cell precursors.60 The remission rate for ALL has improved dramatically over the past 
few decades, due to the development of chemotherapies and the use of stem cell 
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transplantation. Indeed, the 5-year event-free survival has improved from 10% in the 1960s 
to about 90% these days.61 Up to now, different factors have been associated with an 
increased risk of ALL, such as high doses of radiations, or genetic syndroms such as Down 
syndrom or Ataxia telangiectasia. 
CLL is a monoclonal disorder characterized by a progressive accumulation of non-
functional lymphocytes. CLL is the most common form of leukemia in adults and constitutes 
28% of all leukemia cases, with an incidence of 1 to 5 per 105 people worldwide.62 CLL 
affects mostly elderly patients. Unlike ALL that is characterized by a sudden burst of 
leukemic cells, CLL leukemic cells tend to build up over time, and many people do not have 
any symptoms when it is diagnosed. Wide range of genetic variations like hypermutation of 
the immunoglobulin heavy-chain genes (IGHV) or genomic aberrations reflect the clinical and 
biological heterogeneity of the disease.63 
AML occurs more frequently in adults than in children. This is highlighted by a median 
age at diagnosis of 63 years. While AML is characterized by the rapid expansion of abnormal 
blasts of the myeloid lineage, it is a very heterogeneous disease. Indeed, AML classification 
is defined on the basis of the presence of specific chromosomal and/or molecular alterations. 
The 2 systems commonly used in the classification of AML are the French-American-British 
(FAB) system and the World Health Organization (WHO) system. The FAB system 
discriminates AML into 8 different sub-types based on morphology and cytochemistry.64 The 
WHO classification was introduced to include newer prognostic factors such as molecular 
markers and chromosome translocations. The WHO system identifies 4 AML subgroups: 
AML with recurrent genetic abnormalities, AML with multilineage dysplasia, therapy-related 
AML and myelodysplasic syndromes, and those that do not fall into any of these groups. 
These 2 systems created a minimum of 17 subclasses of AML, allowing physicians to identify 
subgroups of patients with different prognosis and who might benefit from specific treatment 
strategies. Thus, the 5-year survival can range from 3% to more than 80% depending on the 
AML sub-type.65 Several factors have been associated with an increased risk of AML, such 
as high doses of radiations, benzene exposure, treatment with some chemotherapeutics 
drugs or Down syndrom. 
The existence of a small population of leukemic cells that are alone capable to initiate 
leukemia and to reconstruct all the different existing subpopulations within the tumor was first 
demonstrated in AML. 
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VI. Leukemic Stem Cells 
 
Leukemic Stem Cells (LSCs) were first identified by the observation that a CD34+, 
CD38- AML leukemic cell subpopulation alone is capable of engrafting after injection into 
NOD/SCID immunodeficient mice, thus producing a disease similar to human AML.66 This 
small fraction of leukemic cells alone was able to proliferate extensively both in-vitro and in-
vivo. Indeed, the extended self-renewal capability of these cells was demonstrated by 
successful engraftment into secondary recipient mice. First referred as leukemia initiating 
cells, these cells were later described as LSCs or cancer stem cell (CSCs). This minor 
fraction in the tumor retained (or acquired) the self-renewal and proliferation characteristics 
of normal stem cells and is alone capable to reconstruct all the different existing 
subpopulations within the tumor.67 These observations suggest that leukemic transformations 
occur in primitive normal hematopoietic cells, which then give rise to leukemia through clonal 
expansion (Figure 7). On the other hand, the leukemic transformation may also occur by re-
acquisition of self-renewal capabilities by committed normal progenitors that will then be able 
to initiate leukemia (Figure 7).67 
Although this concept is still widely discussed, numerous studies have since 
demonstrated the existence of such subpopulations in almost all types of cancer including 
hematopoietic, brain, bladder, liver, lung, skin, ovary, pancreas, prostate, colon and breast 
cancers.66,68–77 
 
Figure 7 : Model of leukemic stem cell transformation. Leukemogenesis can occur by 
acquisition of genetic abnormalities in a HSC that give rise to a LSC with self-renewal 
capability. Alternatively, it can happen in a progenitor cell that will re-acquire self-renewal 
capability. 
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The concept of CSC is derived from the similarities that exist between normal SCs 
and CSCs. The signaling pathways used by both normal SCs and CSCs overlap and are 
based on embryonic signaling pathways allowing self-renewal capabilities. However, while 
normal SCs fate is tightly controlled, CSCs display increased proliferation capabilities, thus 
leading to tumor growth. Although the concept remains controversial, new observations from 
clinical studies and basic research have led to a more comprehensive CSC model of 
tumorigenesis, tumor recurrence, and metastasis formation. Located at the top of the tumor 
hierarchy, CSCs constitute a subpopulation of malignant cells capable of self-renewal and 
differentiation. Thus, they are able to generate all cell types present in a tumor, including 
non-CSC progeny, which form the tumor bulk. CSCs are described by their unique ability to 
engraft into immunodeficient mice, to recapitulate the tumor of origin both morphologically 
and phenotypically in xenografts, and to be serially transplanted. Just like normal HSCs, 
LSCs are usually rare and represent only a small cell fraction in the tumors. It has been 
demonstrated that about 1 in 102 to 104 AML leukemic cells are able to form colonies in CFC 
assay in-vitro, and only 1 to 4% of leukemic cells formed colonies in spleen after murine 
transplantation and were described as LSCs.78 However, LSC-enriched populations have 
been reported to represent extremely variable proportions of bulk tumor cells, ranging from 
0.2% to 82.5% in leukemia and lymphoma genetic mouse models.79 Moreover, the frequency 
of CSCs might increase during tumor progression, as recently shown by in-vivo limiting 
dilution assays comparing grade 1 and grade 3 breast tumors.80 LSCs, which are considered 
to originate from hematopoietic stem or progenitor cells, not only adopt the regulatory 
machinery operating in normal HSCs but establish their own mechanisms against apoptosis 
and senescence. 
Clinically, the CSC discovery predicts that if the eradication of tumor cells induces 
remission, only the destruction of CSC can lead to a cure (Figure 8).81 
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Figure 8 : Involvement of cancer stem cells in the re-emergence of the disease after 
treatment. While conventional therapies used in the treatment of cancers manage to kill 
most of the cancer cells, they are ineffective against CSCs. After treatment discontinuation or 
upon accumulation of genetic abnormalities, these cells will gradually allow the reconstitution 
of the tumor mass and the gradual resurgence of the disease. This predicts that only the 
destruction of CSCs can lead to a cure in cancers. 
 
VII. Cancer Stem Cells and resistance to treatment 
 
Most of the treatments used in cancer are based on cytotoxic molecules targeting 
rapidly cycling cells, one of the main properties of cancer cells. However, these treatments 
are problematic for 2 different reasons. The first one is that chemotherapy also harms normal 
cells that rapidly divide under normal circumstances like bone marrow, digestive tract and 
hair follicles cells. The second one is that CSCs, or at least some of them, are able to survive 
to this treatment. These resistant CSCs can persist during treatment and will eventually 
acquire additional alterations leading to relapses of the disease in patients (Figure 8). 
Different mechanisms have been identified for their involvement in CSCs resistance to 
treatment. One of them is the possibility for CSCs to enter into quiescence. In that case, the 
cells are not dividing and will not be sensitive to chemotherapeutic treatments. Other 
mechanisms are dependant on specific SC properties that allow these cells to survive all 
along an individual’s lifetime, such as high DNA repair ability, over-expression of anti-
apoptotic proteins, drug efflux transporters and detoxifying enzymes.11 
Finally, CSCs are also supported by their microenvironment for their survival and can 
even subvert the tumor niche to resist to treatments. 
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VIII.Cancer stem cell niche 
 
Just like normal SCs, CSCs are located in a peculiar microenvironment. However, the 
response of CSCs to the signals provided by their microenvironment can be totally altered. 
Indeed, in a healthy context, these signals are sufficient to control SC fate, while in cancer 
they are not able to control CSCs fate as cancer is characterized by an abnormal 
amplification of malignant cells. For example, it has been demonstrated that CML CD34+ 
cells respond to hypoxia with a reduction in division number while this is not the case for 
normal CD34+ cells.44 Moreover, several studies have demonstrated that tumor cells can 
alter their microenvironment, leading to the production of abnormal signals that can even 
contribute to the tumor phenotype.82 This has been particularly well illustrated in ALL, where 
leukemic cells dissemination into the BM of irradiated mice lead to the alteration of the 
normal microenvironment, depending on the level of leukemic cell engraftment.82 It was 
further demonstrated that in response to chemotherapy, leukemic cells were able to recruit 
mesenchymal cells by production of a set of cytokines, including GDF-15, a member of the 
TGF-β signaling pathway. This led to the formation of a protective microenvironment and to 
the resistance of ALL leukemic cells under chemotherapy.82 In addition, the alterations of the 
microenvironment by leukemic cells can even lead to the disruption of normal hematopoietic 
cells behavior, as demonstrated by the analysis of BM microenvironment after 
transplantation of healthy human CD34+ cells in a ALL mouse xenograft model.83 Current 
evidences demonstrate that homeostatic processes such as inflammation, hypoxia and 
angiogenesis contribute to the maintenance and control of CSCs fate by providing the 
appropriate signals within the microenvironment.84 As the niche is involved in the protection 
and the maintenance of normal SCs, an increasing amount of evidences also indicates that it 
could also be involved in CSCs resistance to anti-cancer treatments.82,85 
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Cancer remains one of the leading causes of mortality worldwide. One of the 
main causes of treatment failure in cancers is the development of drug resistance by 
cancer cells. The persistence of cancer stem cells (CSCs) might explain cancer 
relapses as they could allow reactivation of cancer cells proliferation following 
therapy, leading to disease persistence and ultimately to patients’ death. Clinically, it 
is crucial to develop therapeutic strategies able to target resistant CSC in order to 
cure the patients (Figure 8). Thus, it is necessary to understand the key processes 
occurring within the CSC niche to identify potential therapeutic targets that can serve 
as the basis for development of more effective treatments. In this context, Chronic 
Myelogenous Leukemia (CML) is the reference model of a true HSC alteration by a 
t(9;22) chromosomal translocation directly responsible of the leukemic 
transformation.86 Thus, CML represents a unique model to study LSC biology and to 
understand the mechanisms of CSC transformation and resistance to treatments. 
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Chapter 2 : Chronic Myelogenous Leukemia 
 
I. Introduction to CML 
  
Chronic myelogenous leukemia (CML) is a myeloproliferative disorder resulting from 
the clonal expansion of a transformed multipotent HSC.87 CML is characterized by the 
t(9;22)(q34;q11) reciprocal chromosomal translocation, which leads to the formation of the 
Bcr-Abl  oncogene, directly responsible of the leukemic transformation (Figure 9).88 BCR-ABL 
fusion protein is a hyperactive and deregulated tyrosine kinase that promotes leukemic 
growth by disrupting a broad range of signaling pathways involved in cell survival, 
proliferation, and differentiation.86 The molecular basis for the myeloid expansion is puzzling 
as BCR-ABL transforms HSC and is present in all hematopoietic compartments including 
myeloid, erythroid, B-lymphoid and T-lymphoid cells.67 By studying female patients with X 
chromosome linked heterozygous alleles, CML was demonstrated to be a clonal disease that 
origins from a single multipotent HSC.87,89 CML was the first cancer to be linked to a unique 
and clear genetic abnormality, the chromosomal translocation known as the Philadelphia 
(Ph) chromosome, so-called because it was first discovered and described in 1960 in 
Philadelphia.90 This chromosomal abnormality is the hallmark of CML as it is found in about 
90% of patients. The remaining 10% of CML patients have variant translocations that may be 
complex involving chromosomes 9 and/or 22 with one or more other chromosomes. Among 
them, 5% of CML cases display cytogenetic variants of the classic Ph chromosome. About 
2.5% of the remaining CML patients are Ph chromosome negative but do have cryptic Bcr-
Abl gene fusion detectable on molecular analysis. Hence, only about 2.5% of CML patients 
are negative for both the Ph chromosome and the Bcr-Abl fusion gene.86 This unique genetic 
abnormality allowed the researchers to develop targeted therapies blocking BCR-ABL 
tyrosine kinase activity. Imatinib, the first tyrosine kinase inhibitor (TKI) developed, has 
proved to be very efficient to induce the remission of a majority of CML patients.91 However, 
none of TKIs available to date seem to eradicate undifferentiated BCR-ABL+ cells that may 
serve as a reservoir for additional oncogenic events leading to disease progression and 
requiring continued treatment.92 Therefore, CML represents a unique model to study LSC 
biology and to elucidate some of the mechanisms of therapeutic resistance. 
? ??
 
Figure 9 : BCR-ABL formation by chromosomal translocation in CML. The balanced 
genetic translocation t(9;22) characteristic of CML involves a fusion of the Abelson oncogene 
(Abl) from chromosome 9 with the breakpoint cluster region (Bcr) gene on chromosome 22 in 
a hematopoietic stem cell. This leads to the formation of the Bcr-Abl oncogene directly 
responsible of the leukemic transformation. 
  
II. Epidemiology 
 
CML constitutes about 15% of all leukemia and is considered a rare disease as its 
annual incidence rate vary from 0.6 to 2.0 cases per 100 000 inhabitants.86 The incidence 
increases with age and is slightly higher in men than in women (men to women ratio of 
1,4:1).93 The prevalence is steadily increasing due to the substantial prolongation of survival 
that has been achieved by targeted therapies. CML occurs at any age, though very rarely in 
children as it represents only 5% of childhood leukemia. The median age at diagnosis is 
about 65 years.94 However, the initiating event or events are still unknown: there are no 
known hereditary, familial, geographic, ethnic or economic associations. Benzene exposure 
has been identified as a cause of AML, but while some cases of CML have been reported in 
benzene-exposed workers, CML does not appear to be related to benzene exposure.95 The 
only risk factor that has been associated with an increased CML occurrence is high levels of 
radiations. Indeed, follow-up of Hiroshima Japanese adult survivors after exposure to atomic 
bomb radiations revealed high rates of cancer, with an abnormally high peak in CML 
incidence 6 years after the accident. Correlation study between dose exposure and CML 
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occurrence suggests the existence of a threshold for CML development somewhere between 
0.5 Gy and 0.09 Gy.96 
 
III. BCR-ABL formation and structure 
 
The balanced genetic translocation t(9;22)(q34;q11.2) characteristic of CML involves 
a fusion of the Abelson oncogene (Abl) from chromosome 9q34 with the breakpoint cluster 
region (Bcr) gene on chromosome 22q11.2. The molecular consequence of this translocation 
is the generation of a Bcr-Abl fusion oncogene, which in turn translates into a BCR-ABL 
oncoprotein. 
1. Abl gene 
 
The Abl proto-oncogene is the normal cellular homologue of the transforming gene of 
Abelson murine leukemia virus, a virus that causes pre-B cell leukemia in mice (Figure 10A). 
ABL is a 145 kDa protein that shows very low tyrosine kinase activity in the normal context. 
This protein is distributed in both the nucleus and cytoplasm of cells, and shuttles between 
the two compartments. It transduces signals from cell-surface receptors in response to 
growth factors and adhesion receptors to regulate cytoskeleton structure.97 Abl can be 
activated by cell-cycle progression, DNA damage and integrin mediated adhesion. Abl 
tyrosine kinase is increased during cell-cycle progression to S phase. Activated Abl 
phosphorylates C terminal domain of RNA polymerase II and enhances transcription. In 
addition, Abl is activated in response to DNA damage and induces cell-cycle arrest or 
apoptosis.98 
2. Bcr gene 
 
The breakpoint cluster region (Bcr) gene leads to the formation of a 160 kDa protein, 
that can oligomerizes, autophosphorylates and transphosphorylates several protein 
substrates (Figure 10A).99 BCR deficient mice develop normally but display excessive levels 
of oxygen metabolites produced by neutrophils following their activation.100 Having different 
types of structural and functional properties, BCR protein may be involved in different 
signaling pathways and serve as the cross point of these pathways, but the understanding of 
the biological function of BCR protein is still limited. 
3. Bcr-Abl isoforms 
 
Depending on the precise location of the fusion, different sizes of the Bcr gene will be 
attached to the Abl gene, and distinct Bcr-Abl isoforms will be obtained (Figure 10A). 
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Consequently, the molecular weight of BCR-ABL can range from 185 to 230 kDa. This 
difference in structure influences the biological and clinical phenotypes associated with the 
Bcr-Abl variants. Three clinically important variants exist, referred as p185 (e1a2 junction), 
p210 (b2a2 or b3a2 junction), and p230 (e19a2 junction) isoforms, usually associated with 
distinct types of leukemia.101 P185 is associated with 20% to 30% of ALL, p230 with a subset 
of patients with chronic neutrophilic leukemia (CNL) and p210 with 90% of CML. Still, the 
isoforms expression is not exclusive as p210 occurs in 40% of BCR-ABL+ ALL, p185 occurs 
in 2% to 3% of CML, and p230 in a few cases of CML.101,102 In addition, co-expression of 
p185 and p210 has been observed in some CML patients.103 Different isoforms of p210 can 
also be produced by alternative splicing, namely, b2a2 and b3a2. However, there is no 
consensus on the biological consequences, as some studies suggested no difference in 
prognosis between patients with b2a2 versus b3a2 transcripts while other studies claimed 
the opposite.104 In addition to the formation of the chimeric Bcr-Abl gene on chromosome 22, 
the reciprocal translocation also leads to the formation of the chimeric Abl-Bcr gene on 
chromosome 9.105 Although transcriptionally active, very little is known about the biology of 
Abl-Bcr as it doesn’t appear to have any functional role in CML. However, it has recently 
been suggested that Abl-Bcr could contribute to the leukemic phenotype in BCR-ABL+ ALL 
by inducing B-cell commitment.106,106 
4. p210 BCR-ABL structure 
 
Structurally, BCR-ABL protein contains multiple domains (Figure 10B). The Abl 
sequences encode Src-homology (SH3 and SH2) domains, SH1 tyrosine kinase domain, 
DNA-binding domain, actin-binding domain, nuclear localization signals, and nuclear export 
signal. The Bcr region encodes a coiled-coil oligomerization domain, serine/threonine kinase 
domain, pleckstrin homology (PH) domain, a Dbl/cdc24 guanine nucleotide exchange factor 
homology domain, several serine/threonine and tyrosine phosphorylation sites, and binding 
sites for the Abl SH2 domain, Grb2, and 14-3-3 proteins.107 The SH2 domain of BCR-ABL 
recruits signaling proteins such as p62dok, c-Cbl, and Rin1. Binding and phosphorylation of 
these molecules may be functionally important as SH2 mutations in BCR-ABL affect the 
course of disease in biological models. The actin-binding domain directly links BCR-ABL to 
the cytoskeleton, and facilitates tyrosine phosphorylation of cytoskeletal proteins.108 
 
? ??
 
Figure 10 : Structural and functional domains of BCR-ABL. (A) Structure of Bcr, Abl, and 
Bcr-Abl isorforms. (B) p210 BCR-ABL contains a coiled-coil oligomerization domain at the N-
terminus. Then there is a serine/threonine kinase domain, a Rho guanine nucleotide 
exchange factor (Rho-GEF) domain, a Src homology 3 (SH3) domain, a SH2 domain and a 
SH1 tyrosine kinase (TK) domain and a nuclear localisation signal (NLS). At the C-terminus 
are located DNA- and actin-binding domains. 
 
IV. Molecular and functional consequences 
 
1. Molecular consequences 
 
BCR-ABL forms dimers or tetramers in vivo that autophosphorylate each other. 
Fusion of Bcr to Abl inhibits the latter’s SH3 kinase regulatory domain, resulting in 
constitutive activation of the Abl tyrosine kinase in BCR-ABL. The BCR-ABL fusion protein 
acts as an onco-protein by recruiting adaptor molecules, phosphorylating signaling 
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molecules, and activating several signaling pathways that lead to cell transformation. 
Examination of the signaling pathways differentially regulated in CML led to a better 
understanding of BCR-ABL mediated leukemogenesis. BCR-ABL is involved in the alteration 
of diverse intracellular signaling pathways, including Ras-MAPK, PI3K-Akt, and JAK-STAT 
pathways.109 BCR-ABL binds several adaptor proteins such as growth factor receptor bound 
protein 2 (Grb2), v-Crk avian sarcoma virus CT10 oncogene homologue-like (CrkL) protein 
and Src homology containing (Shc) protein. As BCR-ABL substrates represent a very 
extensive number of proteins, some examples will be discussed here to illustrate their 
functional consequences. 
2. Functional consequences 
 
Because of its effects on a wide range of cell signaling pathways, BCR-ABL 
expression profoundly alters HSCs functional properties. BCR-ABL is known to protect CML 
cells from apoptosis. Transduction of BCR-ABL in hematopoietic cell lines leads to an 
increase of anti-apoptotic genes expression, such as B-cell lymphoma-2 (Bcl-2), B-cell 
lymphoma-extra large (Bcl-xL) and myeloid cell leukaemia-1 (Mcl-1).110 Thus, CML CD34+ 
cells become more resistant to a large range of cytotoxic agents compared to their normal 
counterparts.111 
Normal hematopoietic immature cells are dependent on growth factors to proliferate 
and survive.112 For example, IL-3 growth factor regulates proliferation, differentiation and 
survival of hematopoietic cells by activating intracellular signaling pathways including Ras, 
MAPK, PI3K-Akt, and JAK-STAT. However in CML, BCR-ABL transforms hematopoietic cells 
and leads to IL-3 independence in vitro.113 Hence, BCR-ABL+ quiescent CML cells 
proliferation can be initiated without any added growth factor, while this is not possible for 
normal quiescent hematopoietic cells. Interestingly, BCR-ABL also promotes autocrine 
secretion of IL-3 in immature CML cells.114 This aberrant autocrine production may confer a 
proliferative advantage to immature CML cells compared to normal ones. BCR-ABL can also 
replace growth factors signaling and drive the G1 to S cell-cycle phase transition. Thus, this 
implies that BCR-ABL is able to activate mitogenic signaling pathways. For example, BCR-
ABL has been demonstrated to activate Rat sarcoma (Ras) signaling, leading to the 
subsequent activation of Raf, MEK and ERK, and to an increase of cell proliferation.115 This 
process plays a central role in the pathogenesis of CML as impairment of Ras signaling 
inhibits proliferation of primary CML cells and BCR-ABL+ cell lines.116 
In a physiological context, HSCs homeostasis is controlled by their interactions with 
their BM microenvironment. Indeed, the proliferation of normal hematopoietic progenitors is 
significantly inhibited when these cells are cultured in contact with BM stromal cells or in 
adhesion to fibronectin, suggesting that integrin-dependent adhesion inhibits normal 
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progenitor cell proliferation.39 However in CML, BCR-ABL was shown to alter integrin-
mediated adhesion of CML cells to their BM microenvironment, leading to an abnormal 
circulation of immature CML progenitors in the peripheral blood.117 Thus, the abnormal 
expansion of CML progenitors, their growth advantages over existing normal progenitors and 
their evasion from the BM may be related to their inability to integrate and to transduce 
negative signals from integrin-mediated adhesion to the BM microenvironment.117 However, 
this is controversial as in some cases, BCR-ABL-transduced hematopoietic cells displayed 
increased adhesive capabilities to their environment.118 
Interestingly, in transformed cells, BCR-ABL has also been demonstrated to bind 
actin filaments (F-actin), a major determinant of cell mechanical behavior, and to induce its 
redistribution into punctate, juxtanuclear aggregates. By designing BCR-ABL mutants unable 
to bind F-actin but with an active kinase domain, it was demonstrated that the binding to F-
actin seems to be involved in the transforming ability of BCR-ABL.108 
To summarize, BCR-ABL kinase expression up-regulates cell proliferation by 
controlling cell-cycle, decreases apoptosis, increases cytokine-independent growth, 
decreases adhesion to the bone marrow stroma, and produces cytoskeletal abnormalities. 
As a result, BCR-ABL expression alone is recognized as the driving force of leukemogenesis 
in CML. 
 
V. Diagnosis 
 
Approximately 50% of CML patients are being diagnosed before they have become 
symptomatic as part of a routine check-up that reveals an elevated white blood cell count. 
Thus, more than 90% of CML patients are being diagnosed during the chronic phase (CP) of 
the disease.91 However, considering the variable but generally long phase that precedes CP-
CML diagnosis in different individuals, this suggests a high variability in the precise stage of 
the disease when the diagnosis is made. This bear important consequence as it affects how 
biological data are analyzed and how the results of clinical trials are interpreted. When 
symptoms are present they are usually non-specific and gradual in onset. They may include 
fatigue due to a lack of red cells causing anemia, frequent infections and slow healing due to 
a lack of normal white blood cells, increased sweating and unusual bleeding or bruising from 
various sites due to a very low platelet count, loss of appetite and weight loss. If the spleen is 
enlarged there may be abdominal pain or discomfort and a feeling of fullness when eating. 
An enlarged spleen can be observed during physical examination of CML patients but has 
become less common because of earlier diagnosis. The diagnosis must be confirmed by 
cytogenetic analysis to detect the Philadelphia chromosome and/or the BCR-ABL 
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rearrangement in peripheral blood or bone marrow cells.91 In almost 5% of the cases, a Ph 
chromosome cannot be detected, and confirmation of diagnosis rests on molecular genetic 
methods, like fluorescent in situ hybridization (FISH) or reverse transcriptase-polymerase 
chain reaction (RT-PCR). 
 
VI. Prognosis 
 
In solid tumors, staging and treatment planning are usually based on the tumor size 
and the spreading of tumor cells from their original site. However this form of staging is not 
used in CML because the disease is typically widespread at the time of diagnosis. Thus, 
different scores (Sokal, Hasford, EUTOS) have been devised to help physicians predict 
which patients are more likely to have progressive disease. Among them, the Sokal score is 
the most commonly used, and derives from a multivariate survival analysis of 813 CP-CML 
patients at diagnosis.119 Spleen size, platelet count and percentage of blast cells in the blood 
must be measured and performed before any treatment. The score, which is a hazard ratio, 
is calculated using the following formula: exp (0.0116 x (age [years] – 43.4)) + (0.0345 x 
(spleen size [cm] – 7.51) + (0.188 x ((platelets [109/L]/700)^2 – 0.563)) + (0.0887 x (blasts [%] 
– 2.10)). Three risk groups have been determined: low-risk (Sokal score < 0.8, 39% of 
patients), intermediate-risk (0.8< Sokal score <1.2, 38% of patients) and high-risk (Sokal 
score > 1.2, 23% of patients). Although prognostic scores have been established before 
tyrosine kinase inhibitors (TKIs) development, they still allow the discrimination of risk groups 
with different prognosis, response rate, progression-free survival and overall survival, even 
for patients treated with TKIs. Before the clinical use of TKIs, the median survival time for 
CML patients was comprised between 3 to 5 years from time of diagnosis. TKIs development 
led to very significant improvements in patient’s survival and quality of life. A follow-up of 832 
patients who achieved a stable cytogenetic response under Imatinib (TKI actually used for 
CML first-line therapy) treatment found an overall survival rate of 95.2% after 8 years, which 
is similar to the rate in the general population. Less than 1% of patients died because of 
leukemia progression, leading to a general agreement that this drug will prevent disease 
progression in the majority of patients.120 However, the minority of patients who were 
diagnosed in blast crisis gained much less benefit from TKIs introduction. The degree and 
timing of hematologic, cytogenetic and molecular responses provide very important 
prognostic information as time-dependent variables. In particular, the prognostic importance 
of complete cytogenetic response (CCyR) has been confirmed. 
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VII. Disease evolution 
 
Clinically, the natural course of the disease includes three distinct phases. Without 
treatment, leukemic cells tend to acquire additional genetic abnormalities over time, leading 
to disease progression from an initial chronic phase (CP) to an accelerated phase (AP) and 
to an inexorable fatal blast crisis (BC). The acquisition of secondary genetic changes is 
thought to be the consequence of BCR-ABL inhibitory effects on cellular DNA reparation 
mechanisms, thus leading to genomic instability.121 For example, loss of p53 function might 
be important for CML disease progression, as p53 is inactivated in almost 30% of CML blast-
crisis cases.122 The initial phase is characterized by a progressive myeloid expansion, with 
accumulation of myeloid progenitors and mature granulocytes in the bone marrow (BM) and 
peripheral blood. During this phase, CML cells have been shown to be functionally 
heterogeneous and capable of maintaining a hierarchical organization caricaturing normal 
hematopoiesis, with only a fraction of the cells being actually responsible for disease 
maintenance and propagation, thus behaving as leukemia-initiating stem cells. Upon 
acquisition of secondary mutations, this chronic phase evolves through an accelerated phase 
into an acute leukemia-like blast crisis involving either myeloid (about half of the blast crisis), 
B lymphoid (about a quarter of the blast crisis) or myeloid/lymphoid biphenotypic cells (about 
a quarter of the blast crisis).122 Ultimately, this leads to a failure of the blast phase cells to 
differentiate and hence to a rapid accumulation of non-functional cells in the bone marrow 
and peripheral blood. Hence, the blast crisis is characterized by the presence of at least 30% 
blast cells in the bone marrow or circulating blood. The blast crisis, now increasingly rare but 
still encountered, is usually associated with significant symptoms. Clinically, BC resembles 
acute leukemia, with a poor prognosis and often resistance to therapy. The median survival 
time for myeloid and lymphoid BC-CML is 4 months to 5 months and 12 months, 
respectively.123 
 
VIII.Treatment 
 
1. Conventional therapies 
 
The history of CML treatment begins in 1878 with the use of arsenic to decrease the 
levels of white blood cells in patients. The early 1900s was then marked by the discovery of 
X-rays and the clinical use of radiotherapy. Whole body or splenic radiation gradually 
became the reference treatment for this disease until the 1950s, but was only palliative, as it 
did not improve overall survival of the patients.86 
From the 1950s, a cell-cycle non-specific alkylating chemotherapeutic agent called 
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busulfan was employed, and was able to maintain partial hematologic response in most CML 
patients, however with serious side-effects. Indeed, chronic use of busulfan has been 
associated with a syndrome that stimulates adrenal insufficiency, manifested by skin 
pigmentation, weakness, fever, and diarrhea, or with pulmonary fibrosis. Prolonged aplasia 
of the marrow can also occur with busulfan.124 
Hydroxyurea, an inhibitor of DNA synthesis and cell-cycle, was introduced to treat 
CML in the 1970s. Hydroxyurea is less toxic than busulfan and sustains the chronic phase of 
the disease for a longer time. The major side effect of hydroxyurea is that it causes 
suppression of hematopoiesis that is reversible. The median survival of CML patients treated 
with hydroxyurea is about 5 years, and is longer than for patients treated with busulfan, 
which is about 3,75 years. Unfortunately, both busulfan and hydroxyurea treatments simply 
keep the tumor size under control without affecting its subsequent course. Under these 
treatment conditions, progression from the chronic phase to the fatal blast phase is 
inevitable.125 
In the early 1980s, stem cell transplantation (SCT) was developed as a revolutionary 
therapy and remains the only curative treatment for CML patients. SCT involves the 
introduction of donor (allogeneic) or the patient’s own treated (autologous) HSC into the 
patient after treatment with high doses of chemotherapy and/or radiation to destroy all bone 
marrow cells (cells used for autologous transplant are withdrawn prior to this step), in the 
hope that they will repopulate the patient’s marrow and replace the CML LSC.126 However, its 
relevance in the post-Imatinib era is debated. Indeed, only about 20% of CML patients are 
suitable for allogeneic SCT due to age of the patient, fitness and donor availability. Moreover, 
SCT can also be responsible of transplant-related mortality that ranges from 20% in low-risk 
CML patients to 73% in high-risk patients.126 The high mortality rate is usually caused by 
graft-versus-host disease and opportunistic infections. Yet, it remains an important option, 
particularly for younger patients with HLA (Human leukocyte antigen) identical siblings with 
the hope of cure, or patients who are intolerant or resistant to TKIs. 
In the 1980s, Interferon alpha (IFNα) became the first line therapy of CML patients 
who were not eligible for allogeneic SCT. It was the first treatment that consistently produced 
durable cytogenetic remissions in 10% to 20% of CML patients.86 IFNα is a cytokine 
produced by leukocytes and mainly involved in innate immune response. However there are 
early side effects (fever, fatique, anorexia, nausea…) as well as later side effects (apathy, 
thrombocytopenia, renal or cardiac dysfunction…). Combination of hydroxyurea and 
interferon led to 73% of hematologic response rate and 58% of cytogenetic remission rate in 
chronic phase CML patients.86 While IFNα monotherapy is no longer recommended because 
of TKIs development, its combination with Imatinib is currently being tested in phase III 
prospective studies. 
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2. Tyrosine Kinase Inhibitors 
 
As the understanding of the molecular biology of CML progressed further, BCR-ABL 
became an attractive therapeutic target for CML. In the mid-1990s, Imatinib (also known as 
STI-571 or Gleevec), a phenylaminopyrimide derivative with potent tyrosine kinase inhibitory 
activity and selectivity for Abl, c-Kit, and platelet-derived growth factor receptor (PDGF-R) 
was developed by random screen of a large number of synthesized ATP-competitive 
compounds. Indeed, Imatinib binds to a pocket of the catalytic domain of the Abl tyrosine 
kinase and competitively inhibits the binding of adenosine triphosphate (ATP), thereby 
resulting in inhibition of autophosphorylation and inhibition of substrate phosphorylation 
(Figure 11).127 The activation loop in the enzymatic site of Abl controls its kinase activity by 
switching between active and inactive conformations. Imatinib binds to Abl only when it is in 
the inactive state and prevents it from changing into the active conformation.127 Imatinib 
inhibits proliferation and causes apoptosis in BCR-ABL+ cell lines and primary cells both in-
vitro and in-vivo, with very low toxicity for BCR-ABL- cells, demonstrating the specificity of 
this drug against BCR-ABL+ cells.128–130 This first tyrosine kinase inhibitor (TKI), competitively 
inhibiting the BCR-ABL kinase, was approved based on the results of the International 
Randomized Study of Interferon-α versus STI571 (IRIS) trial showing that at 18 months, 
76.2% of the patients achieved complete cytogenetic response (CCyR) and 96.7% were free 
from disease progression.131 The update of the IRIS study has confirmed and extended the 
earlier results, reporting a progression-free survival of 84% and an overall survival of 88% 
after 6 years.132 Until recently, Imatinib has become the gold standard for CP-CML care. 
Since the advent of this molecule (Figure 12A), CML has become the first cancer in which a 
standard medical treatment may give to the patient a normal life expectancy. 
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Figure 11 : Mechanism of action of Imatinib on BCR-ABL. ATP binding is essential for 
BCR-ABL to phosphorylate substrates and subsequently activate downstream pathways that 
promote cell survival and proliferation leading to CML. Imatinib can bind to the inactive state 
of BCR-ABL at its ATP binding site, and inhibit the phosphorylation of substrates that would 
activate downstream signaling and lead to CML. 
 
The response to Imatinib may fall into three categories, namely optimal, suboptimal 
and failure. In case of ‘failure’, second-line treatment is based on second-generation TKIs 
dependent on the identified Bcr-Abl mutation, namely Nilotinib and Dasatinib.133 About 50% 
of CP-CML patients resistant or intolerant to Imatinib achieve a CCyR with either agent, but 
both agents are ineffective in the case of a T315I BCR-ABL kinase domain (KD) mutation. 
The response to either agent is usually rapid, and within 6 months it may be possible to 
decide to continue with the second-generation TKIs or to move to allogeneic SCT, if the 
patient is eligible. In the case of suboptimal response to Imatinib, which frequently represents 
a transitory state, the best treatment option is still a matter of investigation. The patients can 
be continued on Imatinib, same dose or higher dose, but are also eligible for a trial with 
second-generation TKIs. Once a patient has progressed to advanced phase, further 
treatment depends on prior therapy, and may include other TKIs, different from those used in 
chronic phase, experimental targeted agents or cytotoxic chemotherapy, always with the 
purpose of performing an allogeneic SCT, whenever it may be possible. 
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Figure 12 : Tyrosine kinase inhibitors molecular structure. (A) Imatinib structure. A high-
throughput screening of chemical libraries at Novartis was performed to identify a starting 
molecule, which was called pyrimidine A. This compound served as a lead compound and 
was then tested and modified to develop Imatinib. With a replacement of the imidazole group 
with a benzamido group, the compound's specificity increased while its activity as a kinase 
inhibitor remained the same. Subsequently, introducing a methyl subtituent ortho to the 
pyrimidinyl-amino group enhanced the potency. (B) Nilotinib structure. Nilotinib is a 
phenylamino-pyrimidine derivative that is structurally related to Imatinib. (C) Dasatinib 
structure. Dasatinib is a thiazolylaminopyrimidine developed as the hydrochloride salt. (D) 
Bosutinib structure. Bosutinib is a 4-anilinoquinoline-3-carbonitrile inhibitor. (E) Ponatinib 
structure. Ponatinib is a N-phenylbenzamides derivated compound. 
 
Second generation TKIs (Nilotinib, Dasatinib, Bosutinib) have emerged to target BCR-
ABL in order to overcome Imatinib resistance. Nilotinib (also known as AMN107 or Tasigna) 
is a rationally designed specific inhibitor of Abl tyrosine kinase (Figure 12B). Apart from Abl 
kinase, Nilotinib also inhibits the activity of c-kit and PDGF-R.134 Nilotinib was designed to 
have higher binding affinity than Imatinib to the ATP binding site on the kinase domain of 
BCR-ABL.135 Just like Imatinib, Nilotinib binds to the inactive conformation of Abl kinase, and 
blocks its tyrosine kinase activity. Nilotinib inhibits 32 out of 33 Imatinib-resistant BCR-ABL 
mutants except the T315I mutation.135,136 Nilotinib exhibits about 20 times more potency than 
Imatinib in Imatinib sensitive and insensitive BCR-ABL+ cell lines. Although Nilotinib is much 
more effective than Imatinib in BCR-ABL+ cell lines, Nilotinib and Imatinib are equally potent 
in human primary CD34+ CML cells, and only have anti-proliferative effect instead of 
eradicating these cells.137 Nonetheless, clinical studies have demonstrated the effectiveness 
and safety of Nilotinib in Imatinib resistant or intolerant CML patients,138 leading to the 
approval of Nilotinib by FDA for treating adult BCR-ABL+ CP- and AP-CML patients who are 
resistant to or intolerant of prior therapy including Imatinib, and subsequently newly 
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diagnosed adult BCR-ABL+ CP-CML patients.139 
Dasatinib (also known as BMS 354825 or Sprycel) is a dual Src/Abl tyrosine kinase 
inhibitor (Figure 12C). It also targets c-kit and PDGF-R.140 Dasatinib is 325-fold more potent 
than Imatinib in cells expressing wild-type BCR-ABL protein.138 Almost all BCR-ABL kinase 
domain mutations can be inhibited by Dasatinib except once again the T315I mutation. 
Dasatinib binds to both active and inactive conformations of Abl kinase, rendering it much 
higher binding affinity than Imatinib.141 Clinical trials demonstrated the efficacy of Dasatinib in 
all phases of Imatinib resistant or intolerant CML patients, and it is well tolerated.142 Dasatinib 
and Nilotinib have equivalent response rates with a complete hematologic response rate of 
about 87% and 92% respectively in CP-CML patients.143 Dasatinib was approved by FDA for 
treatment of adult BCR-ABL+ CML and ALL patients who are resistant to or intolerant of prior 
therapy (such as Imatinib), as well as newly diagnosed adult BCR-ABL+ CP-CML patients. 
However, Dasatinib is still not able to eliminate the primitive quiescent CML stem cell 
population.144 For this reason, although both Nilotinib and Dasatinib have improved effects in 
suppressing CML than Imatinib, they are still not able to cure CML. 
Bosutinib (also known as Bosulif or SKI-606) is a dual Src/Abl TKI with a more potent 
in-vitro inhibitory activity against BCR-ABL than Imatinib and a minimal inhibitory activity 
against c-kit and PDGF-R, which are potentially associated with some toxicities reported for 
other TKIs (Figure 12D).145 While Bosutinib seems more efficient than Imatinib to induce 
major molecular response by 24 months (59% versus 49%), more Bosutinib-treated patients 
suffered adverse events and had to stop the treatment compared to Imatinib-treated patients 
(25% versus 9%).145 Bosutinib is ineffective against the T315I mutation. Bosutinib was 
recently approved by the FDA for the treatment of adult BCR-ABL+ CML with resistance, or 
intolerance to prior therapy. 
Several third generation TKIs were designed to target T315I, but only a few agents 
have shown clinical activity. Ponatinib (also known as Iclusig or AP24534) is a third 
generation TKI that seems to be the only effective drug in patients with T315I mutation 
(Figure 12E). Based on positive phase 1 and phase 2 trials, Ponatinib was approved for the 
second-line treatment of CML and BCR-ABL+ ALL in 2012.146 However, due to severe 
vascular adverse events such as blood clots formation and narrowing of blood vessels, its 
use in clinic is still debated. 
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IX. Monitoring treatment results 
 
1. Hematologic response 
 
Monitoring the patient to see how they respond to treatment is very important 
because this will allow to accurately assess the treatment efficiency and to provide an early 
indication of emerging drug resistance. First, the hematologic response is usually checked 
about 3 months after the beginning of TKI treatment by blood cell count. When blood cell 
counts return to normal (leukocyte count < 10 × 109/L), no immature cells are observed in the 
blood, and the spleen has returned to normal size, it is called a complete hematologic 
response (CHR) (Figure 13).133 A partial hematologic response is similar to this, but not all of 
the above conditions are met. 
2. Cytogenetic response 
 
Then, karyotyping of FISH analysis can also be performed to monitor the percentage 
of BCR-ABL+ cells among the total bone marrow cells. A complete cytogenetic response 
(CCyR) occurs when no cells with the Philadelphia chromosome can be found in the bone 
marrow (Figure 13). A partial cytogenetic response (PCyR) occurs when less than 35% of 
cells still have the Philadelphia chromosome. A minor cytogenetic response occurs when 
35% to 90% of cells still have the Philadelphia chromosome.133 
3. Molecular response 
 
Finally, the blood or the bone marrow may also be checked by real-time quantitative 
reverse-transcription polymerase chain reaction (qRT-PCR) to measure the amount of Bcr-
Abl transcripts. A major molecular response (MMR) means that the amount of Bcr-Abl mRNA 
detected is very low (≥ 3 log reduction compared to the standardized baseline) (Figure 13).147 
Achieving an MMR is an important predictor of progression-free survival in CML.148 A 
complete molecular response (CMR) means that the Bcr-Abl transcripts are not detected, or 
at extremely low levels (≥ 4.5 log reduction compared to the standardized baseline). This is 
especially important since the use of second-generation TKIs (Dasatinib and Nilotinib) as 
frontline therapy for CP-CML, where higher response rates are achieved at earlier time 
points when compared with standard-dose Imatinib therapy.133 However, the results of 
treatment monitoring have to be considered with caution, as poor adherence to TKI treatment 
has recently been described as the principal factor contributing to the loss of cytogenetic 
responses and treatment failure in patients on long-term therapy.149 
? ??
 
Figure 13 : Monitoring TKIs treatment efficiency in CML patients. Hematologic response 
is the first objective to attain when treating patients and corresponds to the normalization of 
blood cell counts. Then, the cytogenetic response will display the percentage of BCR-ABL+ 
cells among the total bone marrow cells. Finally, the molecular response is the most 
sensitive assay, as the qRT-PCR technique will allow the detection of very low Bcr-Abl 
transcripts levels, the aim being to attain the lowest Bcr-Abl level as possible. 
 
X. Mechanisms of TKI resistance 
 
1. Definition 
 
Despite the positive results obtained in previous studies, approximately 30% of CML 
patients treated with Imatinib do not achieve a complete cytogenetic response, while others 
have drug resistance or cannot tolerate drug-related toxicities.150 Resistance is defined on 
the basis of its time of onset. Primary resistance is a failure to achieve a significant 
cytogenetic response, whereas secondary or acquired resistance is the progressive 
reappearance of the leukemic clone after an initial response to the drug (Figure 14).151,152 
Primary resistance can be further divided into primary hematologic resistance, which occurs 
in 2% to 4% of cases who fail to normalize peripheral counts 6 months after treatment, or 
primary cytogenetic resistance, which is more common and occurs in approximately 15% to 
25% of patients who fail to achieve any level of cytogenetic response (CyR) at 6 months, a 
major CyR (MCyR) at 12 months or a CCyR at 18 months.153 Secondary resistance occurs in 
those who have previously achieved and subsequently lost their response to the treatment 
(Figure 14). Complete elimination of CML clones has rarely been achieved by TKIs because 
of the development of a variety of cell-intrinsic and cell-extrinsic protective mechanisms. 
Extrinsic mechanisms are supported by the interplay between LSCs and their protective 
bone marrow microenvironment, the so-called “leukemic niche” (Figure 14). Intrinsic 
resistance will be further divided between BCR-ABL dependent and independent 
? ??
mechanisms (Figure 14). BCR-ABL dependent mechanisms include increased BCR-ABL 
expression and point mutations within the BCR-ABL kinase domain. BCR-ABL independent 
mechanisms are not so well understood and include mostly defects in drug transport in and 
out of the leukemic cells and activation of secondary oncogenic pathways.154
 
 
Figure 14 : Resistance to tyrosine kinase inhibitors treatment: description and 
mechanisms. Resistance to TKIs treatment can be primary or secondary, defined as 
hematologic, cytogenetic or molecular, and can involve BCR-ABL dependant or independent 
mechanisms. The most frequent mechanism involved in TKIs resistance is the development 
of point mutations in BCR-ABL kinase domain as well as BCR-ABL over-expression. Other 
mechanisms have also been identified such as activation of BCR-ABL independent signaling 
pathways, increase of drug efflux or decrease of drug uptake. But some resistance 
mechanisms are still unknown and could involve LSCs that may survive TKIs treatment, for 
example through entry into a quiescent state or the alteration of their microenvironment. 
2. BCR-ABL mutations 
 
The development of point mutations in the kinase domain is the most frequent 
mechanism of acquired resistance as it is found in about 40% to 50% of cases.154 These 
mutations are not induced by the drug, but rather, arise through a process where rare pre-
existing mutant clones are selected due to their capacity to survive and expand in the 
presence of the drug, thus gradually outgrowing drug sensitive cells. More than 100 different 
point mutations leading to the substitution of approximately 50 amino-acids in the kinase 
domain have been isolated from resistant CML patients so far, and this number is likely to 
increase with the development of more sensitive methods of detection.154 The substitution of 
the amino acid threonine with isoleucine at position 315 of the ABL protein, or T315I, was the 
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first and most frequent mutation observed in resistant patients.155 This is the most 
problematic mutation to deal with in clinic because of its resistance to all approved BCR-ABL 
inhibitors, prior to Ponatinib. Designed to be effective against T315I mutations, this third 
generation TKI lead to 82% of achieved major cytogenetic response (MCyR) and 40% of 
achieved MMR in patients with the T315I mutation in a phase I trial.156 However, significant 
adverse effects were observed in patients treated with this drug compared to other TKIs, 
including fatigue, nausea, thrombocytopenia, rash, pancreatitis, arterial thrombotic events 
and hepatotoxicity. 
3. BCR-ABL over-epression 
 
BCR-ABL over-expression has also been described as a resistance mechanism in 
CML patients, by increasing the amount of target protein needed to be inhibited by the 
therapeutic dose of Imatinib. Increased BCR-ABL levels due to amplification of the BCR-ABL 
gene was first described in resistant CML cell lines generated by exposure to gradually 
increased doses of Imatinib.157 Cells expressing high levels of BCR-ABL are far less 
sensitive to Imatinib and will also more rapidly develop Imatinib resistant mutant subclones 
compared to cells with low BCR-ABL expression levels.155 This is thought to be related to an 
increased genomic instability induced by high levels of BCR-ABL in some clones, thus 
leading to a higher propensity to develop mutations anywhere in the genome, including in the 
BCR-ABL kinase domain.121,158,159 
4. Drug efflux increase 
 
Multidrug resistance (MDR) is a well-known phenomenon involved in mammalian 
cells resistance to a number of anticancer agents following drug exposure.160 This is due to 
the presence of efflux pumps, evolved defense mechanisms present in animals, fungi and 
bacteria to protect them against harmful substances by excluding them from the cells. In 
most cases, the resistance is mediated by an increased expression at the cell surface of the 
Pglycoprotein (Pgp) encoded by the MDR1 (ABCB1) gene. Pgp is an ATP-dependent efflux 
pump with broad substrate specificity, which primarily reduces intracellular drug 
concentrations, leading to the failure of effective levels of the drug to reach its target.161 
Imatinib and other TKIs have been demonstrated to be substrates of Pgp and the 
intracellular levels of Imatinib were shown to be significantly lower in Pgp-expressing cells.162 
Pgp over-expression was observed in an Imatinib-resistant CML cell line, and was 
demonstrated to confer Imatinib resistance. However, clinical studies have failed to find a 
similar association, and inhibition of MDR1 does not seem to enhance the effect of Imatinib 
against BCR-ABL activity.163 Thus, the significance of Pgp expression in Imatinib resistance 
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has yet to be fully clarified. Another drug efflux pump over-expressed in many human tumors, 
the breast cancer resistance protein (BRCP) encoded by the Abcg2 gene, was also found to 
be functionally expressed in CML LSC and has been implicated in TKIs resistance. 
Nevertheless, a recent study showed that ABCB1163 and ABCG2164 seem to have a minimal 
functional role in the transport of Imatinib in primary CML CD34+ cells. 
5. Drug uptake decrease 
 
The failure of TKIs to effectively inhibit leukemic cells could also result from 
impairment of drug uptake by influx pumps, so that it never reaches its effective intracellular 
concentration. It has been reported that Imatinib is actively transported into cells by organic 
cation transporter 1 (OCT1), a member of the solute carrier transporters encoded by the 
Slc22 gene family, and that OCT1 inhibition decreases the intracellular concentration of 
Imatinib.165 OCT1 expression has been correlated with intracellular Imatinib uptake or activity 
in CML cells and may thus determine the therapeutic outcome in patients. Indeed, the OCT1 
gene is expressed at significantly higher levels in mononuclear cells (MNC) from patients 
who achieved a complete cytogenetic response (CCyR) to Imatinib than from those who 
were more than 65% Ph chromosome-positive after 10 months of treatment.165,166 
Interestingly, low OCT1 activity has been demonstrated to reduce Imatinib uptake in CD34+ 
CML cells.167 However, neither Nilotinib nor Dasatinib cellular uptake was significantly 
affected by OCT1 activity.165,168 
6. Activation of BCR-ABL independent signaling pathways 
 
Another resistance mechanism observed in CML cells is the activation of BCR-ABL 
independent signaling pathways that will be sufficient to cause disease progression even 
when BCR-ABL activity is inhibited by TKIs treatment. Such activated secondary signaling 
pathways have been identified, like Lyn kinase, Ras/Raf/MEK kinase, Fyn/Erk or STAT 
signaling.150 For example, Lyn, a Src family kinase expressed on myeloid cells169 and 
activated in BCR-ABL expressing cells has been demonstrated to be over-expressed and 
activated in Imatinib resistant CML cell lines.170,171 Interestingly, Lyn suppression by a Src 
kinase inhibitor resulted in reduced proliferation and survival of the Imatinib resistant but not 
the sensitive cell line. Lyn over-expression and BCR-ABL independent activation were 
described in CML cells from Imatinib resistant patients. Since BCR-ABL binding leads to Lyn 
activation and, in cells with high Lyn expression or activation,172 inhibition of BCR-ABL kinase 
by Imatinib is not sufficient to abolish BCR-ABL mediated signaling completely, it is possible 
that both BCR-ABL and Lyn inhibition are needed to prevent this resistance to Imatinib.173 
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7. Autophagy 
 
Autophagy is another possible mechanism for CML cells to survive under TKI 
treatment. Autophagy is a pathway that degrades proteins or organelles to maintain cellular 
homeostasis, and also generates energy under starvation or other cellular stress.174 Imatinib 
has been demonstrated to induce autophagy in CML cell lines as well as in primary CML 
cells.175 Blockage of autophagy with chloroquine increases Imatinib induced apoptosis in 
CML cells.174 Interestingly, this phenomenon was also observed in CML progenitor and stem 
cells.175 This indicates that autophagy may serve as a survival mechanism for CML cells 
under TKI treatment,176 and that autophagy inhibition by drugs may be used to potentiate 
TKI-induced apoptosis in primitive CML cells.177 
 
Other mechanisms have also been described, like low serum drug concentration, or 
Imatinib sequestration by increased serum protein α1 acid glycoprotein, which binds Imatinib 
and impairs subsequent binding to BCR-ABL.178 Elevated transcript levels of prostaglandin-
endoperoxide synthase 1/cyclooxygenase 1, which encodes an enzyme that metabolizes 
Imatinib, has also been associated with primary resistance.179 In some cases, the resistance 
mechanisms have yet to be identified, and one of the hypothesis that could explain those 
mechanisms is the existence of LSCs, that could survive to drug treatment due to their 
intrinsic specific properties and to their interactions within their microenvironment. 
 
XI. CML LSC persistence and resistance 
 
1. LSC persistence 
 
Although TKIs advent has proved remarkably effective to improve CML patients care, 
even patients in complete cytogenetic remission (CCyR) still harbor minimal residual 
disease, therefore sustaining detectable disease over the years. Indeed, none of the 
therapeutic agents available to date seem able to eradicate some discrete undifferentiated 
BCR-ABL+ cells. Recent evidences suggest that BCR-ABL+ LSCs are insensitive to TKIs 
treatment and can regenerate the disease upon drug discontinuation in 61% of cases, thus 
requiring continued treatment.180 These cells may also serve as a reservoir for additional 
oncogenic events leading in some cases to disease progression and secondary resistance 
mechanisms. Therefore, the degree to which the levels of residual disease can be reduced 
during therapy has become an increasingly recognized objective of CML clinical trials, 
assuming that reduction of this tumor load is of prognostic relevance. 
 
	   61	  
2. Resistance and oncogene independence 
 
CML treatment relies on the concept of oncogene addiction, postulating that some 
tumours depend on one single dominant oncogene for growth and survival, so that inhibition 
of this specific oncogene is sufficient to block the tumorigenic phenotype.181 In CML, Imatinib 
treatment has proved particularly effective to repress BCR-ABL tyrosine kinase activity 
leading to inhibition of cell proliferation and apoptosis. However, recent in-vitro and in-vivo 
results demonstrated that CML LSCs might not be “oncogene addicted”.181 This was 
demonstrated by serial transplantation of CML LSCs after abrogation of BCR-ABL 
expression using a tet-off inducible transgenic mouse model of CML-like disease in which 
p210-BCR-ABL expression is targeted to murine BM stem and progenitor cells.181 Indeed, 
after serial transplantations, donor-derived CML LSCs in which BCR-ABL expression had 
been induced and subsequently shut off were able to persist in-vivo and reinitiate leukemia in 
secondary recipients upon BCR-ABL re-expression. The results of this study are particularly 
striking, because they mean that as normal HSCs, CML LSCs (or at least some of them) do 
not depend on BCR-ABL expression for their survival. However, these cells still harbor the 
BCR-ABL oncogene, and are able to reconstitute the disease upon TKIs treatment arrest or 
acquisition of secondary mutations (Figure 15).181 But more importantly, these LSCs also 
display normal HSCs intrinsic properties such as high DNA repair ability, quiescence 
potential, over-expression of anti-apoptotic proteins, of drug efflux transporters and of 
detoxifying enzymes. These properties allow normal HSC to persist throughout an 
individual’s entire life to maintain a physiological hematopoiesis, while in LSCs the 
consequences will be an increased resistance to drug treatment. Thus, it is crucial to 
understand the specific mechanisms of LSCs resistance and to develop new therapies to 
efficiently eliminate these cells without damaging normal HSCs. 
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Figure 15 : Resistance to treatment, the leukemic stem cells hypothesis. Unlike 
differentiated leukemic cells, LSCs are suspected to survive to TKIs treatment, probably by 
their capability to enter into a quiescent state. Then, these cells could lead to relapses in the 
patients, after arrest of the treatment or by different despite unknown mechanisms, probably 
involving the acquisition of secondary alterations. 
 
However, LSCs do not only rely on their intrinsic mechanical properties for their 
survival. Indeed, like normal HSCs, CML LSCs are also located in the BM microenvironment 
that produces different signals participating in SC fate and survival. 
 
XII. Microenvironment involvement 
 
1. Quiescence 
 
Although less well studied, there is some evidence that LSCs resistance to TKIs treatment 
may also be supported by their bone marrow microenvironment. In-vitro182 and in-vivo183?
studies have demonstrated that TKIs have an anti-proliferative effect on CML LSCs, causing 
them to enter reversible cell-cycle arrest and accumulate in a quiescent state. However, 
these cells are resistant to TKIs induced apoptosis even with intracellular levels of TKIs 
similar to those observed in more mature CML cells.154 Thus, such cells may persist in a 
dormant state as a residual and highly resistant population of CML LSC with the capability to 
repopulate the leukemic clone, even in patients who are in complete molecular response with 
undetectable Bcr-Abl transcripts. Quiescent LSCs represent less than 1% of the total CML 
stem/progenitor cell population. Therefore, forcing these cells out of dormancy is required to 
eliminate them. Stimulating quiescent LSCs to enter the cell-cycle with granulocyte colony 
stimulating factor (G-CSF) reduces the overall non-cycling cell population in-vitro but, in 
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clinical practice, does not impact on disease outcome.184 Recently the farnesyl transferase 
inhibitor BMS-214662 was found to kill quiescent CML progenitors and blast crisis CML cells 
in-vitro and its effect was enhanced when combined with either Imatinib or Dasatinib, making 
it a promising agent for clinical development.185 Moreover, BCR-ABL specifically inhibits 
CXCR4, the receptor for SDF1, a chemokine produced by stromal cells that mediates the 
homing of CD34+ progenitor cells to the bone marrow microenvironment.186 Interestingly, 
Imatinib has recently been found to restore CXCR4 expression, which promotes the 
migration of CML cells to the BM.187 CML cells homing is associated with G0-G1 cell-cycle 
arrest, inhibition of their proliferation, and enhanced survival in a quiescent state under TKIs 
treatment. Therefore, pharmacological inhibition of CXCR4 is expected to reverse this 
mechanism of primary resistance, a concept already demonstrated with the CXCR4 
antagonist Plerixafor (also known as AMD3100).188 Thus, combining inhibitors of CXCR4 and 
TKIs may represent a potential opportunity for future CML care.	  
2. Soluble factors 
 
In a recent study, the authors prepared conditioned media from different human BM 
stromal cell lines, and then cultured CML cells in these media in presence or absence of 
TKIs. For some conditioned media but not for all, they observed an enhanced resistance of 
CML cell lines under TKIs treatment. They then determined the cytokines specifically 
produced in conditioned media favoring resistance, and identified several molecules 
signaling through JAK2/STATS pathway (G-CSF, GM-CSF, and IL-6).189 Others molecules 
produced in the BM microenvironment have also been identified for their role in CML cells 
resistance to TKIs, such as Fibroblast growth factor 2 (FGF2). Indeed, it has been 
demonstrated that FGF2 signaling through FGF receptor 3/RAS/c-RAF/mitogen-activated 
protein kinase pathway induced K562 cell line growth in both short- and long-term assays 
under Imatinib treatment. Resistance could be overcome with Ponatinib, a TKI inhibitor that 
targets both BCR-ABL and FGF receptor.190 Clinically, resistant CML patients without kinase 
domain mutations who responded to Ponatinib treatment displayed increased FGF2 levels in 
their bone marrow. Moreover, FGF2 levels in the bone marrow of CML patients decreased 
during Ponatinib response, further suggesting that FGF2-mediated resistance is interrupted 
by FGF receptor inhibition.190 
3. Cell adhesion-mediated drug resistance 
 
Although CML is characterized by a vast expansion of the malignant cell population 
that leave the BM microenvironment prematurely, some leukemic cells maintain their 
adhesion potential and can still be found within the BM. The BM microenvironment has been 
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demonstrated to efficiently protect leukemic cells against apoptosis induced by TKIs, 
cytotoxic drugs and gamma-irradiation. Indeed, CML cells in contact with stromal cells or 
extracellular matrix components such as fibronectin may acquire resistance to TKIs by a 
process known as cell adhesion-mediated drug resistance (CAM-DR).191 Indeed, adhesion 
mediated by α5β1 integrin has been demonstrated to induce an increased drug resistance in 
CML cells, by inducing the degradation of the pro-apoptotic BCL-2 family member protein 
Bim.192 However, the exact mechanisms involved are still not clearly identified, but may also 
involve other mechanisms such as cell-cycle arrest. Moreover, another study demonstrated 
that antibody-mediated targeting of the CD44 adhesion receptor could prevent trafficking of 
CML LSCs to the BM, decrease engraftment in immunodeficient mice and promote LSC 
differentiation.193 These results are particularly interesting, as CD44 has been described as a 
CSC marker in different types of cancer, such as ovarian cancer, breast cancer or AML, and 
because of the development of very promising drugs targeting this receptor.194 Due to the 
central role of cell interactions in HSCs and LSCs control by their microenvironment, more 
and more studies use co-culture systems to reproduce these interactions and to identify the 
functional consequences in-vitro. In a recent study, CML leukemic stem (CD34+, CD38-) and 
progenitor (CD34+, CD38+) cells co-cultured with human BM mesenchymal stromal cells, 
leading to a significant inhibition of CML cells apoptosis following TKIs exposure.195 This was 
associated with the maintenance of colony-forming ability and engraftment potential in 
immunodeficient mice. Using transwell assays, they demonstrated that contact between the 
two cell populations was required to protect CML LSCs during TKI treatment. Further 
analysis then revealed the role of N-cadherin receptor activation of Wnt-mediated β-catenin 
signaling in MSC-mediated protection of CML progenitors from TKI.195 
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Despite the success of targeted therapies against BCR-ABL with the 
development of TKIs, a residual disease is still detected in many CML patients, 
probably due to the persistence in-vivo of CML LSCs. In some cases, resistance to 
TKIs treatment appears, involving different mechanisms with 30% of unknown origin 
that could be attributed to LSCs survival. LSCs are controlled by a variety of 
biochemical and biomechanical signals from the leukemic niche. Thus, deregulation of 
these signals could contribute to LSC emergence and resistance. In this context, co-
culture systems have demonstrated that physical interactions (such as adhesion) 
between CML LSCs and their bone marrow stroma are involved in TKI resistance. 
Interestingly, cell adhesion is crucial for mechanical signals transduction. Moreover, 
recent studies also evidenced the key role of mechanical signals in the control of stem 
cell fate as well as in cancer processes. As such, mechanical signals provided by the 
bone marrow microenvironment could also be involved in the control of LSCs fate and 
resistance to TKIs treatment. 
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Chapter 3 : cell mechanics 
 
I. Cell structure and stiffness 
 
1. Introduction  
 
Cell stiffness is given by their ability to resist to mechanical deformation. Cell intrinsic 
mechanical properties mainly rely on the organization and polymerization of filamentous 
proteins from the cytoskeleton. The cytoskeleton is composed of three distinct filament 
systems: microtubules, actin microfilaments, and intermediate filaments that are involved in 
the control of cell architecture, shape and stiffness. Microtubules and actin microfilaments 
are built from homogeneous globular proteins, called tubulin and actin, respectively, and 
serve as tracks for molecular motors. In contrast, intermediate filaments are made of diverse 
fibrous proteins. These three cytoskeletal filament systems are in constant link with each 
other through a group of proteins called cytolinkers.196 Indeed, the disruption of intermediate 
filaments network organization can also disturb the spatial organization of microtubules or 
actin microfilaments.197 
 Interestingly, a recent study compared the contribution of each of these cytoskeletal 
components on chondrocytes mechanical properties.198 Before mechanical testing, 
cytochalasin D, acrylamide, or colchicine were used to disrupt actin microfilaments, 
intermediate filaments, or microtubules, respectively. Cells were subjected to a range of 
compressive strains and allowed to recover to equilibrium. Inhibition of actin microfilaments 
had the greatest effect on bulk compressive stiffness while intermediate filaments and 
microtubules were each found to play an integral role in either the diminution 
(compressibility) or retention (incompressibility) of original cell volume during compression.198 
2. Actin filaments 
 
Actin cytoskeleton is a network of filaments of 6 nm in diameter that are important for 
anchoring plasma membrane proteins, for producing cell movement and for cell division.  
Inside cells, actin exists in two states, the monomeric protein, called G-actin for globular actin 
and the 6 nm filament, called F-actin for filamentous actin.199 Thus, to understand the 
structure, dynamics and mechanical properties of actin networks in cells, one must consider 
the process by which F-actin is formed from G-actin and how it is regulated. Nucleation of F-
actin polymerization requires the formation of an actin trimer from G-actin monomers bound 
with an energy-storing ATP nucleotide. This results in a nucleation rate that is slow due to 
the cubic dependence on actin concentration and also the required presence of ATP. The 
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cell can therefore regulate actin polymerization by varying the availability of actin, ATP or 
through the use of monomer-binding proteins that promote (profilin)200 or inhibit (thymosin)201 
monomer binding to filaments or the ATP-ADP exchange. Actin filaments are in highest 
concentration near the surface of cells, in the actin cortex, where they often exist as short 
filaments of a few hundred nanometers, forming an isotropic cross-linked mesh. The F-actin 
cortex is largely responsible for controlling cell shape and dynamic surface motility and is 
also believed to play an important role in anchoring membrane proteins.202 Longer 
microfilaments can also be organized into highly cross-linked bundles, called stress fibers, 
which serve as contractile elements within cells. In addition, these structures may be 
important for producing contractility to generate directional force during cell motility. Actin 
stress fibers can attain up to 10 µm and are part of the contractile apparatus in muscle cells 
and in non-muscle adherent cells. The formation of a third microfilament-based structure, the 
contractile ring, is critical for the separation of a cell into its two progenies during cytokinesis. 
These cytoskeletal structures are important to maintain connections between the cells 
and their microenvironment, that is to say the surface on which they grow. In adherent cells, 
the extremities of actin filaments aggregate at specific locations on the plasma membrane, 
known as focal adhesions that link the cytoskeleton to the ECM via integrin receptors.203–205 
Thus, integrins located at the membrane form the link between ECM proteins such as 
fibronectin and intracellular actin cytoskeleton. On the intracellular side, many actin-binding 
proteins are involved in the integrin-actin connection such as talin, vinculin, α-actinin or 
filamin.206 Other membrane-associated signaling molecules such as focal adhesion kinase, 
paxillin or src-kinase then regulate these proteins. Actin-membrane association is critical for 
mechanical integrity at the cell surface as well as for the coupling of external forces into the 
cell. Actin-binding proteins are capable to control F-actin cytoskeleton network, and 
consequently cell stiffness.207 For example, bundling is achieved by parallel filament cross-
linking by molecules such as fimbrin or α-actinin.208,209 Meshes are formed by cross-linking at 
right angles (filamin) or branching (Arp2/3 complex, cortactin).210 These differences in 
cytoskeletal structure can in turn translate into local effects on cell stiffness. Indeed, a recent 
study combining interference RNA (RNAi) to atomic force microcopy (AFM) in endothelial 
cells demonstrated that loss of cortactin or α-actinin-4 expression significantly decreased 
endothelial cell peripheral stiffness.207 These results were also correlated by alterations of F-
actin organization. 
Moreover, F-actin usually associates with myosin, a molecular motor that converts 
chemical energy to mechanical energy though ATP hydrolysis, thus generating force and 
movement.211 The myosin motor protein is considered the key effector in many cellular 
processes including cell division, muscle contraction or cell movement, thus playing a central 
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role in cell biology. The small myosin-I isoform can be anchored to a membrane or lipid 
vesicle and is therefore critical for trafficking of membrane proteins. The myosin-II isoform is 
larger and often self-assembles into thick filaments aligned parallel to long actin filaments, 
with many sites of interaction between the myosin heads and the actin filaments. These 
types of actomyosin interactions are termed cross-bridges, whose dynamic cycling is 
responsible for large force production and shortening of contractile fibers. It is well known 
from the literature that cell stiffness is determined in large part by the actin cytoskeleton.212–
215 Indeed, disruption of F-actin cytoskeleton with cytochalasin D or latrunculin B has been 
demonstrated to induce cell softening in different models.216 
3. Microtubules 
 
Microtubules are long, hollow cylindrical filaments, approximately 25 nm in diameter, 
and are responsible for large-scale cellular properties, such as organelle organization, 
stabilization of mechanical structures, force transmission across the cytoplasm, and 
processes like cell division.217 They are the major constituents of mitotic spindles, which are 
involved in chromosome separation during mitosis and meiosis. Microtubules are formed 
from the polymerization of two globular proteins, alpha and beta tubulin. Their polymerization 
depends on the concentration of αβ-tubulin dimers and guanosine triphosphate (GTP) in 
solution. Tubulin dimers can bind two molecules of GTP, one of which can be hydrolyzed 
subsequent to assembly. During polymerization, the tubulin dimers are in the GTP-bound 
state. The GTP bound to α-tubulin is stable and it plays a structural function in this bound 
state. However, the GTP bound to β-tubulin may be hydrolyzed to guanosine diphosphate 
(GDP) shortly after assembly. The assembly properties of GDP-tubulin are different from 
those of GTP-tubulin, as GDP-tubulin is more prone to depolymerization. Microtubules are 
nucleated and organized by microtubule organizing centers (MTOCs), such as the 
centrosome found in the center of many animal cells. Contained within the MTOC is another 
type of tubulin, γ-tubulin, which combines with several other associated proteins to act as a 
template for α/β-tubulin dimers to begin polymerization.217 Especially in axons and dendrites 
of neurons, microtubule associated proteins (MAPs) bind along the length of microtubules 
and stabilize them.197 Important differences in the specific molecular interactions give rise to 
distinct kinetic and mechanical properties of microtubules. The motor proteins kinesin and 
dynein bind to microtubules and move in opposite directions. Because microtubules can 
span the entire length of a cell, kinesin and dynein are critically important in large-scale 
trafficking of proteins or vesicles along microtubules.218 
Interestingly, differences in microtubules polymerization can affect local cell stiffness, 
as demonstrated in a recent study using carbon fiber-based systems to analyze the 
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mechanical properties of single cardiomyocytes.219 The impact of microtubule organization 
was assessed by treating the cells with colchicine, a microtubule-depolymerizing agent, or 
with paclitaxel, a microtubule-polymerizing agent. It was found that stiffness depends on 
microtubule polymerization.219,220 A simulation model of the myocyte in which microtubules 
serve as compression-resistant elements further confirmed the experimental results. 
Microtubules are involved in various pathological conditions of the heart including 
hypertrophy and congestive heart failure. Thus, these results suggests that changes in 
cardiomyocytes’ mechanical properties may have a significant influence on the diseased 
heart that is subject to complex strain fields in the body.219 Finally, taxol, a drug that 
facilitates microtubule polymerization, increased endothelial cell stiffness by 10%.221 
4. Intermediate filaments 
 
Contrarily to microtubules and actin microfilaments, intermediate filaments are apolar 
and are made of diverse fibrous proteins. Indeed, intermediate filaments share a common 
domain organization but have distinct primary sequences as over 70 human genes encode 
them. Intermediate filaments are divided into six major classes on the basis of similarities in 
sequence.222 They are differentially expressed during development and exhibit cell and tissue 
specificity. For example, while epithelial cells express diverse keratins, mesenchymal, 
endothelial, and hematopoietic cells express vimentin, muscle cells express desmin and 
neuronal cells express neurofilaments.222 Intermediate filaments are composed of 
polypeptide rods, arranged in rope-like fibers that are about 10 nm in diameter. They are 
known to resist rupture under large force. Indeed, a network of intermediate filaments is often 
found as a laminating layer adjacent to cellular membranes, where it provides mechanical 
support. They are concentrated around cell-cell junctions, but are also found in other parts of 
the cell including the nucleus. 
The nuclear lamina is a structure located along the inner nuclear membrane and the 
peripheral chromatin. This supporting network is composed of lamin A and lamin C filaments 
cross-linked into an orthogonal lattice, which is attached via lamin B to the inner nuclear 
membrane through interactions with a lamin B receptor.222 Lamins are involved in the 
regulation of most nuclear activities including DNA replication, RNA transcription, nuclear 
and chromatin organization, cell cycle regulation, cell development and differentiation and 
apoptosis.223,224 
Specialized cell junctions called desmosomes and hemi-desmosomes hold epithelial 
cells of organs and skin together. Desmosomes mediate cell-cell adhesion,217 and hemi-
desmosomes are responsible for attaching cells to the underlying basement membrane.225 
The intermediate filaments in one cell are thus directly connected to the intermediate 
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filaments in a neighboring cell via desmosomes or to the ECM via hemi-desmosomes. As a 
result of the connections between intermediate filaments and these cell junctions, shearing 
forces are distributed from one region of a cell layer to the entire sheet of epithelial cells, 
providing strength and visco-elasticity to the entire epithelium. Intermediate filament-
associated proteins (IFAPs) cross-link intermediate filaments with each another, forming a 
bundle called tonofilament or a network, and also with other cell structures including the 
plasma membrane.226 
 In epidermal cells, bundles of keratin, an intermediate filament, are cross-linked and 
anchored to desmosomes.208 The structural integrity of keratin network has been 
demonstrated to be essential in order for the skin layer to withstand abrasion. Indeed, 
expression of mutant keratin proteins in cells causes intermediate filament networks to 
breakdown into aggregates.227 Without their normal bundles of keratin filaments, mutant 
basal cells become fragile and easily damaged, causing the overlying epidermal layers to 
delaminate and blister. In mice, this leads to the appearance of gross skin abnormalities that 
resemble the human skin disease epidermolysis bullosa simplex.227 Death of these cells 
appears to be caused by mechanical trauma from rubbing of the skin during movement of the 
limbs. Just like the role of desmin filaments in supporting muscle tissue, keratin filaments 
play a crucial role in maintaining the structural integrity of tissues by mechanically reinforcing 
the connections between cells.228 
5. Membrane lipid composition 
 
 While cytoskeleton molecules have been identified as key elements in the regulation 
of cell structure and stiffness, other cellular component may also be involves in these 
processes. This is the case for example for lipid membranes. The lipid bilayer is a thin polar 
membrane made of two layers of lipid molecules with proteins embedded in it.229 These 
membranes are flat sheets that form a continuous barrier surrounding all cells as well as their 
nucleus and other sub-cellular structures. Biological membranes typically include several 
types of lipids other than phospholipids. A particularly important example in animal cells is 
cholesterol, which helps strengthen the bilayer and decrease its permeability.230 Indeed, a 
recent study investigated the effect of cellular cholesterol on membrane deformability of 
bovine aortic endothelial cells.231 Cellular cholesterol content was depleted by exposing cells 
to methyl-beta-cyclodextrin or enriched by exposing cells to methyl-beta-cyclodextrin 
saturated with cholesterol. Mechanical properties of the cells with different cholesterol 
contents were then compared by micropipette aspiration. Cholesterol depletion of bovine 
aortic endothelial cells resulted in a significant decrease in membrane deformability 
indicating that cholesterol-depleted cells are stiffer compared to control cells.231 Repleting the 
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cells with cholesterol reversed the effect. While cholesterol concentrations had no apparent 
effect on F-actin content, disrupting F-actin with latrunculin A abrogated the stiffening 
effect.231 Thus, this suggests that cholesterol depletion increases the stiffness of the 
membrane by altering the properties of the submembrane F-actin and/or its attachment to 
the membrane. 
6. Plasma membrane potential 
 
 Although the lipid membrane can control cell stiffness by interactions with underlying 
actin cortex, it is also involved in molecules trafficking inside and outside the cells. Indeed, 
ion pumps and ion channels embedded in the membrane regulate ions concentrations, thus 
controlling electric potential.232 Plasma membrane potential is the difference in electric 
potential between the interior and the exterior of a cell. Interestingly, it was recently 
demonstrated that the electrical plasma membrane potential difference is involved in the 
control of endothelial cell stiffness.233 Using a novel technique that combines fluorescence-
based membrane potential recordings with atomic force microscopy based stiffness analysis, 
it was shown that membrane depolarization is associated with a decrease in the stiffness of 
endothelial cells. Moreover, experiments using actin-destabilizing agent cytochalasin D 
indicated that change of the electrical field across the plasma membrane acts by affecting 
cortical actin polymerization/depolymerization ratio and thus cell stiffness.233 The stiffness of 
vascular endothelial cells is crucial to mechanically withstand blood flow and, at the same 
time, to control deformation-dependent nitric oxide release.234,235 This depolarization-induced 
decrease in the stiffness of endothelial cells could play a role in flow-mediated nitric-oxide-
dependent vasodilation, thus also impacting tissue stiffness.236,237 
7. Impact of ECM on cell structure and stiffness 
 
 Cells are located in a microenvironment containing other cells, but also ECM 
elements. The ECM also contains key growth factors, such as angiogenic factors and 
chemokines that interact with cell surface receptors and give each tissue its tensile and 
compressive strength and elasticity.238 Cellular interactions with ECM are mainly mediated by 
focal adhesions,239 large and dynamic protein assemblies that connects ECM to the cell 
cytoskeleton, involved in the regulation of nearly every major cellular behavior, including 
growth, division, survival and movement.240 Indeed, cells can sense not only the composition 
of the surrounding ECM, but also its topography, rigidity, and anisotropy.241 Moreover, cells 
dynamically react to changes in applied force or tension generated by, or in response to 
ECM dynamics. Cells respond to extrinsic forces from the ECM by modifying their behavior, 
remodeling the ECM itself,242 and exerting counter-tension through actomyosin-dependent 
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contractility.203 In normal cells, this “mechano-reciprocity” is in controlled equilibrium and is 
important for tissue homeostasis. This concept implies that changes in microenvironment 
stiffness will affect cell stiffness and vice-versa, potentially affecting cell behavior. 
II. Mechanical forces 
 
Cells within tissues are continuously exposed to physical forces that participate in the 
control of their shape and fate. Depending on tissue type, physiological or pathological 
conditions, distinct forces will be exerted on cells by their environment (Figure 16). These 
forces are characterized by their magnitude, orientation, frequency and duration.243–246 
Shear forces are induced by fluid flow over cell surfaces in blood vessels and cavities 
or by forces acting within tissues and act in parallel to the plasma membrane.247 They are the 
main forces exerted in vascular system where the blood flow induces shear stress on 
endothelial cells, but are also prominent in bone marrow, as fluid flow exerts shear stress on 
stromal cells and adherent hematopoietic cells. Tensile forces can be generated by the 
internal tension of cell cytoskeleton, in link with ECM stretching or contraction of surrounding 
cell layers.248 Compressive forces act contrariwise to tensile forces and can be generated by 
cell hypertrophy or cellular proliferation.249 They are mainly observed in response to cell 
expansion during embryonic and tumor processes. Hydrostatic pressure results from gravity 
acting on fluid filled cavities and pores and from extrinsic forces acting inside and onto the 
surrounding tissue resulting from muscle contraction or body weight.250 Similar to shear 
forces, hydrostatic pressure is very prominent in the vascular system. Finally, tissue stiffness 
will be determined by the tissue composition (cell types, ECM proteins), the degree of ECM 
cross-linking as well as the contractility of surrounding cells. Tissue stiffness is a mechanical 
signal that requires reciprocal force sensation by active cell body contraction. In-vivo, cells 
persist in a tensegrity-based force balance with their surroundings, which also determines 
their stiffness.251 The nature of these forces can change in pathologies such as 
cardiovascular disease and cancer. 
Because mechanical signals can influence cell structure and fate, this means that 
cells are able to sense mechanical signals and to translate them into biochemical signals 
involved in their regulation. As a result of research efforts from a variety of disciplines, we are 
beginning to understand the molecular basis of mechano-transduction process. 
 
 
 
? ??
 
Figure 16 : Mechanical forces that act on the cellular level in-vivo. Collective cell-cell 
and cell-matrix interactions allow the propagation of mechanical forces within tissues. 
Extrinsic influences like fluid flow, hydrostatic pressure and substrate deformation lead to 
additional forces acting on the cells and result in cell straining. Tensile and compressive 
forces are generated by intrinsic cell-cell interactions in a tissue collective. Mechanical 
triggers are perceived on the cellular level by different subcellular structures, such as cell-cell 
adhesion, cell-matrix adhesion complexes, and different cytoskeletal and nucleoskeletal 
structures. Adapted from Kopf et al, 2013. 
 
III. Mechanical signals transduction 
 
 The conversion of mechanical signals into biochemical cellular responses is termed 
mechano-transduction. While we are just beginning to understand how these mechanical 
signals are sensed and transduced into biochemical informations by cells, several mechano-
transduction mechanisms have already been identified. The primary mechano-sensor initially 
responsible for the biochemical translation of mechanical forces also remains uncertain. 
1. Integrin-mediated signaling 
 
 As the main receptors that connect the cytoskeleton to the ECM, integrins mediate 
cellular adhesion to the growth substrate and have been described as major cellular 
components to mediate force detection at the plasma membrane and to trigger pleiotropic 
mechano-transduction pathways.252 Integrins convey mechanical forces from ECM to the 
cytoskeleton, thus controlling many different signaling pathways. Thus, it has been 
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suggested that integrin-dependent molecular signaling is a key signaling platform for cellular 
responses to various forms of mechanical stress, including cell adhesion.252 Indeed, many of 
the signals triggered by physical forces are consistent with known effects on focal adhesions 
such as increased integrin clustering and focal adhesion kinase (FAK) phosphorylation, that 
can in turn control several downstream pathways like ERK or JNK signaling.205 
2. Stretch Activated Channels (SACs) 
 
Mechano-sensitive ion channels that become more permeable to soluble ions in 
response to mechanical signals are supposed to function through a protein ‘gate’ which is 
physically separated under force.253 For example, TRP calcium ion channels were identified 
for their ability to permit transient calcium influx in stretched cells.254 It has been shown that 
cells cultured on substrates with different stiffness exhibit changes in the amplitude of 
calcium ion oscillations, demonstrating that SAC permeability is related to active sensing of 
the cell physical microenvironment.232 Furthermore, cells plated on substrates with a stiffness 
gradient showed even stronger calcium ion oscillations. While changes in calcium ion 
concentration can affect a number of signaling pathways, other mechano-sensitive channels, 
such as the TRAAK potassium ion channels, are also activated upon mechanical stress-
induced membrane deformations.255 
3. Force-induced protein unfolding 
 
Force-inducible proteins are capable of unfolding under applied force, exposing 
binding domains for other proteins and signaling molecules. For example, talin, a focal 
adhesion protein that binds to integrins and actin, has been shown to unfold under stretching 
forces as low as 12 pN and expose up to 11 binding domains for vinculin, another focal 
adhesion protein.256 Furthermore, the focal adhesion protein p130Cas, which binds to FAK 
and associates with talin, has been shown to unfold under applied force to activate the 
Crk/C3G-Rap1 signaling cascade resulting in activation of MAPK pathway.257 Another 
protein, receptor-like tyrosine phosphatase alpha (RPTPα) has been shown to associate with 
α integrins, catalyzing binding to fibronectin and vitronectin in a force-dependent manner via 
the Src family kinase cascade.204 Thus, a connection can be made between force-dependent 
unfolding of focal adhesion proteins and signaling cascades that may ultimately affect gene 
expression. 
4. Control of ligand bioavailability 
 
Cell regulation does not only occur via secreted molecules, but also through ligand 
presentation by the ECM. For example, both TGF-β and BMP ligands can bind to ECM 
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proteins.258–261 Depending on the ECM composition, the degree of crosslinking as well as the 
deformation in response to force, bioactivity and bioavailability of soluble ligands may be 
altered. Such mechanism has been already identified for TGF-β ligands.262–264 Following 
secretion, TGF-β binds to latent TGF-β binding proteins (LTBPs) via its pro-peptide.262 Then, 
LTBPs anchor TGF-β to the ECM leading to the repression of TGF-β bioactivity.262 However, 
in response to mechanical signals, integrin-dependent unfolding of this complex leads to a 
release of active TGF-β ligands.265,266 A related mechanism, involving ECM molecules in the 
regulation of ligand bioavailability, might also apply for BMP ligands, but experimental studies 
have yet to be been performed. Furthermore, both TGF-β and BMPs themselves regulate SC 
fate267 and thereby the composition and mechanical properties of the ECM.268,269 
Consequently, this represents a reciprocal interplay between BMP signaling, ECM production 
and mechano-transduction. 
5. Mechano-sensitive genes control 
 
Finally, mechano-sensing can be directly coupled to the nuclear envelope and thus to 
transcriptional regulation. The cytoskeleton is anchored to the nucleus via linker of 
nucleoskeleton and cytoskeleton (LINC) complexes, which contain nesprins, sun, and lamin 
proteins.270 LINC complexes form an integral part of the nuclear envelope and are connected 
to networks and filaments in the nucleus. Although mechanistically still unclear, force 
transmission through cytoskeletal structures in the cytosol and via LINC complexes regulate 
chromatin dynamics and may therefore act as mechano-transducer upon cellular 
deformation.271 In addition, mechanical stretch has been shown to regulate the expression 
and localization of chromatin remodeling enzymes called tension-induced proteins (TIPs). 
For example, it has been demonstrated that mechanical stress is sufficient to trigger 
TIP1 expression and nuclear localization in embryonic mesenchymal SCs, thus regulating 
the expression of lineage-specific genes.272 While many different genes have been described 
to be controlled by mechanical signals, most of these genes identified so far appear to be 
linked with stemness properties, such as c-fos,273 c-jun,273 Twist-1274 or BMP-related 
genes.243 
IV. Stem cell fate control 
 
 To date, many genes associated with SC properties have been found to be controlled 
by mechanical signals. However, the role of intracellular tension275 and extracellular 
biophysical factors276 has only recently been acknowledged as critical determinant of cell 
biology and SC fate.277 
Interestingly, it has been demonstrated that cell substrate stiffness is able to control 
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mesenchymal SC differentiation toward specific lineages.278 Indeed, when these cells were 
cultured on moderately stiff matrices (11 kPa, muscle-like stiffness), they engaged toward 
myogenic lineage, while culture on stiffer matrices (34 kPa, bone-like stiffness) led to their 
engagement toward osteoblastic lineage (Figure 17). Thus, these results indicate that SC 
engagement into a specific lineage depends on the presence of a matrix reproducing the 
original tissue’s stiffness. Finally, as inhibition of myosin II led to the inhibition of all elasticity-
directed lineage specification, this suggests a crucial role for actin-myosin cytoskeleton in the 
control of SC fate through transduction of mechanical signals.275,278 Since then, numerous 
studies have confirmed the role of mechanical signals in SC differentiation. 
In addition, mechanical stress has also been demonstrated to induce human 
embryonic SC self-renewal while inhibiting their differentiation.279 It was further demonstrated 
that mechanical signals must act synergistically with biochemical signals to influence SC 
fate. Interestingly, culture of human embryonic SC on soft substrates also led to an increase 
of their self-renewal potential by maintaining high levels of Oct3/4, Nanog and Alkaline 
Phosphatase (AP) activities. 
In another study, polyacrylamide gels with different stiffness were used to culture 
human mesenchymal SC. Using this strategy, it was demonstrated that mesenchymal SC 
remained quiescent when cultured on soft substrates but retained their proliferation and 
differentiation capabilities.280 
Finally, mechanical signals can also promote SC proliferation. This was particularly 
well illustrated in an in-vivo study were low magnitude mechanical signals (LMMS) were 
applied on C57BL/6J mice with a vertically oscillating platform.281 In this study, six weeks of 
LMMS increased the overall BM stem cell population by 37% and the number of 
mesenchymal SCs by 46%. Concomitant with the increase in SC number, the differentiation 
potential of mesenchymal SCs was biased toward osteoblastic and against adipogenic 
differentiation, as reflected by up-regulation of the transcription factor Runx2 and down-
regulation of PPARγ.281 
 
? ??
 
Figure 17 : Mechanical signals control stem cell fate. The control of stem cell fate by 
mechanical signals has been particularly well demonstrated in mesenchymal stem cells 
(MSC), thanks to the research performed to understand arthritis appearance, phenomenon 
thought to be linked to mechanical signals. Mesenchymal stem cells were cultured on 
substrates with different stiffness, leading to engagement into different cell lineages. 
 
Although the crucial role for cell mechanics in SC control has been observed, the 
potential role of mechanical signals in the control of CSC fate has yet to be determined. 
Moreover, recent studies evidenced alterations of cancer cell intrinsic mechanical properties, 
which could potentially be associated with alterations of cancer cell response to external 
mechanical signals. 
V. Cell stiffness and cancer 
 
1. Probing cell mechanical properties 
 
With the recent advances in biomechanics and nanotechnology, it has now become 
possible to probe single living cell stiffness. For example, biophysical tools such as atomic 
force microscopy,282 micropipette aspiration or optical stretcher have been used to probe cell 
mechanics.283 Young's modulus or elastic modulus (E) has been extensively used to 
measure cell mechanical properties.284 Young's modulus describes tensile elasticity, that is 
the tendency of an object to deform along an axis when opposing forces are applied along 
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that axis. It is defined as the ratio of tensile stress to tensile strain (E = tensile stress / tensile 
strain). A material is said to be elastic if it deforms under stress and returns to its original 
shape when the stress is removed. The relationship between stress and strain (force and 
deformation) is linear and the deformation energy is returned completely. A stiffer material 
will display a higher elastic modulus. However, cell response to external force may also 
contain a viscous component. Viscoelasticity is the property of materials that exhibit both 
viscous and elastic characteristics when undergoing deformation. Viscosity is a measure of 
the resistance of a fluid to being deformed by either shear stress or extensional stress. The 
relationship between stress and strain is non-linear for viscoelastic material and the 
deformation energy is not returned completely. Shear modulus or modulus of rigidity (G) is 
the elastic modulus we use for the deformation which takes place when a force is applied 
parallel to one face of the object while the opposite face is held fixed by another equal force. 
It is defined as the ratio of shear stress to shear strain (G = shear stress / shear strain). The 
shear modulus is part of the derivation of viscosity and is also used to measure cell 
mechanical properties.285 The bigger the shear modulus the more rigid is the material since 
for the same change in horizontal distance (strain) you will need a bigger force (stress). 
2. Alteration of cancer cell stiffness 
 
Tumor process is usually characterized by a palpable stiffening of the tissue. 
However, little is known about the effects of cell transformation and compaction on single cell 
stiffness. Over the past decade, there has been growing evidence indicating that the 
mechanical properties of cancer cells are altered. Many studies suggests that the increased 
deformability of cancer cells, due to an altered F-actin cytoskeleton could be involved in their 
migration and invasion capabilities. 
In 2007, a comparative stiffness analysis of live metastatic cancer cells obtained from 
the body pleural fluids was performed in patients with lung, breast and pancreas cancer by 
atomic force microscopy (AFM).286 Within the same samples, it was found that metastatic 
cancer cells were more than 70% softer compared to benign cells that line the body cavity. 
This work shows that mechanical analysis can distinguish cancerous cells from normal ones 
even when they display similar shapes. These results indicate that nanomechanical analysis 
correlates well with immunohistochemical testing currently used for the detection of cancer. 
Consistent with this study, the same group then demonstrated that metastatic tumor cells are 
more than 80% softer than benign cells using a cytocentrifugation method that yields 
morphologically indistinguishable cells.287 Thus, this suggests that it is unlikely that 
morphology alone is sufficient to explain the differences observed between healthy and 
metastatic cancer cells. In addition, another study also demonstrated that metastatic ovarian 
cancer cells are softer than non-metastatic ones.288 Moreover, it has been observed that PC3 
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prostate cancer cells are softer compared to non-tumorigenic PNT2 prostate cells.289 In 
another AFM study, the mechanical properties of two mammary epithelial cell lines were 
compared. It was demonstrated that tumoral MCF-7 cells are softer compared to benign 
MCF-10A cells.283 These cell stiffness alterations were correlated with differences of F-actin 
polymerization, and were also confirmed in another study using a microfluidic optical 
stretcher.290 However, these results cannot be generalized for breast cancer cell stiffness as 
no other cell lines were tested. Moreover, these two cell lines are not very informative as 
MCF-10A cells were obtained from a patient with fibrocystic disease and MCF-7 were 
derived from a metastatic pleural effusion site. Nevertheless, these results were confirmed in 
other studies comparing the deformability of MCF-10A, MCF-7 and MDA-MB-231 breast 
cancer cell lines by optical stretching, further demonstrating that cell stiffness decreased with 
acquisition of metastatic competence.291,292 Finally, a magnetic tweezer study demonstrated 
that ovarian cancer cells with the highest migratory and invasive potential are five times 
softer than cells with lower invasion potential.293 It was further shown that decreasing cell 
stiffness by pharmacologic inhibition of myosin II increased invasiveness, whereas increasing 
cell stiffness by restoring expression of the metastasis suppressor TβRIII/betaglycan 
decreased invasiveness. These findings are the first demonstration of the relation between 
the stiffness and the invasiveness of cancer cells and show that mechanical phenotypes can 
be used to grade the metastatic potential of tumor cell populations.293 
While the aforementioned studies demonstrated that cancer cells are softer than 
healthy ones, they restricted their analysis to metastatic cells, often highly structurally 
rearranged. Thus, we cannot conclude for generalized decreased cell stiffness in cancer, 
except for advanced metastatic processes. However, one of the first studies analyzing the 
mechanical properties of tumor cells demonstrated a decreased stiffness in cancer bladder 
cells compared to normal counterparts by scanning force microscopy.294 Another interesting 
study recently demonstrated that transfection of healthy rat intestinal epithelial IEC-18 cells 
with c-K-ras oncogene was sufficient to decrease their stiffness.295 An increase in cell 
stiffness heterogeneity was also observed. 
Moreover, opposite differences were also observed. Indeed, in a recent study, a 
microfluidic device was used to electrically measure volume and transit time of single 
lymphocytes obtained from healthy donors and CLL patients.296 By testing thousands of cells, 
it has been demonstrated that CLL lymphocytes are stiffer as compared to healthy ones, 
which was also confirmed by AFM indentation analysis. This observation is in sharp contrast 
with precedent studies performed on adherent metastatic cells. However, the underlying 
molecular mechanism involved in alteration of cell stiffness has not been identified. While 
difference in F-actin density was often thought to be responsible for deformability differences, 
no connection was found between actin level and cell deformability in human CLL cells. 
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Since cell nuclei are known to be significantly stiffer compared to cytoplasm and cell 
membrane,297 the enlarged nuclei observed in CLL cells could contribute to the longer transit 
time observed in microfluidic channels.296 One of the vascular complications observed in 
acute leukemia is leukostasis that occurs when leukemic cells accumulate in the 
microvasculature and damage vital organs. Previous work has shown that leukemic blasts 
are stiffer than their more mature counterparts and have suggested that cell deformability 
may play a significant role in leukostasis.298 Interestingly, a recent study demonstrated that 
increased leukemic cell stiffness is associated with symptoms of leukostasis in pediatric 
ALL.299 
Furthermore, another study also reported the impact of chemotherapy on leukemic 
cell mechanical properties. After exposure to dexamethasone or daunorubicin, ALL and AML 
cells’ stiffness was analysed using AFM or microfluidic channels.300 The results 
demonstrated that chemotherapy exposure increases leukemic cell stiffness. However, even 
if this stiffness increase was observed before cell death, apoptosis has been involved in 
alterations of cell stiffness but induced opposite results depending on the cell type 
studied.300,301 Thus, it would be interesting to check if cells that do not die upon 
chemotherapy also display an increased stiffness in response to chemotherapy, to ensure 
that this is not an artefact related to cell death. As deformability of blood cells is known to 
influence vascular flow and contribute to vascular complications, these observations suggest 
that chemotherapy itself may increase the risk of vascular complications in acute leukemia.300 
However, the opposite effect was observed after treatment of B-lymphoma cells with 
monoclonal antibody rituximab.302 In that case, the cells became dramatically softer after 
treatment. While the underlying mechanism has not been identified, the authors suggested a 
potential effect for CD20 in the remodeling of cell membrane and cytoskeleton after binding 
of rituximab.302 
Interestingly, differences in cell mechanical properties have been proposed as 
prognostic markers not only for metastatic potential but also for response to anti-tumoral 
treatment. Indeed, a recent study used AFM to compare the mechanical properties of 
circulating tumor cells from prostate cancer.303 It was demonstrated that castration-resistant 
prostate cancer cells were three times softer compared to castration-sensitive cells. This 
suggests that mechanical properties of metastatic cells may serve as novel and effective 
biomarkers to detect the presence of castration resistant prostate cancer. However, no clues 
were provided on the molecular basis of the differences observed. The potential of cell 
mechanics in prognosis was confirmed in ovarian cancer cells where sensitive cells showed 
dose-dependent increase in cell stiffness upon cisplatin treatment while no differences were 
observed for resistant cells.304 This effect was correlated with alterations of F-actin 
cytoskeleton. 
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Although the contribution of the cell mechanical properties in invasion processes is 
not completely clear, it was recently evidenced that greater elasticity of cancer cells helps 
them metastasize by squeezing through the body tissues and capillaries.305 Up to now, while 
alterations of cell mechanical properties were observed in different types of tumors, cancer 
cells were often found to be softer compared to healthy ones (Figure 18). Interestingly and at 
the opposite of solid tumors, leukemic cells tend to become stiffer compared to healthy ones, 
as observed in CLL and ALL processes. However, this needs to be confirmed in other 
hematologic malignancies. Moreover, the structural alterations responsible of cell stiffness 
alterations are often unknown, even if alterations of F-actin have often been observed.305 
 
 
Figure 18 : Alteration of cell mechanical properties in cancer. Table summarizing the 
alterations of cancer cells mechanical properties identified so far. The cells’ specificities, the 
techniques used, the impact on cell stiffness and the possible identified structural alterations 
are listed. A “minus” represents a decrease of cell stiffness in cancer cells, a “plus” an 
increase. 
 
Because of mechano-reciprocity between cells and their microenvironment, alteration 
of cancer cell stiffness could also impair microenvironment stiffness as well as the 
mechanical forces perceived by adherent neighbor cells (through cell-ECM or cell-cell 
interactions). In tumors, mechanical changes in the environment (compressive stress due to 
tumor growth or ECM alterations) are supposedly exploited by tumor cells to facilitate local 
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growth, invasion, and spread.241 Thus, cancer cell stiffness modifications could lead to an 
alteration of mechanical signals production and to an alteration of cancer cells response to 
mechanical signals. 
VI. Alteration of mechanical signaling in cancer 
 
Despite the crucial role of mechanical stress in physiological processes such as cell 
growth, differentiation, and apoptosis, it can also be involved in pathological processes. 
Alteration of external mechanical signals in tumors is often detected as a palpable ‘stiffening’ 
of the tissue. This observation appears in contrast with the decreased stiffness previously 
described in cultured cancer cells and biopsies from cancer patients.287 This paradox is 
associated with high remodeling and stiffening of the peripheral tumor stroma resulting from 
the accumulation of aberrant ECM deposition and organization.306–312 For example, breast 
tumorigenesis is accompanied by collagen cross-linking leading to ECM stiffening.308 This 
stiffening may be partially attributed to cancer-associated fibroblast (CAFs)313 secreting lysyl 
oxidase (LOX), an enzyme that cross-links collagen IV found in ECM. ECM stiffening forced 
integrin clustering, promoted focal adhesions, enhanced PI3K signaling, and increased tumor 
invasive properties.314 
 Interestingly, a recent study demonstrated that the expression of both Myc and Twist1 
oncogenes is increased in response to transient compression in APC deficient colon tissue 
explants, but not in wild-type colon explants.315 The mechanical activation of Myc and Twist1 
expression in APC deficient colon can be prevented by blocking β-catenin phosphorylation 
using Src kinase inhibitors. Microenvironmental signals are known to cooperate with genetic 
lesions to promote the nuclear β-catenin accumulation that drives colon cancer. These 
results suggest that mechanical stimulation produced during intestinal transit or tumor growth 
could be interpreted by cells of preneoplastic colon tissue as a signal to initiate a β-catenin 
dependent transcriptional program leading to cancer initiation.315 
In cancer processes, and particularly in solid tumors, compressive mechanical stress 
is produced during cell growth in a restricted matrix.249,316,317 This was demonstrated in a 
study where single cancer cells were co-embedded with fluorescent micro-beads in agarose 
gels. During spheroid growth, changes in micro-bead density allowed to detect an increase of 
mechanical stress during tumor growth. This was further correlated with a suppression of cell 
proliferation and induction of apoptotic cell death through the mitochondrial pathway in 
regions of high mechanical stress.317 Thus, mechanical stress increases in tumor context, 
and probably affects tumors growth by controlling cell functions. Interestingly, inhibition of 
spheroids growth under mechanical stress had already been observed, but was 
accompanied by a decrease of both cell proliferation and apoptosis.318,319 However, opposite 
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effects have been suggested in mice studies. High tumor interstitial fluid pressure (TIFP) is a 
characteristic of most solid tumors that generates mechanical forces affecting the tumor 
cortex.249 Solid epithelial tumors were grown in nude mice generating different ranges of 
TIFP. Strikingly, tumor drainage led to a rapid decline of TIFP, together with visible relaxation 
of the tumor cortex and a decrease of tumor cell proliferation. In addition, molecular analysis 
showed a decreased phosphorylation of proliferation-associated p44/42 mitogen-activated 
protein kinase and of Ki-67 proliferation marker after TIFP lowering.249 These data suggest 
that mechanical stress induced by TIFP is a positive modulator of tumor proliferation. These 
results are in line with another study demonstrating that extracellular pressure stimulates 
colon cancer cells proliferation by activating protein kinase C alpha (PKCα) signaling.320,321 
 Finally, another study demonstrated that compressive stress stimulates migration of 
mammary carcinoma cells.322 The enhanced migration under compression was 
accomplished by a subset of cells displaying localized fibronectin deposition, stronger cell-
matrix adhesion and stabilization of persistent actomyosin-independent cell extensions. This 
suggests that compressive stress accumulated during tumor growth can induce coordinated 
migration of cancer cells by stimulating enhancing cell-substrate adhesion and migration. 
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In conclusion, while the role of cell mechanics just begins to be understood, 
mechanical stress has been reported to play a role at al levels of tumorigenesis, 
including tumor initiation,315 control of tumor size318,319 and tumor progression.322 So 
far, little is known about how mechanical stress affects cancer cell phenotype or the 
molecular pathways involved. However, BMP signaling has been described as a key 
pathway in the transduction of compressive mechanical signals produced during 
tumor growth. 
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Chapter 4 : BMP signaling pathway 
 
I. Discovery 
 
The bone morphogenetic proteins (BMP) were discovered in the 1960s from extracts 
of demineralized bone marrow.323 These molecules have been identified by their 
osteoinduction ability, that is to say, their capability to induce the formation of bone structures 
and are now widely used in orthopedic surgery.324,325 BMP are glycosylated extracellular 
matrix-associated molecules that belong to the transforming growth factor beta (TGF-β) 
superfamily.326 The molecules of the TGF-β superfamily are usually classified according to 
their sequence homology. Because of this, BMPs are often associated with growth and 
differentiation factor (GDF) molecules.327 BMPs have highly conserved molecular structures 
in animals. Recently, scientific advances have led to the isolation and cloning of these 
molecules allowing to refine their classification. BMPs can thus be grouped into sub-classes, 
as it is the case for BMP2 and BMP4 that share more than 80% of sequence homology.328 
BMPs are generally described as "multifunctional" proteins. They can regulate many cellular 
processes (proliferation, differentiation, apoptosis, chemotaxis...) in a variety of different cell 
types (hematopoietic, epithelial, mesenchymal, neural...) both during embryonic development 
and in adult tissues.329 BMPs have been widely studied in embryonic development and in 
bone remodeling related processes and therefore it is logical that their biological roles are 
best known in these two areas. It is now clear that this unique and essential signaling 
pathway plays a major role in physiological as well as in pathological processes.330 
II. BMP signaling pathway 
 
BMPs ligands are secreted as larger precursor molecules with an N-terminal 
latency/signal peptide,331 which is cleaved by extracellular proteases such as furin to release 
the mature protein.332 The mature protein dimerizes to form the bioactive complex. BMP 
molecules can form homo- or hetero-complexes that will allow signal transduction within the 
cells.333 
Main track BMP signaling, called canonical pathway, involves type II receptors with 
serine/threonine kinase activity (BMPRII) on which binds the ligand and type I receptors 
(BMPRI) determining the specificity of the dimer. Three different type II receptors (BMP 
receptor II [BMPRII], activin receptor II [ACTRIIA and ActRIIB]) and three type I receptors 
(also called activin-like receptor kinase [ALK]: BMPRIa [ALK3], BMPRIb [ALK6] and ACTRIa 
[ALK2]) have been identified.334 Type II receptors possess similar structures. However, 
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among type I receptors, ALK2 has a different structure from that of BMPRIa and BMPRIb. 
Indeed, it has been demonstrated that the extracellular region structure of BMPRIa and 
BMPRIb gives them greater affinity for both BMP2 and BMP4. Upon ligand binding, a 
hexameric complex of two type I receptors, two type II receptors, and a BMP ligand dimmer 
is formed, resulting in the phosphorylation and activation of type I receptors. BMPRI 
phosphorylation by BMPRII triggers the cascade phosphorylation of Smad effectors335 (small 
mothers against decapentaplegic homolog) 1, 5 and 8, the formation of a complex with 
Smad4 that relocates into the nucleus where it binds to co-factors and transcription 
factors336,337 to regulate the transcription of target genes such as Id (Inhibitor of 
differentiation)338 and Runx (Runt-related)339 genes (Figure 19). This complex either directly 
bind to Smad-binding elements (SBE), or indirectly through interactions with DNA-binding 
transcription factors and by associating with co-activators/co-repressors and histone-
modifying factors. 
Recently, different signaling pathways independent of Smad proteins, named non-
canonical pathways, have been implicated in BMP signaling and can for example involve 
ERKs (extracellular-signal-regulated kinases), JNK (c-Jun N-terminal kinase), MAPK/p38 
(mitogen-activated protein kinase), phosphoinositide (PI)3 kinase/Akt, protein kinase C 
(PKC), and Rho-GTPases signaling pathways (Figure 19).340–345 
 
? ??
 
Figure 19 : BMP signaling pathway. Representative scheme of the BMP signaling pathway 
that displays the main components of the signaling cascade including extracellular (soluble 
molecules), membrane, cytoplasm and nuclear located responding elements as well as some 
BMP target genes. Canonical and non-canonical pathways are shown in this figure. 
 
These signaling pathways are tightly controlled by a set of soluble, membranous and 
cytoplasmic regulators. The BMP pathway is inhibited by inhibitory Smads (Smad6 and 
Smad7),346 which inhibit the phosphorylation of Smad effectors and recruit Smad ubiquitin 
ligases (Smurf1 and Smurf2) to promote the proteasomal degradation of receptors and Smad 
effectors.347,348 Smad7 inhibits all TGF-β family members,349 while Smad6 is more selective 
towards BMP family members.350 BMP signaling is also controlled by secreted BMP 
antagonists able to bind to BMPs and prevent their engagement with their cognate receptors, 
such as chordin, follistatin, FLRG or noggin.351,352 In addition, co-receptors such as endoglin, 
betaglycan or RGM family members can modulate the interactions between BMP ligands and 
receptors.353,354 BMPs can also bind to the decoy receptor BMP and activin membrane-
bound inhibitor (BAMBI), that resembles the type I receptors but lacks an active kinase 
domain and consequently sequesters ligands from the active receptors and inhibits BMP 
signaling.355 The co-factors that will be recruited in the nucleus may influence the regulation 
of target genes, thus leading to different functional effects such as cell proliferation, 
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differentiation or even self-renewal.336,337 Moreover, it has been demonstrated that 
phosphatases such as PP1 and PP2A are able to attenuate BMP signaling by 
dephosphorylation of both receptors and Smad effectors.356 Recent studies have also 
demonstrated that BMP pathway is regulated by epigenetic mechanisms of hypo- and hyper-
methylation of genes promoters, as well as through microRNAs.357–359 
Furthermore, crosstalk exists between and BMP and other signaling pathways such 
as Wnt, JAK/STAT, Ca2+/Calmodulin or TGF-β.360,361 For example, although conventionally 
thought to respond to BMP signals, it has been demonstrated that Smad5 is also capable to 
transduce the inhibitory signal of TGF-β1 and TGF-β2 on proliferation of human 
hematopoietic progenitor cells.362 Finally, a growing number of adapter proteins and 
interactions with other signaling pathways have been evidenced,363 which demonstrates the 
importance and complexity of the BMP pathway. 
III. Mechanical signals transduction through BMP signaling pathway control 
 
Mechanical signals are integrated into the BMP signaling pathway by modulating 
BMP pathway elements expression or by direct modulation of BMP signal transducers. 
Bioreactor systems allowing cyclic compressive loading have been developed to study bone 
cell compliance in three-dimensional environments. Using this strategy, it has been 
demonstrated that early BMP signaling events are strongly potentiated by mechanical forces 
in human fetal osteoblasts.364 Indeed, Smad1/5/8 phosphorylation increased both in intensity 
and duration under BMP2 stimulation with concurrent mechanical loading. In addition, Smad-
independent pathways involving MAPK and Akt/PKB were initiated, as shown by p38, Erk1/2 
and Akt phosphorylation. Conversely, in some cases, mechanical signals can also suppress 
BMP-mediated signaling. For example, it has been demonstrated that cell stretch using a 
Flexcell system suppresses the BMP4 induction of mesenchymal SC adipogenesis 
potentially through ERK up-regulation but not via the down-regulation of Smad or p38/MAPK 
signals.365 
Mechanical signals can directly influence BMP ligands expression leading to an 
alteration of autocrine signaling. It has been shown that mechanical loading leads to a 
transcriptional regulation of several BMP ligands, such as BMP2, BMP4, BMP6 and 
BMP7.243,364,366,367,367,368,368–371 However, these molecules were found up-regulated in some 
studies, while their expression was decreased in other studies in response to mechanical 
stress. These differences probably depend on cell context, experimental setup as well as 
duration and quality of mechanical signals provided. Expression analysis revealed that 
mechanical loading also controls TGF-β superfamily antagonists such as noggin, sclerostin, 
gremlin and follistatin.367,372–374 Moreover, while this has not been very well documented yet, 
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mechanical signals can impact the expression of intrinsic BMP signaling pathway elements 
as it was evidenced for Smad6 gene.375 
Interestingly, mechanical signals can also control endocytosis of membrane 
receptors, a process involved in the regulation of ligand-receptor interaction and degradation. 
Thus, receptor internalization is a common means to regulate signaling intensity and 
duration. For example, it has been evidenced that hypoosmotic-induced mechanical stress 
inhibited BMP2 endocytosis thus leading to an increase of Smad1 nuclear translocation in 
mouse pluripotent mesenchymal cells.376 Interestingly, endocytosis is also connected to 
mechano-biological components. The potential role for BMP receptors in mechanical signal 
transduction has been proposed because of their co-localization with integrins,377,378 that are 
key transducers of mechanical signals. Indeed, it has been demonstrated that endocytosis of 
integrin receptors depends on ECM stiffness and that altered endocytosis can also affect 
BMP receptor endocytosis and signaling.379 Recently, it has been shown that endocytosis of 
integrin receptors depends on extracellular matrix stiffness and that this altered endocytosis 
also affects BMP receptor endocytosis and signaling.379  
 Finally, oscillatory shear stress was demonstrated to sustain BMPRIb and α5β3 
integrin interaction, leading to an increase of Smad1/5 activation through the Shc/FAK/ERK 
pathway.378 
IV. Functions 	  
1. Biological functions 
 
To date, over 20 different BMP molecules have been identified,380 that are involved in 
an impressive number of biological processes in many tissues during embryonic 
development but also in adults tissues. However, given the functional overlap and 
redundancy between the soluble ligands and the lack of knowledge about the specification of 
soluble BMP through one or another receptor, the biological function of this pathway has 
proved very difficult to decode. In a normal context, BMPs are key players in adult stem cell 
biology.380 They are involved in the control of the overall functional and phenotypic properties 
of the stem cell population (self-renewal, proliferation, differentiation, apoptosis, 
quiescence...). They can act directly on stem cells380 or through their microenvironment,50 
contributing to the tight balance of this system. In the tumorigenic context, alterations of the 
BMP signaling pathway are involved in the deregulation of the interaction between stem cells 
and their microenvironment and, as such, participate to the different steps of the 
transformation process.381,382 Targeted disruptions of murine BMP4, BMP2, BMPRIa or 
BMPRII all result in early embryonic lethality and reduced formation of mesoderm.383–387 BMP 
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pathway also plays key roles during later development processes, especially during bone 
formation, cardiogenesis and hematopoiesis, as well as sustaining adult tissue 
homoeostasis.330 
2. Stem cell regulation 
 
At present, the involvement of the BMP pathway in SC biology is clearly established 
during the embryonic period and begins to be decoded in the adult, particularly in humans. 
Indeed, recent studies have demonstrated a key role for BMPs in the regulation of both SC 
and their microenvironment. BMP transduces a signal within SC, thus regulating their 
functional properties (self-renewal, proliferation, differentiation, apoptosis, quiescence...). 
These effects are especially more complex as they depend on the cellular context studied 
and the BMPs involved. Indeed, while BMP4 promotes the self-renewal of humans HSC in 
vivo,388 which was demonstrated by its ability to increase the HSC repopulation activity in 
irradiated NOD/SCID immunodeficient mice, this protein has different effects in other SC 
types. For example, in the human nervous system, BMP4 stops neural SC (NSC) in G0/G1 
phase of the cell-cycle.389 This effect is reversible as the cells retain their SC properties. 
Maintenance of NSC quiescence involves the BMPRIa receptor and Smad4 in response to 
BMP2 and BMP4. Hence, BMPs control the SC functional properties depending on the 
cellular context, but also on the species involved. Indeed, in the murine system, BMP4 
doesn’t induce quiescence, but leads to NSC commitment to differentiation, with the loss of 
stem cell potential and the acquisition of mature cells properties.390 BMP pathway is also able 
to maintain SC quiescence in mouse epithelial tissue, thus regulating follicular391 and 
intestinal392 SC self-renewal through control of the Wnt/beta-catenin pathway. BMP4 also 
promote the survival of SC and maintain their pluripotency in the mesenchymal system.393 
These examples illustrate the complexity of BMP signal specification, the biological resultant 
being the integration of many parameters. In the pancreas, BMP4 induces the proliferation 
and differentiation of the pluripotent AR42J rat pancreatic carcinoma cell line.394 The injection 
of a BMP4 neutralizing antibody in IFNy-/- NOD mice reduces the expansion of pancreatic 
progenitor cells. Thus, BMP4 seems to control both expansion and terminal differentiation of 
pancreatic progenitors. Finally, in the neural system, concentration gradients of BMP4 
condition NSC engagement into different lineages,395 suggesting a spatial regulation of 
BMP4 action on neurogenesis and a dependency towards environmental signals.396 Thus, 
BMPs are conditional inducers of SC commitment towards specific lineages, whose final 
biological effects depend on the presence of specific cofactors.397 BMP may thus maintain 
SC pluripotency, or, conversely, induce SC differentiation. 
While the BMP signaling pathway seems to be involved in the control of SCs in most 
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adult tissues, it has been particularly well studied in the hematopoietic context, because of its 
importance in HSC fate control. 
3. Hematopoiesis control 
  
Microenvironmental signals control HSCs fate by activating some of their intrinsic 
signaling pathways. Several of them are conserved embryonic pathways including Wnt, 
Hedgehog, TGF-β, Notch, BMI1/polycomb398 as well as BMP pathway. Multiple cell types 
within the BM niche produce BMPs, including stromal cells, megakaryocytes and platelets.399 
In addition, osteoblasts have been shown to secrete several BMPs, including BMP2, BMP4 
and BMP7.400,401 These molecules can then become incorporated into the ECM and act 
through an autocrine or paracrine signaling. BMP4 effect on hematopoietic development in 
the mouse has been established from of its genetic deletion, which disrupts mesoderm and 
blood cell formation in the yolk sac.383 BMP2, BMP4, BMP7 and Smad proteins have been 
implicated in the self-renewal and maintenance of HSCs, expansion of progenitor cells and 
their differentiation into the mature lineages of the hematopoietic system.388,402,403  
In 1999, it has been demonstrated that members of the BMP family regulate self-
renewal, proliferation and differentiation of CD34+, CD38-, Lin- HSCs extracted from human 
bone marrow and cord blood by combining in-vitro and in-vivo assays388. It was shown that 
high concentrations of BMP2 and BMP7 lead to an inhibition of the proliferation of CD34+, 
CD38-, Lin- cells while maintaining their in-vivo repopulating capabilities along with 
phenotypic and functional properties of immature cells.388 However, while at low 
concentrations BMP4 led to the proliferation and differentiation of these cells, at high 
concentrations, BMP4 was able to maintain their HSC phenotypic and functional 
properties.388 This illustrate the primordial role of BMP pathway in HSC control as well as the 
complexity of this family of molecules which despite using the same signaling pathways can 
mediate different functional effects on a same cell population. 
Our group later demonstrated direct involvement of BMP molecules in HSC 
differentiation. In the human hematopoietic system, BMP pathway was identified as a 
conditional inducer of human HSCs commitment, depending on the type of BMPs involved. 
Indeed, whereas BMP2 or activin A directed differentiation of human CD34+ progenitors 
towards erythrocytic lineage in absence of EPO,404 BMP4 favored their commitment towards 
megakaryocytic lineage (Figure 20).399 This suggests that BMP2 and BMP4 do not share 
redundant biologic function in the regulation of hematopoiesis,404 despite their high level of 
homology. However, these effects may also depend on the co-factors involved in these 
processes. Indeed, BMP4 was shown to induce erythrocytic commitment in cooperation with 
SCF and EPO,405,406 while BMP4 alone induced megakaryocytic differentiation.399 
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Conversely, BMP2 do not seem to be involved in megakaryocytic differentiation.399 Another 
study also demonstrated the role of Smad5 in BMP4 signaling as Smad5 inhibition in human 
hematopoietic progenitors lead to the inhibition of BMP4 mediated erythropoiesis.407 
Interestingly, it was recently demonstrated that Smad6, a BMP inhibitor, was capable to 
inhibit erythropoiesis in human cord blood HSCs by blocking Smad5-mediated BMP4 
signaling in presence of EPO.408 Thus, these data suggest that Smad6 indirectly maintains 
stemness by preventing spontaneous erythropoiesis in HSCs.408 
Even if its role in hematopoiesis has not been extensively studied, BMP7 also seems 
to participate in the control of HSCs number.409 Indeed, low-doses of BMP7 improved the 
proliferation of total cells, CD34+ cells and CD34+, CD38- cord blood cells without affecting 
the colony-forming ability or the engagement of CD34+ cells. Moreover, cord blood-derived 
CD34+ cells cultured with BMP7 for 10 days showed better engraftment and multi-lineage 
reconstitution ability after engraftment into irradiated NOD/SCID mice.409 
Moreover, Smad5 has been shown to negatively regulate the proliferation and self-
renewal of early yolk-sac-derived multipotent hematopoietic progenitors.362,410 This was 
shown by Smad5−/− yolk sacs that gave rise to an increased number of granulocyte-
macrophage colony-forming units by CFC assay. However, this effect was explained by a 
decreased sensitivity to TGF-β1 inhibition of hematopoiesis,362 while the possibility for 
soluble BMPs involvement was not tested, even though they are the main upstream ligands 
of Smad5. 
While the previous examples indicate direct regulation of HSCs by BMPs, their impact 
can also be indirect. Indeed, it has recently been demonstrated that BMP4 is able to induce 
integrin-α4 expression in immature human Lin-, CD34+ cells through Smad-independent 
pathway, thus increasing their homing and subsequent hematopoietic reconstitution 
capabilities in irradiated mice.411 
? ??
 
Figure 20 : Role of BMP2 and BMP4 in the regulation of hematopoietic stem cells fate. 
Soluble BMPs, such as BMP2 and BMP4 are produced by the bone marrow 
microenvironment, but also by hematopoietic cells themselves. These molecules will trigger 
the activation of the intrinsic BMP signaling pathway in HSCs, leading to different functional 
consequences, ranging from differentiation to self-renewal or even quiescence, depending 
on the stage of cell immaturity or the presence of additional co-factors. 
  
Finally, our group demonstrated in 2006 that the BMP signaling pathway is also 
involved in the regulation of HSCs through the direct involvement of its soluble inhibitors 
follistatin and FLRG.412 Indeed, the results obtained showed that follistatin and FLRG interact 
with fibronectin and that this interaction is accompanied by an increase in the adhesion of 
normal human hematopoietic progenitors to fibronectin.412 Interestingly, HSC adhesion to the 
BM stroma has been demonstrated to decrease their proliferation39 and to induce 
quiescence,413 mechanism probably involved in CML LSC resistance to TKIs.187 Hence, BMP 
pathway could also be involved in the regulation of HSCs fate through control of their 
interactions with their BM microenvironment. 
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V. Microenvironment control 
 
1. Physiological context 
 
One of the major difficulties to analyze BMP effects on SC biology lies in the 
multiplicity of biological effects often seemingly contradictory. The biological effects are 
conditioned both by intrinsic parameters (signaling pathways elements) and extrinsic 
parameters in a specific environment (co-factors and soluble BMPs production). Thus, from 
embryogenesis to adulthood, BMPs act under the control of the cellular microenvironment in 
multiple systems. Whatever the studied system, SCs reside in niches consisting of a 
multitude of cell types that synthesize compounds such as BMP proteins. These, in turn, are 
able to act on the different elements and actors of the niche and will participate in the control 
of SC fate. Indeed, BMPs distribution and action in time and space are dictated by the niche 
itself (size and composition), whose elements are also under the control of the BMP 
pathway.50 For example, BMPs have been described as key regulators of mesenchymal SC 
(MSC) differentiation toward different lineages: adipocytes, osteogenic or chondrogenic.414,415 
The dialogue between SCs and their niche thus creates a perpetual, dynamic and reciprocal 
regulatory network. Thus, the balance between these different parameters allows a fine 
control of SC biology in their microenvironment. 
The use of BMPRIa deficient mice has, for first time, demonstrated the proof of the 
indirect action of the BMP pathway on HSCs through control of the hematopoietic niche. 
Indeed, the increased number of osteoblasts in the bone marrow of BMPRIa-/- mice led to a 
significant expansion of HSCs in these animals.50 This study evidenced that the BMP 
signaling controls the hematopoietic niche size through regulation of osteoblast production, 
which will act as a support for HSC amplification. Thus, this study remarkably demonstrated 
that alterations of the BMP signaling pathway can be involved in abnormal proliferation of 
different cell types such as osteoblasts or HSCs, and possibly in tumorigenic processes. 
Interestingly, another study demonstrated the crucial role of BMP4 in the 
maintenance of a competent HSC niche.416 Indeed, serial transplantation studies reveal that 
BMP4-deficient recipient mice have a microenvironmental defect that reduces the 
repopulating activity of wild-type HSCs. Furthermore, wild-type HSCs that successfully 
engrafted into BMP4-deficient recipient mice show a marked decrease in functional HSC 
activity when tested in a competitive repopulation assay.416 Even though the exact 
mechanism is still unknown, as BMP4 is able to induce HSCs homing through control of 
integrin-α4 expression,411 the loss of BMP4 in the BM microenvironment could impair HSC 
homing, consequently leading to the progressive loss of their HSC properties. 
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2. Tumoral context 
 
At present, many studies suggest that the CSC microenvironment could be altered 
without being formally transformed. In leukemias, some studies suggest that the alterations 
could affect both cell populations present in this microenvironment and the components of 
the ECM such as integrins, cytokines, fibronectin or Wnt pathway ligands. The alteration of 
the microenvironment has also been reported in solid tumors, leading to the disruption of 
collagen and fibronectin fibers, the clustering of integrins and the abnormal activation of 
different signaling pathways.307,310,417,418 
The majority of hematological malignancies are characterized by more or less marked 
alterations of the bone marrow composition, with often myelofibrosis that increases with 
disease progression.419 Yet, BMPs are known for their involvement in osteogenic 
processes.324,325 Hence, an alteration of the BMP pathway, embodied for example by an 
alteration of the soluble BMPs concentrations in the bone marrow, could be involved in this 
myelofibrosis.420 Interestingly, it has been demonstrated that Imatinib, the first-line treatment 
of CML, increases the transcriptional expression of BMP2 in human MSCs421 and is able 
restore a consistent bone marrow structure.422 
Moreover, multiple myeloma (MM) is characterized by a progressive destruction of 
the bone tissue due to enhanced osteoclastogenesis and suppressed osteoblastogenesis.423 
A recent study revealed that Pim-2, a kinase involved in tumor progression and bone loss in 
MM, is able to abrogate BMP2-induced osteoblastogenesis in-vitro. This highlight the crucial 
role for BMP pathway control in the regulation of the BM niche, and illustrates how alterations 
of this pathway can lead to alterations of the BM microenvironment, thus participating in 
tumor progression.424 
Finally, the importance of the BMP pathway in the control of SC microenvironment 
has also been observed in other tissues. Interestingly, our group recently evidenced that 
BMP alterations in the breast microenvironment are involved in early steps of SC 
transformation.425 Specifically, it has been demonstrated that BMP2 production by tumor 
microenvironment is up-regulated in luminal tumors. While BMP2 is involved in the control of 
early luminal progenitors maintenance and differentiation under physiological conditions, 
chronic exposure of immature human mammary epithelial cells to high BMP2 levels initiated 
transformation toward a luminal tumor-like phenotype. It was further demonstrated that 
BMP2 signaling was mediated by BMPRIb receptor. This study also suggests that 
microenvironment-induced over-expression of BMP2 may result from carcinogenic exposure, 
thus providing new evidences for the role of microenvironment alterations in tumorigenic 
processes through altered BMP signaling.425 
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VI. BMP signaling pathway, cancer and cancer stem cells 
 
BMP signaling pathway is involved in different pathological processes such as 
cancer381 or osteoporosis,426 but also in conditions affecting the heart, lungs, eyes and 
reproductive organs.330 The role of the BMP family in cancer processes has been particularly 
well documented. The diversity of cancer types concerned demonstrates the importance and 
pervasiveness of this signaling pathway in tumorigenic processes and cancer dissemination. 
These observations are sometimes used clinically as prognostic factors or for the 
identification and classification of some tumors. This is the case for example in prostate 
cancer where the loss of BMPRII expression is a good prognostic factor.427 BMP2 expression 
constitutes a factor of poor prognosis in gliomas428 and could be associated with tumor 
progression in gastric cancer.429 The expression of membrane BAMBI inhibitor also seems to 
be suppressed by epigenetic modification in a subtype of high-grade prostate cancer.430 
While the major role of the BMP pathway in oncogenic processes is undeniable, it is 
only very recently that its involvement in CSC biology was suspected.382 BMPs are key 
regulators of normal SC biology and recent studies have started to demonstrate their role in 
CSC biology. In glioblastoma, BMPRIb has been involved in the maintenance of the CSC 
phenotype.358 Indeed, in the tumor, there is a refractory cellular fraction to the BMP4-induced 
differentiation that persists and that is able to promote tumor reconstitution. In this CSC 
subpopulation, BMPRIb expression is quenched by methylation of its promoter and its re-
expression in response to a demethylating agent can restore CSC differentiation under 
BMP4 treatment.358 Treatment of neural CSC by BMP4 decreases their proliferation without 
affecting their viability, induces their differentiation into neural precursors and reduces their 
ability to form tumors in NOD/SCID mice. Thus, BMP4 reduces the neural CSC pool by 
pushing them towards a differentiation process and therefore constitutes a potential 
therapeutic agent in this very aggressive disease.431 However, while BMPs are highly 
expressed in glioblastomas (particularly BMP2 produced by CSC, but also BMP7 produced 
by adjacent NSC), they do not manage to induce CSCs differentiation in-vivo. Interestingly, a 
recent study demonstrated that Gremlin1, a BMP antagonist, is secreted by CSCs432 and is 
able to protect them against the BMP-induced differentiation.433 
In melanoma, the existence of CSC was evidenced in humans in 2006.434 These CSC 
express specific markers such as ABCB5 (ATP-binding cassette sub-family B member 5) 
and over-express BMPRIa.435 However, the functional role of the BMP pathway in melanoma 
CSC has not been described yet. 
Our group recently demonstrated that BMP alterations in the breast microenvironment 
are involved in early steps of SC transformation.425 However, alterations of the BMP pathway 
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were also observed in tumor cells themselves, as an increased BMPRIb expression was 
observed in luminal tumor cells. BMPRIb expression was increased after chronic exposure to 
BMP2, and was further shown to be required for BMP2-induced transformation of immature 
mammary epithelial cells.425 
VII. BMP signaling pathway in leukemia 
 
BMP signaling pathway is deregulated in various bone-related disorders and cancers, 
including acute promyelocytic leukemia (APL or AML M3). Indeed, BMP2, BMP4, BMP7, as 
well as the receptors BMPRIa, BMPRIb and BMPRII, were shown to be up-regulated in APL 
leukemic blasts, with levels returning to normal in patients who responded to all-trans-retinoic 
acid (ATRA) treatment.436 In patients who did not respond to ATRA therapy, BMP elements 
expression remained high in the malignant promyelocytes. This study highlights the potential 
for the use of the BMP pathway as a minimal residual disease molecular marker in APL.436 
Interestingly, another study assessed the role of BMPs in the response of AML M3 cells to 
ATRA treatment. It was demonstrated that BMP2, BMP4 and BMP6 were able to block 
ATRA-mediated differentiation of leukemic promyelocytes by inducing the expression of 
inhibitor of differentiation (ID) genes.437 These results further suggest the possible use of 
BMP antagonists as complementary therapeutic strategy for ATRA-resistant patients. 
Furthermore, it has recently been demonstrated that expression of CBFA2T3-GLIS2 
fusion protein in a small subset of acute megakaryoblastic leukemia (AMKL)438 patients was 
able to increase the self-renewal capability of committed myeloid progenitors along with 
megakaryocytic differentiation, in part through enhanced BMP2 and BMP4 signaling.439 
 Mesoderm Inducer in Xenopus Like1 (MIXL1), a homeobox transcription factor 
aberrantly expressed in AML and lymphomas was identified for its leukemogenic potential 
both in-vitro and in-vivo. Interestingly, a recent study demonstrated that BMP4 is able to 
induce MIXL1 expression in human HSCs.440 The anti-apoptotic advantage conferred by an 
increased MIXL1 expression was reversed upon type I BMP receptor inhibition, suggesting 
the BMP pathway as a potential target for therapy. Interestingly, MSX1, another homeobox 
transcription factor, was found to be over-expressed in 11% of T-ALL patients. In that case, it 
was demonstrated that the increased MSX1 expression was due to the inhibition of BMP4 
signaling by chordin-like1 (CHRDL1) inhibitor.441  
These results illustrate the duality of the BMP pathway that can either repress or 
activate tumorigenic processes. This is further supported by recent studies demonstrating 
that BMP4 and BMP6 are able to induce apoptosis of multiple myeloma (MM) cells by Smad-
dependent repression of MYC424,442. However, the exact role of BMP signaling pathway in 
leukemic maintenance and progression is still not clearly defined. 
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These results demonstrate that BMP signals are crucial for SC regulation, 
particularly in the hematopoietic context where BMPs control HSC and their 
microenvironment. In addition, BMP signaling is altered in most cancer processes 
including leukemias, and seems involved in CSC phenotype. Finally, BMPs have been 
described as key regulators of mechanical signals transduction, process also 
involved in HSC regulation and tumorigenic processes. Altogether, these results 
support a potential role for BMP signaling in CML LSC biology, potentially mediated 
by mechanical signals. 
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I. Research problem 
 
One of the main causes of treatment failure in cancers is the development of drug 
resistance by cancer cells. The persistence of CSC might explain cancer relapses as they 
could allow reactivation of cancer cells proliferation following therapy, leading to disease 
persistence and ultimately to patients’ death. Clinically, it is crucial to develop therapeutic 
strategies able to target resistant CSC in order to cure the patients. In this context, CML is 
the reference model of a true HSC alteration by a t(9,22) chromosomal translocation leading 
to the formation of the BCR-ABL fusion protein, with high tyrosine kinase activity and directly 
responsible of the leukemic transformation. Despite the success of targeted therapies 
against BCR-ABL with the development of TKIs, a residual disease is still detected in many 
CML patients, probably due to the persistence in vivo of CML leukemic stem cells (LSCs). In 
some cases, resistance to TKI treatment appears, involving different mechanisms with 30% 
of unknown origin that could be due to LSCs survival. LSCs are controlled by a variety of 
biochemical and biomechanical signals from the leukemic niche. Thus, deregulation of these 
signals could contribute to LSC emergence and resistance. My project aims to determine the 
involvement of the tumor microenvironment (BMP signaling pathway and mechanical stress) 
in the maintenance and resistance of CML LSCs. 
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II. Scientific context 
 
BMP pathway is part of the TGF-β super-family signaling pathway. This signaling 
pathway is crucial for the regulation of HSCs and their microenvironment (Chapter 4). 
Interestingly, TGF-β signaling has been demonstrated to potently inhibit the growth of BCR-
ABL-expressing CD34+ cells isolated from CP-CML patients by inducing cell-cycle arrest.443 It 
was further reported that inhibition of the TGF-β receptor kinase in a quiescent sub-
population of CML CD34+ cells is able to overcome the cell-cycle blockade induced by TGF-
β, and to enhance their sensitivity to Imatinib treatment.443 However, these results are 
probably cell type dependent, as another report suggested that BCR-ABL is able to inhibit 
the cytostatic effect of TGF-β through the AKT/FoxO3 signaling pathway in Ba/F3 and K562 
cells.444 While its role in normal HSCs control is undeniable, the BMP pathway has not been 
extensively studied in the CML context. However, recent studies raised very interesting 
mechanisms supporting the importance of this signaling pathway in CML. For example, the 
impact of Imatinib treatment on human bone marrow mesenchymal stem cell differentiation 
has recently been assessed in-vitro.421 It has been demonstrated that Imatinib, the first-line 
treatment for CML, was able to induce mesenchymal stem cell differentiation toward the 
osteoblastic lineage, together with an increase in osteoblastic markers such as BMP2 and 
Runx2.421 Thus, Imatinib treatment could have a direct impact on BMP production in BM 
microenvironment, leading to the alteration of BMP signaling in healthy and CML immature 
cells. Moreover, as discussed in this study, this could lead to an alteration in the cellular 
composition in the BM niche, affecting others mechanisms involved in HSCs regulation. This 
is further supported by the study previously discussed, demonstrating that BMP signaling is 
able to control hematopoietic niche size through regulation of osteoblast production, which 
acts as a support for HSC amplification.50 Although this has not yet be reported in the 
literature, some evidences advocate for a potential role of the BMP pathway in CML 
phenotype. For example, Twist-1, an embryonic transcription factor recently identified as a 
new predictive factor for the effect of TKIs on CML cells,445 can regulate or be regulated by 
the BMP pathway, depending on the cellular context.446–449 BMP signaling is also altered in 
different types of cancers381 including leukemia and is involved in CSC properties.382 CML is 
characterized by the alteration of the bone marrow structure with disease progression,419 and 
BMPs have first been identified for their role in regulating bone morphogenesis.324,325 CML 
arises from the alteration of a HSC, and BMPs are key regulators of hematopoietic stem 
cells.50,388 Finally, CML is also characterized by the alteration of hematopoiesis, particularly 
of myelopoiesis,450 and BMPs are known regulators of hematopoietic stem cells commitment 
(Figure 21).399,404 
? ???
 
Figure 21 : BMP pathway and Chronic Myelogenous Leukemia. CML is characterized by 
the alteration of the bone marrow structure with disease progression, and BMPs have first 
been identified for their role in regulating bone morphogenesis. CML arises from the 
alteration of a hematopoietic stem cell, and BMPs are key regulators of hematopoietic stem 
cells. CML is also characterized by the alteration of hematopoiesis, particularly of 
myelopoiesis, and BMPs are known regulators of hematopoietic stem cells commitment. 
Finally, some embryonic genes are re-expressed in CML such as Twist-1, gene that control 
or that can be controlled by BMP pathway depending on the cellular context. 
 
Interestingly, BMP pathway is a key regulator of mechanical signals transduction in 
cells (Chapter 4), that are also involved in SCs regulation (Chapter 3). Moreover, recent 
studies have demonstrated the role of cell mechanics in HSCs regulation. Due to their faculty 
to circulate through blood vessels, hematopoietic cells experience a wide variety of dynamic 
forces. Thus, their viscoelastic response under fluid shear stress and deformation have been 
extensively studied. Variations in blood viscoelasticity have been observed in conditions such 
as cardiovascular disease, peripheral vascular disease, sickle cell anemia, diabetes and 
stroke.451,452 Bone marrow provides a number of distinct mechanical environments 
associated with sinusoids, blood vessels, and mineralized bone matrix. Several of these 
regions are complex but well characterized niches comprised of osteocytes, osteoblasts, 
osteoclasts, endothelial cells, mesenchymal stromal cells, as well as mature blood lineages 
such as macrophages.452 Thus, HSCs can experience a wide array of elasticities in the BM, 
from under 1 kPa for adipose tissue to 100 kPa for collagenous bone.452 However, the role of 
physical signals in HSCs fate control just begins to be deciphered. Interestingly, a recent 
study revealed for the first time the critical role of biomechanical forces in hematopoietic 
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development.46 Using mouse embryonic SC differentiated in-vitro, it has been demonstrated 
that fluid shear stress increases the expression of Runx1, a master regulator of 
hematopoiesis,453 in CD41+, c-Kit+ hematopoietic progenitor cells, concomitantly increasing 
their hematopoietic colony-forming potential. It was further demonstrated that abrogation of 
nitric oxide, a mediator of shear-stress-induced signaling, compromises hematopoietic 
potential in-vitro and in-vivo.454 In addition, another study suggested the importance of 
substrate elasticity in the control of hematopoietic stem and progenitor cell fate.455 Indeed, 
culturing mouse Lin−, Sca-1+, c-Kit+ or human Lin−, CD34+, CD38+ immature hematopoietic 
cells on a tropoelastin substrate led to a two- to three-fold expansion of undifferentiated cells, 
including progenitors and mouse stem cells. Treatment with cytokines in the presence of 
tropoelastin had an additive effect on this expansion. While an increase in cell forming colony 
(CFC) content was observed in cells cultured on tropoelastin-coated plates compared to 
controls, no difference in the size or type of colonies was observed.455 Mice HSCs were then 
cultured on control or tropoelastin-coated plates and transplanted into mice, demonstrating a 
higher repopulating capabilities after culture on tropoelastin-coated plates. These biological 
effects required substrate elasticity, as neither truncated nor cross-linked tropoelastin 
proteins could reproduce the phenomenon, and inhibition of mechano-transduction signals 
abrogated these effects.455 These evidences support the use of optimal physical substrates 
that may complement existing approaches to support and expand HSCs. As a crucial role for 
cell mechanics was recently evidenced in HSCs fate control, mechanical signals could also 
be involved in pathologic processes such as leukemia, where these signals are likely to be 
altered. Due to its confinement by bones, the bone marrow has a unique mechanical 
environment that can be affected by external factors, such as blood flow, physiological 
activity, aging or disease.452 This could prove especially important in the tumoral context, 
where uncontrolled proliferation of leukemic cells entails their compaction within their 
microenvironment, resulting in constant mechanical stress (Figure 22).316 Moreover, in CML, 
Imatinib treatment has been demonstrated to re-establish a coherent medullar structure in 
treated patients (Figure 22).422 Thus, changes in the bone marrow mechanical environment 
during the course of the disease may also affect the fate of resident HSCs or LSCs. Finally, 
alterations of intrinsic mechano-transduction pathway in leukemic cells could impair their 
capability to sense and/or respond to mechanical signals. 
 
? ???
 
Figure 22 : Possible alterations of the mechanical signals in the CML bone marrow 
environment. Like in most hemopathies, CML is often characterized by a hyper-cellularity in 
the bone marrow, eventually leading to the alteration of the bone marrow structure, with the 
appearance of myelofibrosis in some cases, which is accentuated with disease progression. 
Imatinib treatment has been demonstrated to re-establish a coherent medullar structure in 
CML patients. These differences in cellularity as well as in bone marrow structure could 
possibly lead to an alteration of the mechanicals signals provided by the microenvironment to 
HSCs and LSCs. 
 
 
Given the crucial role of both BMP signaling and mechanical signals in HSC 
regulation, and their involvement in cancer, it is reasonable to speculate that alteration of 
these processes could be involved in the leukemic phenotype in CML. 
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III. Thesis project 
 
My project aims to determine the involvement of the tumor microenvironment in 
maintenance and resistance of CML LSC. For that, we first assessed the potential role of 
BMP signaling in immature CP-CML cells by combining functional and molecular assays to 
the analysis of tumor microenvironment in more than 70 CP-CML patient samples at 
diagnosis without any treatment. We then evaluated whether BMP pathway could be 
involved in immature CML cells resistance to TKIs treatment by performing resistance 
assays and analyzing sensitive and resistant CML patient samples (at diagnosis, resistance 
status obtained after clinical follow-up of at least 2 years). In parallel, we benefited from the 
expertise of the physics laboratory in microsystems design and mechanical measurements to 
understand how mechanical stress exerted by the microenvironment could influence 
immature CML cells fate. We used atomic force microscopy to compare the mechanical 
properties of single living CD34+ normal or CML cells. Finally, we used an innovative system 
allowing a defined confinement of in-vitro cultured cells to evaluate the impact of external 
mechanical stress on CD34+ CML cells functional properties as well as their response to 
TKIs. We hope that this transdisciplinary approach will help to identify key molecules in the 
transduction of signals potentially involved in maintenance and resistance of LSCs and thus 
offer new targets to counter these effects. 
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Materials 
 
I. Human primary cells 
 
After informed consent in accordance with the Declaration of Helsinki and local ethics 
committee bylaws (from the Délégation à la recherche clinique des Hospices Civils de Lyon, 
Lyon, France), peripheral blood and bone marrow samples were obtained from CML patients 
at diagnosis or during follow-up and from healthy allogeneic donors. Mononuclear cells were 
separated using a Ficoll gradient (Bio-Whittaker) and were then subjected to CD34 
immunomagnetic separation (Stemcell Technologies). The purity of the CD34+ enriched 
fraction was checked by flow cytometry and was over 95% on average (Figure 23). Selected 
bulk CD34+ cells were seeded at 6x105 cells/ml and cultured in serum-free Iscove’s Modified 
Dulbecco’s Medium (IMDM) (Invitrogen) in the presence of 15% BSA, Insulin and Transferrin 
(BIT) (Stemcell Technologies) supplemented with 10 ng/ml interleukin-6 (IL-6), 50 ng/ml stem 
cell factor (SCF), 10 ng/ml IL-11 and 10 ng/ml IL-3 (Peprotech). Stromal cells were isolated 
by plating bone marrow samples from healthy donors or CML patients at 5x104 cells/cm2 in 
Alpha Modified Eagle's Medium (α-MEM) (Invitrogen) supplemented with 10% Fetal Calf 
Serum (FCS) and culturing them for 2 to 3 weeks. Cells were allowed to attach for 7 days, 
then any non-adherent cells were carefully removed and fresh medium was added. When the 
primary cultures became almost confluent, remaining stromal cells were washed twice in 
PBS1X and harvested using trypsin-EDTA (Life Technologies). 
? ???
 
Figure 23 : Primary samples process. Mononuclear cells were separated using a Pancoll 
gradient (Bio-Whittaker) and were then subjected to CD34 immunomagnetic separation. 
Before the gradient separation and for bone marrow samples only, the plasma was 
harvested and 5x104 cells/cm2 were plated in α-MEM medium to culture stromal cells. 
 
II. Cell lines 
 
The BCR-ABL- hematopoietic cell line TF-1 (ATCC CRL-2003) has been derived from 
a patient with erythroleukaemia and was maintained at 1x105 cells/mL in Roswell Park 
Memorial Institute (RPMI-1640) medium (Invitrogen), 10% FCS and granulocyte macrophage 
colony-stimulating factor (GM-CSF, 10 ng/mL) (Sandoz Pharmaceuticals). Engineered TF1-
GFP and TF1-BCR-ABL-GFP cell lines were obtained by transduction with an MSCV-based 
retroviral vector456 encoding either the enhanced green fluorescent protein cDNA alone 
(EGFP) as a control or the BCR/ABL-cDNA upstream from an IRES-eGFP sequence (Figure 
24). EGFP+ TF1 cells were sorted using a Becton Dickinson FACSAria. The BCR-ABL+ 
hematopoietic cell line KCL22 (ATCC CRL-2003) has been established from the pleural 
effusion of a CML patient in blast crisis and was maintained at 1x105 cells/mL in RPMI-1640 
medium (Invitrogen) and 10% FCS.457 The stromal cell line HS27A (ATCC CRL-2496) has 
? ???
been derived from a human bone marrow and was maintained at 1x104 cells/mL in RPMI-
1640 medium (Invitrogen) and 10% FCS. The stromal cell line HS5 (ATCC CRL-11882) has 
been derived from a human bone marrow and was maintained at 1x104 cells/mL in 
Dulbecco's Modified Eagle's Medium (DMEM) (Invitrogen) and 10% FCS. The microvascular 
endothelial cell line BMEC-1 has been derived from a human bone marrow and was 
maintained at 1x104 cells/mL in MCDB-131 medium (Invitrogen) and 10% FCS. The murine 
stromal cell line MS5 (kind gift from Dr. Coulombel, Creative Bioarray CSC-C2763) has been 
derived from murine bone marrow and was grown in α-MEM (Invitrogen) supplemented with 
10% FCS at 0,5x104 cells/ml. MS5 cell line was used as feeder to support human 
hematopoiesis in LT-CIC assays. Hematopoietic cell lines were passages twice a week while 
stromal and endothelial cell lines were passaged every 2 weeks. 
 
 
Figure 24 : Engineered BCR-ABL+ CD34+ TF1 cells. Engineered TF1-GFP and TF1-BCR-
ABL-GFP cell lines were obtained by transduction of the human CD34+ TF1 cell line with an 
MSCV-based retroviral vector encoding either the enhanced green fluorescent protein cDNA 
alone (EGFP) as a control or the BCR/ABL-cDNA upstream from an IRES-eGFP sequence. 
EGFP+ TF1 cells were sorted using a Becton Dickinson FACSAria. 
 
III. Soluble molecules
 
BMP2, BMP4 (50 ng/ml) (R&D Systems), sBMPRIa and sBMPRIb (4 µg/ml) (R&D 
Systems) were added as determined399. 
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IV. Microfabricated wells 
  
Microfabricated wells used in AFM setup for mechanical immobilization of suspended 
hematopoietic cells were created as described (Biotray).298 Wells were patterned in arrays 
with diameters ranging from 15 to 20 µm. No differences in cell morphology or viability were 
observed between cells incubated on epoxy-based negative photoresist SU-8 and glass 
surfaces. 
V. Microfabricated structured slides 
 
Structured confining slides used for cell confinement were created in 
Polydimethilsiloxane (PDMS, RTV615, GE) from molds fabricated by regular 
photolithography (Biotray) as described.273,458–460 For fixed height confining slides, one layer 
of epoxy-based negative photoresist SU-8 with the desired thickness was used (the 
thickness of the layer corresponding to the confinement gap: 30 µm, 10 µm, 5 µm and 2.5 
µm). To fabricate the micro-structured glass slide, a drop of PDMS mix (8/1 w/w 
PDMS/crosslinker) was first poured on the mold. Then, a standard microscope coverslip (14 
mm for 24-well plate experiments) previously activated for 2 minutes in a UV-ozone cleaner, 
was pressed onto the PDMS drop to get a residual PDMS layer of minimal thickness. After 
reticulation of PDMS on a hot plate (95°C, 15 minutes), the excess of PDMS was removed. 
The slide was gently lifted by inserting a razor blade between the slide and the mold. The 
surface of the glass slide covered by the microstructured PDMS layer was cleaned in 
isopropanol. Slides were sterilized under UV and incubated in the culture medium for 2 hours 
prior to the experiment. No differences in cell morphology or viability were observed between 
cells incubated on PDMS or plastic surfaces. 
Methods 
 
I. Functional assays 
 
1. Cell counting and trypan blue dye exclusion 
 
The number of viable cells was obtained following trypan blue staining using a 
Malassez counting chamber. The proliferation rate was represented as the ratio of counts at 
the end of the experiment to the number of input cells. 
2. Cell adhesion assay 
 
Adhesion was performed as described.412 Briefly, fibronectin (Sigma) was coated for 2 
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hours at 37°C on 96-well Cellstar dishes (Greiner) using a 50 µg/ml ligand solution in sodium 
bicarbonate buffer (0.1 mM). Plates were blocked with 0.3% BSA in PBS1X for 1 hour at 
37°C. Cells (5.104/well) were labeled for 20 minutes at 37°C with 5 µM calcein-AM (Molecular 
Probes) in RMPI medium containing 0.1% BSA (without phenol red). Cells were then allowed 
to adhere to the coated plates in triplicate wells for 1 hour at 37°C in the adhesion buffer 
(PBS1X with 0.03% BSA). The total fluorescence was quantified using a fluorescence 
analyzer (Cytofluor, PerSeptive Biosystems). Non-adherent cells were then removed, and 
after several gentle washes, the fluorescence of the adherent fraction was quantified. 
Adhesion was calculated as follow: % of adhesion = 100.(fluorescence of adherent 
fraction/fluorescence of whole cells). 
3. Co-culture experiments 
 
HS27A cells (ATCC CRL-2496) were seeded at 2x104 cells/mL in Alpha Modified 
Eagle Medium (αMEM) (Invitrogen) supplemented with 10% FCS for 24 hours. The culture 
medium was then removed and selected CP-CML CD34+ cells were added at 6x105 cells/mL 
and cultured in Iscove’s Modified Dulbecco’s Medium (IMDM) (Invitrogen), 15% BSA, Insulin 
and Transferrin (BIT) (Stemcell Technologies) supplemented with IL-6 (10 ng/mL), Stem Cell 
Factor (SCF) (50 ng/mL), IL-11 (10 ng/mL) and IL-3 (10 ng/mL) (Peprotech) for 7 days. 
4. CFC assay 
 
 The content of treated cells in distinct hematopoietic progenitor categories was 
determined using the colony forming cell (CFC) assay. The assay is based on the ability of 
hematopoietic progenitors to proliferate and differentiate into colonies in a semi-solid media 
in response to cytokine stimulation. The cells were plated in Iscove’s methylcellulose medium 
(Stem Cell Technologies) containing erythropoietin (EPO), SCF, IL-6, GM-CSF, G-CSF and 
IL-3 (Stem Cell Technologies) in 35-mm Petri dishes. After 15 days of incubation at 37°C, the 
colonies formed were enumerated and characterized in situ according to their unique 
morphology (Figure 25). We scored them as early erythroid (over three clusters), early 
myeloid (over 103 cells/colony), late erythroid (one to two clusters), late myeloid (below 103 
cells/colony) as well as mixed colonies. 
5. LTC-IC assay 
 
The content of treated cells in hematopoietic stem cells was determined using the 
long-term culture-initiating cell (LTC-IC) assay. LTC-IC are a distinct, rare primitive 
hematopoietic cell type mostly found in bone marrow, which generate clonogenic cell 
progeny detectable after a minimum of 5 weeks incubation on suitable feeder cells layers. A 
high proportion of the CD34+, CD38- cells in normal human marrow are defined as LTC-IC 
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because they can proliferate and differentiate when co-cultured with cytokine-producing 
stromal feeder layers. As long-term culture initiating ability is considered to be analogous to 
reconstitution of hematopoiesis in irradiated whole animals, determination of LTC-IC is 
thought to be a good measure of true pluripotent hematopoietic stem cells. The cells were 
co-cultured with murine MS5 cell feeder in human long-term culture medium (StemCell 
Technologies) supplemented with freshly dissolved 10 µM hydrocortisone sodium 
hemisuccinate (Sigma-Aldrich), with weekly half-medium change. After 5 weeks, both non-
adherent and adherent cells were harvested, pooled, and washed; and the number of CFC 
produced was expressed as W5 CFC per 1000 initial CD34+ cells and correlated with the 
number of primitive progenitors in the original input suspension (Figure 25). 
? ???
 
Figure 25 : Quantification of hematopoietic stem cells and progenitors. (A) CFC assay 
allow to quantify the content of a cell population in distinct hematopoietic progenitor 
categories. LTC-IC assay allow to quantify the content of a cell population in HSCs. (B) Cell 
content evolution during the 5 weeks of co-culture in the LTC-IC assay. During this period, 
the progenitors present in the starting suspension gradually differentiate into mature cells, 
lose their ability to divide and eventually disappear (blue curve). In contrast, HCSs 
differentiate into dividing progenitors and increase their number (red curve). Finally, CFC 
assay is performed after 5 weeks of co-culture to quantify the progenitor content, 
representative of the number of HSCs in the starting cell suspension. 
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II. Molecular assays 
 
1. RNA isolation and analysis 
 
Total cellular RNA was isolated from samples lysed in TRI-REAGENT (Sigma-
Aldrich). For single CFC colony analysis, RNA extraction was performed using an RNA 
carrier (Glycoblue, Invitrogen). As indicated, 1 µg total RNA were reverse-transcribed with 
Superscript II enzyme (Invitrogen), and qPCR was performed using sequence-specific 
primers (Supplemental Table 1) using the QuantiFAST SyBR Green I kit (Qiagen) on the 
LightCycler 480 II system (Roche Applied Science) using a fast protocol (5 minutes at 95°C, 
10 seconds at 95°C, 30 seconds at 60°C, 10 seconds at 50°C). Samples were analyzed in 
duplicate and normalized to TBP and BGUS gene expression previously selected by geNorm 
analysis. For all samples analyzed, results were validated and normalized using the same 
CD34- healthy-donor cells used as a reference. 
2. Flow cytometry and cell sorting 
 
Cells were incubated with 0.1 µg antibody/106 cells: anti-CD3, anti-CD15, anti-CD33, 
anti-CD34, anti-CD38, anti-CD41, anti-CD61 (BD Biosciences), anti-BMPRIa, anti-BMPRIb 
(R&D Systems), anti-CD14, anti-CD19 (Beckman Coulter), anti-GPA (Invitrogen) at 4°C for 
30 minutes. Conjugated isotype-matched controls were used to assess nonspecific 
fluorescence. Flow cytometry analysis was performed using a FACSCalibur flow cytometer 
(Becton Dickinson) gated on viable cells. Cell sorting was performed using a concentration of 
5-10x106 cells/ml on a FACSAria cell sorter (BD Biosciences) gated on viable cells. To 
determine the frequency of single-cell CFC formation, cells were directly sorted into U bottom 
96-well ultra low attachment plates. 
3. ELISA assay 
 
The supernatant of bone marrow samples obtained from healthy donors and CML 
patients at diagnosis or during follow-up was harvested and cleared. Various dilutions of this 
processed supernatant were placed in 96-well plates (100 µl/well) to quantify proteins using 
the human BMP2-ELISA (Quantikine, R&D) or BMP4-ELISA (DuoSet, R&D) kits following the 
manufacturer’s instructions. Measures were done in triplicate and repeated several times for 
the same experiment. The optical density at 450 nm was determined using a microplate 
reader (Dynex MRX). 
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4. Western blot analysis 
 
Whole cell extracts were prepared by lysis of cells in 2X protein loading buffer (62.5 
mM Tris-HCl, pH 6.8, 10% glycerol, 2% sodium dodecyl sulfate, 5% b-mercaptoethanol, 
0.01% bromophenolblue). Equal amounts of total protein were separated by sodium dodecyl 
sulfate polyacrylamid gel electrophoresis. Western blotting was carried out according to 
standard techniques. Antibodies were diluted in 5% non-fat milk in Tris-buffered saline, 0.1% 
Tween 20 (Sigma). The status of Twist-1, BMPRIb, Abl, Bcr-Abl and GAPDH proteins was 
analyzed by immunoblotting, using mouse monoclonal antibodies recognizing Twist-1 
(abcam), BMPRIb (abcam), Abl (BD Pharmingen) and GAPDH (abcam) followed by 
incubation with an anti-mouse antibody conjugated with horseradish peroxidase (invitrogen) 
and Lumi-Light Plus chemiluminescent substrate (Roche). The films were scanned and 
quantification of the intensity of the bands was performed using ImageJ. 
5. Transfection 
 
TF1-GFP and TF1-GFP-BCR-ABL cell lines were transfected by electroporation with 
1 µg of plasmid per 106 cells using Neon™ Transfection System (Invitrogen). The vectors 
pCAG-ires and pCAG-ires-BMPRIb were designed in our laboratory (details available upon 
request). Transfected cells were selected and maintained under Puromycin (1 µg/ml) 
(InvivoGen) treatment for 6 weeks before performing the experiments. Transfection efficiency 
was measured by flow cytometry for the expression of the cell surface BMPRIb protein. 
6. Immunofluorescence staining 
 
Cells were seeded at 5x105 cells/mL and incubated for 24 hours before the 
experiment. In one hand, suspended cells were centrifuged onto glass slides by using a 
cytospin 4 (Thermo Scientific). In the other hand, suspended cells were allowed to adhere on 
glass cover slips coated with fibronectin (Sigma) in culture treated plates (BD 
Biosciences/Falcon) for 1 hour at 37°C, before removal of the non-adherent fraction. Cells 
were then fixed with 4% paraformaldehyde (PAF) for 15 minutes, permeabilized with 0.1% 
Triton X-100 (Sigma-Aldrich) for 10 minutes, and blocked with 0.2% gelatin (Sigma-Aldrich) 
for 30 minutes at room temperature. The filamentous actin (F-actin) was labeled with 1000-
fold diluted phalloidin-rhodamin (Sigma-Aldrich) for 30 minutes at room temperature. Finally, 
cells were washed twice and and subsequently the nuclei were labeled with 2000-fold diluted 
DAPI (Sigma-Aldrich) in mounting medium (Sigma-Aldrich). Controls for autofluorescence 
were performed by incubating cells without phallodin-rhodamin. Fluorescence images were 
taken using a spectral confocal microscope TCS SP5 AOBS (Leica). 
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7. Immunohistochemistry 
 
Immunohistochemistry was performed on bone marrow resin-embedded core biopsy 
specimens, after endogene peroxydase inhibition by H2O2, heat-induced antigen retrieval 
with DAKO buffer, pH6, antigen labeling overnight with anti BMP2 or anti-BMP4 antibodies (5 
µg/ml), Envision lavelling (Dako), tyramide amplification (Perkin Elmer), followed by 
streptavidine-phosphatase alkaline (Invitrogen) and Liquid Permanent Red (Dako) revelation. 
8. Ki67 staining 
 
Ki67 staining was performed following the manufacturer instructions (BD 
Biosciences). Cells were fixed with 4% paraformaldehyde (PAF) for 15 minutes, 
permeabilized with 0.1% Triton X-100 (Sigma-Aldrich) for 10 minutes, and blocked with 0.2% 
gelatin (Sigma-Aldrich). Cells were then incubated for 30 minutes at room temperature with 
the antibody (Ki67-PE) and washed twice with PBS1X before analysis. Flow cytometry 
analysis was performed using a FACSCalibur flow cytometer (Becton Dickinson) gated on 
viable cells. 
9. Hoescht staining 
 
Suspended hematopoietic cells were centrifuged onto glass slides by using a cytospin 
4 (Thermo Scientific). Cells were then fixed with 4% paraformaldehyde (PAF) for 15 minutes, 
permeabilized with 0.1% Triton X-100 (Sigma-Aldrich) for 10 minutes, and blocked with 0.2% 
gelatin (Sigma-Aldrich) for 30 minutes at room temperature. Cells were washed twice with 
PBS1X and stained for 30 minutes with 1 µg/mL Hoescht 33258 (Life Technologies). Finally, 
cells were washed twice and mounted using mounting medium (Sigma-Aldrich). The 
percentage of dividing cells was then scored using an axiovert 25 microscope (Zeiss). 
10. Cell-cycle analysis 
 
Cells were fixed in 70% ethanol before being labeled with the staining solution (PBS 
0.1% Triton X-100 (Sigma), 200 µg/ml DNAse-free RNAse A (Macherey-Nagel) and 20 µg/ml 
propidium iodide (Sigma)). Cell cycle analysis was performed using a FACSCalibur flow 
cytometer (Becton Dickinson). Data was analyzed using the Watson model on FlowJo (Tree 
Star Inc). 
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III. Atomic Force Microscopy 
 
1. Principle 
 
Atomic force microscope (AFM) is a local probe technique, designed to measure 
interaction forces between a sharp tip and the surface of a sample. The tip is attached to a 
force-sensitive lever, which is fixed at the opposite end to a solid support that is called 
cantilever. Tip and sample are positioned relative to one another with nanometer precision by 
mounting either the solid support base of the lever or the sample support to a piezo-electric 
scanner (tip-scanning or sample-scanning microscopes, respectively). Hematopoietic cells 
were immobilized using fibronectin-coated cover slips or micro-fabricated wells (Figure 26A). 
An electro-mechanical step motor is also used for vertical course adjustments and initial 
approach of tip to sample. As the tip is brought toward the sample, it will eventually come into 
contact with the sample surface, and the lever will be deflected proportionally to the force 
experienced by the tip (at least within a certain limit of small deflections: the linear regime) 
(Figure 26B). The spring constant of the cantilever (0,01 to 0,1 N/m for biological 
applications) is calibrated with the thermal noise method. The microscope rests on a 
vibration-damping air table to minimize background signals as much as possible. Since the 
soft levers used for biological applications have resonance frequencies in the range of 1 to 
20 kHz, they are particularly sensitive to acoustic vibrations. For this reason the AFM used 
here is enclosed in a custom built acoustic isolation box. The deflections of the lever are 
typically measured by optical beam deflection. For optical beam deflection, laser light is 
focused onto the back surface of the lever (opposite to the tip). The reflected laser light is 
directed onto a quadrant photo-diode. Voltage outputs are proportional to vertical or lateral 
deflections of the lever resulting from normal or tortional forces on the tip, respectively. 
Measurements can be performed in aqueous environments, lending itself as a useful tool for 
studying living cells in nearly physiological environments.  AFM can also be combined to a 
variety of optical microscopy techniques such as inverted optical microscope or even 
fluorescent microscopy, further expanding its applicability. This allowed us to study the 
mechanical properties of single living cells. 
? ???
  
Figure 26 : AFM experimental setup. (A) Hematopoietic cells were immobilized using 
fibronectin-coated cover slips or micro-fabricated wells. (B) Single living cells were probed 
using an AFM cantilever controlled by a piezoelectric scanner and a laser tracking system. A 
sharp tip is moved back and forth towards the sample until a set point is reached and a force 
curve is generated. 
2. AFM experiments 
 
The AFM measurements were performed by means of an AFM/STM 5500 (Scientec) 
and a Nanoscope IIIa (JPK, Bruker), using an SNL-10 silicon-tip on nitride AFM cantilever 
(SNL-10; JPK, Bruker) having a spring constant of 0.06 N/m to indent the cells. For each 
experiment, the deflection sensitivity of the cantilever was calibrated on fused silica and the 
cantilever stiffness k was calibrated by the thermal noise method. In each case, the setpoint 
amplitudes and feedback control gains were chosen to minimize the error maps. Before force 
microscopy measurements were made, cells were seeded at 5x105 cells/mL and incubated 
for 24 hours. For suspended cells measurements, cells were pipetted onto the wafer and 
allowed to settle into the micro-wells. For adherent cells measurements, suspended cells 
were allowed to adhere on glass cover slips coated with fibronectin (Sigma) in culture treated 
plates (BD Biosciences/Falcon) for 1 hour at 37°C, before removal of the non-adherent 
fraction. During the experiment, the glass coverslip was mounted on the AFM stage and the 
cells were kept in their culture medium at room temperature (24°C). Indentation was carried 
out at the center of each cell within 2 hours after cells were removed from the incubator at Z 
scan velocity 1 μm.s−1. In all the experiments, images were taken to measure the size of 
each cell. Analysis was performed on data from series of 30 force curves per cell. 
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3. Modeling the force-indentation curves 
 
Generalizing AFM force measurements to non-adherent cells was previously 
performed on myeloid cells, but these authors did not consider that these cells could change 
their mechanical response during their deformation, and they parameterized the force curves 
with a Hertzian model.298 To capture changes in cell mechanical viscoelasticity during 
indentation, we used a strategy inspired from previous studies in material sciences for 
pyramidal indentation of viscoelastic solids. The Sneddon’s variation of the Hertz model 
describes the evolution of the force F with the indentation I, for the case of a pyramidal (or 
conical) and non-adhesive cantilever tip:461 
 
(Equation 1) 
 
 
where ξ=1.4906 for a pyramidal shape tip, α is the half tip angle, Zc is the contact position of 
the cantilever, E and ν are the Young’s modulus and Poisson ratio of the sample. This Hertz-
Sneddon model assumes that the tested material is stationary, therefore it gives an 
estimation of the static Young’s modulus E. When the sample visco-elasticity is not stationary 
(typical of an active material), differential operators must be used:462 
 
(Equation 2) 
 
 
G(t) is the time-dependent shear modulus of the material and I(t) is the cantilever indentation 
inside the material. This shear modulus is defined as the ratio of the shear stress to the 
shear strain. For a constant cantilever displacement rate, I(t)=v0t for t>0 and I(t)=0 for t<0, 
then the previous equation becomes: 
 
(Equation 3) 
 
 
Taking the second derivative of this equation, we get: 
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(Equation 4) 
 
 
G(I) can thus be computed directly from the force-displacement curves by taking their second 
order derivative (their curvature). When G is constant, equation 4 yields equation 1, by 
replacing G by the Young modulus E=2G(1+v). Given that the stress field is axially 
symmetric for a pyramidal indentation, the force-displacement curve is written as an integral 
equation (Equation 2) that straightforwardly leads to the temporal shear modulus G(t) via a 
double derivation in time (Equation 4). As described in the next paragraph, this double 
derivation will be performed using the wavelet transform. 
4. Wavelet Transform analysis of force curves 
 
The continuous wavelet transform is a mathematical technique introduced in signal 
analysis in the early 1980s.463 Since then, it has been the subject of considerable theoretical 
developments and practical applications in a wide variety of fields.464,465 We used wavelet 
transform to smooth force-indentation curves and to detect the contact point. In mathematical 
terms the wavelet transform of a signal f(x) reads: 
 
(Equation 5) 
 
 
A typical analyzing wavelet ψ(x), that is admissible (of null integral) is the second derivative 
of a Gaussian g(0)(x)=e−x2/2, also called the Mexican hat wavelet: 
 
(Equation 6) 
 
 
Via two integrations by part, we then obtain: 
 
(Equation 7) 
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This last equation shows that the wavelet transform computed with g(2) at scale a is nothing 
but the second derivative of the function f smoothed by a dilated version g(0)(x/a) of the 
Gaussian function. Each force curve was analyzed separately by a home-made Matlab script 
using the second derivative of the Gaussian as analyzing wavelet to compute directly the 
local curvature of the force curves (Equation 7). This second derivative of the force curve is 
directly related to the shear modulus G (Equation 4). The optimum wavelet scale for damping 
experimental noise and capturing correctly the curvature variation during indentation was 
chosen equal to 400 nm (scientec system) or 200 nm (JPK system). We used an analyzing 
wavelet of width 60 nm to find the contact points. The JPK system allowed to measure more 
points per curve and to decrease experimental noise. Then the shear modulus was 
estimated using Equation 4. 
 
IV. Cell confinement. 
 
To allow the testing of multiple conditions in the same experiments, we designed 
modified standard polystyrene 24-well plates (BD Biosciences/Falcon, 15 mm diameter) in 
which PDMS pillars fixed on the plate lid held the micro-structured slides (Figure 27)273,458–460. 
When the lid was closed with a clamp, the slides were maintained on the cells with a 
moderate pressure, allowing precise confinement height. Soft PDMS cylinders (0.5 MPa 
young modulus measured), 2.5% longer than the well depth, were molded and fixed on the 
lid of the plate. A 14 mm diameter confinement glass slide bearing PDMS micro-structures 
(fabrication described in materials section) was placed on the top of each cylinder. Cells 
were seeded in the wells at 2x105 cells/mL. For non-adherent cells experiments, 24-well 
plates were coated with fibronectin (Sigma) to allow the adhesion of hematopoietic cell for 1 
hour at 37°C, before removal of the non-adherent fraction. The percentage of adherent cells 
was measured for each experiment. After 2 hours of incubation in fresh medium, the 
modified lid was positioned on the plate and gently clamped, thus confining more than 85% 
of the adherent cells. 
 
? ???
Figure 27 : Experimental setup for cell confinement. The lid of a multiwell plate is 
modified by introducing large PDMS pillars to hold the confinement slides. These pillars have 
the height of the plate, which can be slightly increased with a thin PDMS layer. When the 
multiwell plate containing adherent cells and culture medium is closed with the modified lid, 
the confinement slides are applied on the cells adhering to the bottom of the wells. Large 
pillars that are slightly higher than the well depth deform and apply pressure on the 
confinement slides. 
 
V. Quantitative Phase Imaging 
 
In the last decade, different teams have played a major role in disseminating the 
concepts of quantitative phase microscopy (QPM) for real time probing cellular structure and 
dynamics.466–470 We built in our laboratory a variant of the device of Popescu and co-
authors,471 interposing an amplitude diffraction grating in the image plane of an inverted 
microscope to design simple and compact homemade interferometer, coupled to a high rate 
video camera.472 The optical path length (OPL) measured by this microscope is defined as:  
 
(Equation 8) 
 
 
where nC (respectively n0) is the cell (respectively medium) refractive index, H is the height of 
the cell at position (X, Y), φ is the optical phase given by the interferometric measure, λ=532 
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nm is the optical wavelength. We use this microscope to compare the morphology of cells 
through their phase images, and to extract their OPL, which is directly related to the product 
of their thickness with their relative refractive index (compared to the buffer medium). We 
have here a fast and non-intrusive method for computing the cell refractive index and 
thickness. 
 
VI. Statistical analysis. 
 
Statistical significance was determined using the Wilcoxon-Mann-Whitney test in R-
software version 2.9.2. Bivariate analysis of the variance was carried out using the ANOVA 
method. Significant p-values are indicated by an asterisk (*p<0.05 ; ** p<0.005 ; *** 
p<0.0001). 
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Prmitive CML cell expansion relies on abnormal levels of BMPs 
provided by the niche and BMPRIb over-expression 	  
I. Introduction 
 
Chronic myelogenous leukemia (CML) likely arises from a stem cell (SC) 
transformation induced by the formation of the BCR-ABL oncogene. Without treatment, the 
disease evolves to an inexorable fatal blast crisis. Until recently, Imatinib has become the 
gold standard for chronic phase (CP) CML care. However, some discrete Philadelphia 
positive (Ph+) leukemic stem cells (LSCs) may be insensitive to tyrosine kinase inhibitors 
(TKIs)81,92,144 and therefore sustain detectable disease for many years. None of the 
therapeutic agents available to date seem to eradicate undifferentiated BCR-ABL+ cells that 
serve as a reservoir for additional oncogenic events leading to disease progression92,137,144,181 
and require continued treatment.473,474 Therefore, CML represents a unique model to study 
LSC biology and to elucidate some of the mechanisms of therapeutic resistance. Complete 
elimination of CML clones has rarely been achieved by TKI because of the development of a 
variety of cell-intrinsic and cell-extrinsic protective mechanisms. Extrinsic mechanisms are 
supported by the bone marrow (BM) microenvironment, the so-called “leukemic niche”. Bone 
morphogenetic proteins (BMPs) belong to the transforming growth factor-β superfamily and 
regulate hematopoietic SC fate both directly at various stages of SC differentiation388,403,475 
and indirectly through the control of their microenvironment.50,399 These molecules are 
naturally produced by stromal cells, megakaryocytes and platelets399. In humans, BMP2/4/7 
regulate proliferation, maintenance,402 clonogenicity and repopulating activities of immature 
cell populations.388,411 In the absence of erythropoietin, BMP2 induces cell commitment and 
differentiation towards erythropoiesis,404 while BMP4 sustains SC maintenance and 
megakaryocytopoiesis.399 BMP2/4 are inhibited by follistatin or FLRG binding which are 
soluble glycoproteins naturally expressed in the human BM microenvironment.404,476 
Follistatin and FLRG are involved in the regulation of immature hematopoietic cell 
adhesion,412 thus contributing to the regulation of human hematopoiesis.476 Survival of CML 
LSCs appears to be independent from the BCR-ABL oncogene181,477 which strongly suggests 
the involvement of other signals or of the microenvironment.195 Interestingly, the TGF-β 
family has been involved in the maintenance of CML LSCs.478 BMP signaling is often altered 
in numerous cancers and involved in cancer SCs properties.358 Here we asked if soluble 
BMP levels in the bone marrow of patients with active CML are altered and whether this is 
associated with molecular and/or cellular alterations in the responses of LSCs to BMP. 
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II. Results 
 
1. Molecular alterations in BMP signaling elements in CML cells 
 
To evaluate whether the endogenous BMP pathway is deregulated in CML, we 
compared the gene expression profiles of the main elements of the BMP pathway (Figure 
28A) in normal cells and CP-CML cells at diagnosis prior to any treatment, using quantitative 
PCR (qPCR). We found that the expression of several components was deregulated in CML 
cells (Figure 28B). When compared to normal BM, Smad1 (p<0.0001), Smad4 (p<0.0001), 
Smad6 (p=0.0062) and Id2 (p=0.0025) were significantly down-regulated while BMPRIb 
(p=0.0005), Smad5 (p=0.0455) and Runx1 (p=0.00175) were significantly up-regulated. We 
then investigated if these changes could also affect immature CD34+ CML cells. While 
Smad1 (p<0.0001), Smad8 (p=0.001), and the target genes Id2 (p<0.0001), Id3 (p<0.0001) 
and Runx2 (p<0.0001) were significantly down-regulated, BMPRIb (p=0.017) and Smad6 
(p=0.03) were up-regulated (Figure 28C). These results indicate that the BMP pathway is 
altered in immature CD34+ CML cells at all levels of the pathway. We then performed a 
paired analysis between CD34+ and CD34- cells purified from the same CP-CML samples at 
diagnosis to compare gene expression between immature and mature cells of the same 
patient and calculated a ratio for each individual RNA expression. Almost 60% of the BMP-
signaling components tested appeared to be differentially expressed between the two 
compartments. One of the most conserved alterations in both the CD34+ and CD34- cell 
populations, when compared to their healthy counterpart, was the high levels of BMPRIa and 
BMPRIb transcripts together with the very low expression of Smad1. Our results indicate that 
a major change occurs in the BMP signaling, including an over-expression of type I receptors 
(BMPRI), a down-regulation of Smad-signaling elements and a striking inversion of target 
gene expression. These data show that the BMP pathway is affected at all levels in CML. 
? ???
 
Figure 28 : Expression of BMP signaling elements in primary healthy and CML cells. 
(A) Representative scheme of the BMP signaling pathway that displays the main 
components of the signaling cascade including extracellular (soluble molecules), membrane, 
cytoplasm and nuclear located responding elements as well as some BMP target genes. 
Gene expression (by qPCR) of BMP signaling elements in healthy donor (open bars, n=18) 
and CP-CML samples at diagnosis (closed bars, n=53) for (B) the total number of 
mononuclear cells or (C) CD34+ immuno-selected hematopoietic cells. Results are 
expressed as fold change versus the reference value obtained for each gene using the same 
CD34- healthy donor sample. *p<0.05; **p<0.005; ***p<0.0001 indicate differences between 
the gene expression levels in CML donor samples compared with healthy donor samples. 
 
2. Deregulation of BMPRIb at the cell surface differentiates normal from immature 
leukemic cells 
We analyzed gene expression levels in the following sorted cell subpopulations 
obtained from healthy donor BM samples (n=4) or CP-CML cells at diagnosis (n=3): 
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immature primitive cells (C34+, CD38-); immature progenitors (CD34+, CD38+); lineage 
restricted progenitors (C34-, CD38+); and cells differentiated as monocytes/granulocytes 
(CD14+/CD15+); myeloid (CD33+); megakaryocytes (CD61+/CD41+); erythroid (Glycophorin 
A-GPA+); T (CD3+) and B (CD19+) lymphocytes. We focused on BMPRI as mediators of the 
exogenous effects of BMP and encoded by one of the most significantly perturbed genes at 
diagnosis. The higher expression of the BMPRIa (Figure 29A) and of the BMPRIb (Figure 
29B) was present in almost all of the CML subpopulations indicating that changes in the BMP 
pathway are a hallmark of leukemic subpopulations. We also analyzed their expression in 
cells from patients at diagnosis within the three established patient groups based on their 
Sokal score (low, intermediate or high) and at advanced stages (accelerated phase, blast 
crisis). BMPRIb expression progressively increased with disease phase conversely to that of 
BMPRIa (Figure 29C). However, while the increase of Bmi1 was only observed in late stages 
of the disease according to previous data,479 BMPRIb was highly up-regulated in CP-samples 
(>10-fold) as early as at diagnosis when compared with normal samples and again another 
10-times more elevated during the advanced phases. These data suggest that the 
expression of BMPRIb is early modified during the course of CML. 
? ???
Figure 29 : BMPRIb is specifically deregulated in primary immature CD34+ CML cells. 
Comparative expression of BMPRIa (A) and BMPRIb (B) genes in distinct sorted sub-
populations obtained from healthy donor BM samples (n=4, open bars) and CP-CML patient 
samples at diagnosis (n=3, closed bars). The sub-populations represent: immature primitive 
cells (CD34+, CD38-), immature progenitors (CD34+, CD38+), lineage restricted progenitors 
(CD34-, CD38+), monocytes/granulocytes (CD14/CD15+), mature myeloid cells (CD33+), 
megakaryocytes (CD61/CD41+), erythroid compartments (Glycophorin A-GPA+), T (CD3+) 
and B (CD19+) lymphocytes. Results are expressed as fold change versus the reference 
value for each gene using the same healthy donor sample. *p<0.05; **p<0.005; ***p<0.0001 
indicate differences between the gene expression levels in CML compared with healthy 
samples. (C) Comparative expression of Bmi1, BMPRIa and BMPRIb genes in CD34+ and 
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CD34- cells obtained from healthy donors (n=14, open bars) and CML patients samples 
either in chronic phase (CP) at diagnosis (n=53, grey bars) or in advanced (Adv) phase at 
diagnosis (n=4, closed bars). Results from patient samples in chronic phase at diagnosis are 
sub-divided between low (<0.8), intermediate (0.8–1.2) or high (>1.2) Sokal score (different 
tone grey bars). (D) Flow cytometry analysis of BMPRIa and BMPRIb cell surface expression 
in CD34+ and CD34- cells obtained from healthy donors (n=9, open bars) and CP-CML 
samples at diagnosis (n=14, closed bars) using a Facscalibur® cell analyzer (Becton 
Dickinson). Results are expressed as the % of receptor-expressing cells. *p<0.05 indicate 
differences between healthy and CML samples. Comparative expression of (E) ABL, BCR-
ABL and Bmi1 genes or (F) BMPRIa and BMPRIb genes by qPCR in parental TF1 cells 
either transduced with an empty vector (non BCR-ABL, open bars) or with a vector 
containing BCR-ABL expressing sequence (closed bars). Results represent the mean value 
± SEM of n=7 (E) or n=14 experiments (F). *p<0.05 indicates differences between parental 
TF1 cells transduced with an empty vector and BCR-ABL-transduced TF1 cells. (G) Flow 
cytometry analysis of BMPRIb receptor cell surface expression on either parental TF1 cells 
transduced with an empty vector (non BCR-ABL, open bars) or with a vector containing 
BCR-ABL expressing sequence (closed bars) and as indicated, performed on viable cells 
using a Facscalibur® (Becton Dickinson). Results represent the mean value ± SEM of n=8 
experiments. (**p<0.005 indicates differences between parental TF1 cells transduced with an 
empty vector and BCR-ABL-transduced TF1 cells. 
 
We analyzed BMPRI cell surface expression by flow cytometry. While the increased 
expression of BMPRIa reach statistical significance in mature CD34-, BMPRIb was 
significantly over-expressed in immature CD34+ CML cells (p=0.037 and p=0.04, 
respectively) (Figure 29D). We analyzed the impact of the introduction of BCR-ABL in the 
human cell line TF1, used as a model of immature CD34+ cells that displays clongenic ability 
similar to human BM CD34+ cells and able to differentiate into myeloid lineages.480 When 
compared to a wild type (WT) cell line or when transduced with an empty vector, BCR-ABL-
transduced TF1 cells (TF1-BCR-ABL) increased their transcriptional levels of BCR-ABL and 
ABL as expected (Figure 29E) but not levels of Bmi1 the deregulation of which more likely 
reflects a secondary event479 (Figure 29C). While no difference was observed between 
transduced and un-transduced cells regarding the BMPRIa expression, the transcriptional 
level of BMPRIb increased in TF1-BCR-ABL cells (p=0.014, Figure 29F). This was confirmed 
at the protein level (p=0.0004, Figure 29G). These data indicate that the TF1-BCR-ABL 
model reproduces the deregulation observed in CP-CML patients regarding the BMPRI 
expression patterns that are directly driven by the BCR-ABL oncogene. Data in both primary 
cells and the TF1-model strongly suggest a change in the regulation of LSC by the BMP 
pathway. 
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3. Excess of both BMP2 and BMP4 within the tumoral environment contributes to 
early increases in BMPRIb expression in immature CML cells 
 
We then investigated if soluble BMP involved in the regulation of normal HSC and 
progenitors399,404,476 were present in the CML tumor environment. Using an ELISA assay, we 
measured the levels of BMP4 and BMP2 present in BM plasma obtained from healthy donors 
and CP-CML patients at diagnosis separated into two groups on the basis of their number of 
circulating platelets (elevated: >400G/l or normal: ≤ 400G/l) as a potential source of soluble 
BMPs399 (Figure 30A). We observed a significantly higher level of BMP2 (p=0.0001) and of 
BMP4 (p=0.0008) in patients with normal platelet counts and a further increase in some 
patients with a deregulated platelet count; however, this increase was not significant. Unlike 
BMP4, BMP2 transcripts are elevated in normal CD34+ blood cells and low in CD34- cells 
from healthy donors (Figure 30B). In CML blood, lower levels of BMP2/4 transcripts were 
detected in CD34+ and CD34- cells isolated from the same samples. Conversely, primary 
leukemic stromal cells481,482 displayed higher levels of BMP4 transcripts and BMP2 
transcripts to a lesser extent (Figure 30C). We used BM biopsies to identify the in situ source 
of soluble BMP2 and BMP4 using antibody staining. We observed an increase in BMP2 
staining in mature polynuclear (PN) cells and an increase in BMP4 staining in endothelial 
sinusoid cells (Figure 31D). We also detected higher levels of BMP2 transcripts in CP-CML 
sorted BM-myeloid (CD33+) and -megakaryocytic (CD61+) cells, confirming the probable but 
partial contribution of the megakaryocytic cells to BMP2 levels together with PN cells (Figure 
31A). Our data indicates that the leukemic microenvironment is the main source of soluble 
BMP2/4 involved in the maintenance and expansion of LSCs that do not produce these 
cytokines in an autocrine fashion in the chronic phase. Therefore, in the leukemic context, 
CD34+ cells are exposed to higher concentrations of BMP2/4. We analyzed the effect of such 
a chronic exposure on the expression of the BMPRIb by treating TF1 cell lines with BMP2 or 
BMP4 for 4 weeks. Under these conditions, in the presence of the oncogene BCR-ABL, the 
levels of BMPRIb appeared to be maintained by BMP4 and significantly increased by BMP2 
treatment (p=0.0268) while a slight but not significant effect was observed in non-transduced 
TF1 cells (Figure 30E). 
 
? ???
 
Figure 30 : High levels of BMP2 and BMP4 produced by the CML microenvironment 
contributes to BMPRIb induced expression. (A) ELISA quantification of BMP4 and BMP2 
in BM plasma obtained from healthy donors and CP-CML samples at diagnosis. Data are 
categorized according to circulating platelet number measured for CML patients as either 
normal (≤400G/l) or abnormally elevated (>400G/l). Results expressed in pg/mL represent 
the mean value ± SEM of the indicated number of analyzed samples. *p<0.005 and 
***p<0.0001 indicate differences between the levels of BMP2 and BMP4 in CP-CML samples 
at diagnosis compared with healthy samples. Comparative expression of BMP2 and BMP4 
genes in (B) CD34+ and CD34- cells obtained from healthy (n=19, open bars) and CML blood 
samples (n=41, closed bars), *p<0.0001 indicates differences between the expression of 
BMP2 and BMP4 genes in CML patient blood samples in CP at diagnosis compared with 
healthy samples; and in (C) stromal cells derived from 3 to 4 weeks of culture of un-
manipulated BM samples from healthy (n=4, open bars) and at diagnosis CP-CML samples 
(n=6, closed bars). (D) In situ staining of BMP2 and BMP4 and their control antibody 
performed on sections of bone marrow biopsies from non-hematologic malignancy patients 
(n=2, upper panels) and CP-CML patients at diagnosis (n=3, lower panels). Pictures were 
captured on a DMR microscope using PL FLUOTAR objective (Leica) at a magnification of 
x40/1.00-0.50 oil. The following cells are indicated in the picture: (1) polynuclear neutrophils, 
? ???
(2) immature granular neutrophils (promyelocytes/myelocytes), (3) megakaryocytes, (4) 
erythroblasts and (5) endothelial cells of the sinusoid. (E) Flow cytometry analysis of BMPRIb 
receptor cell surface expression on parental TF1 cells either transduced with an empty vector 
(non BCR-ABL, open bars) or transduced with a vector containing BCR-ABL expressing 
sequence (closed bars) after chronic exposure for 4 weeks to either BMP2 or BMP4 
(50ng/mL). Results represent the mean value ± SEM of n=8 experiments. *p<0.05 indicates 
differences between parental TF1 cells transduced with an empty vector and BCR-ABL-
transduced TF1 cells. (F) Selected CD34+ cells isolated from CP-CML samples were 
incubated in serum-free medium (6x105/mL) for 7 days in the presence of BMP4 or BMP2 
(50ng/mL), with or without co-culture on a stroma composed of HS27A cells seeded at 2x104 
cells/mL 1 day before the experiment. Comparative expression of BMPRIb gene was then 
performed on CP-CML CD34+ cells. Results represent the mean value ± SEM of n=3 
experiments. 
 
Similar results were obtained using primary CD34+ CP-CML cells which displayed an 
amplified BMPRIb expression when co-cultured with the immortalized human BM-stroma cell 
line HS27A483 that over-produces BMP2/4 (Figure 31B and Figure 30F). Together, our results 
show that immature leukemic cells not only display intrinsic alterations due to the BCR-ABL 
oncogene but also increased and sustained high levels of BMPRIb expression regulated by 
their niche. 
 
Figure 31 : Expression of BMP2 and BMP4 in distinct sub-populations. (A) Comparative 
expression of BMP4 and BMP2 genes in distinct sorted subpopulations obtained from 
healthy donor BM samples (n=4, open bars) and CP-CML patient BM samples at diagnosis 
(n=5, closed bars). The subpopulations represent: mature myeloid cells (CD33+) and 
megakaryocytes (CD61+). (B) Expression of BMP4 and BMP2 genes in HS27A cell line (n=6) 
compared with stromal cells from healthy donors (n=4) and CP-CML patients (n=6). Results 
are expressed as a fold change versus the same reference sample. 
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4. BMP2 and BMP4 expand immature CD34+ cells from CP-CML patients 
 
Deregulations in the BMP pathway in immature leukemic cells together with a 
significant increase in available soluble BMP within the leukemic environment predict a 
perturbed response of LSC to BMP. To investigate this hypothesis, we compared the 
biological response of CD34+ immature cells isolated from healthy BM donors or CP-CML 
patients at diagnosis to soluble BMP4 and BMP2. CD34+ cells were incubated for 7 days in 
serum-free medium supplemented with BMP2 or BMP4 (50ng/mL) and analyzed for cell 
viability, proliferation and CD34 cell surface expression. We observed no differences in cell 
viability (Figure 32A) and proliferation (Figure 32B) compared with untreated cells (none), 
which suggests a lack of toxic effects of BMP2 or BMP4 in primitive cells. The number of 
CD34-expressing cells increased in the CML samples in the presence of BMP4 (p=0.03) and 
BMP2 (p=0.026) but not in healthy donors (Figure 32C). This increase in CD34+ cells 
suggests either higher survival rates/maintenance or the amplification of LSC, as shown for 
BMP4 in normal HSC.399,411 We then examined the quantities of stem and progenitor cells 
within the BMP-treated CD34+ cells using LTC-IC and CFC assays. BMP2 had no effect but 
LTC-IC numbers increased with BMP4 by 5.6-fold (p=0.06) in healthy cells and similarly by 
4.7-fold in leukemic cells (Figure 32D). However, 58% (7/12) of healthy CD34+ cells were 
expanded for their LTC-IC content by BMP4 and this frequency decreased to 34% (3/9) in 
CP-CML samples. Surprisingly, while less CML CD34+ cells responded to BMP4, when they 
did, it was more pronounced as indicated by the large number of LTC-IC colonies we 
detected (data not shown). The progenitor compartment (CFC) was increased by both BMP4 
and BMP2 treatment in healthy (1.6-fold and 1.5-fold p=0.024, respectively) and leukemic 
samples (2.5-fold, p=0.033 and 2.4-fold p=0.022 respectively) (Figure 32E). To establish 
whether the maintenance or amplification of CFC or LTC-IC by BMP affect remaining 
residual healthy or leukemic cells, we harvested individual colonies and analyzed them by 
qPCR for their expression of the normal Abelson (ABL) gene and the BCR-ABL oncogene. 
Colonies derived from healthy samples expressed ABL, but not BCR-ABL (data not shown). 
In the presence of BMP2 (5/5) and BMP4 (21/22), colonies detected in LTC-IC assays from 
patient samples were truly leukemic as over 95% of them expressed BCR-ABL (Figure 32F). 
All single CFC colonies (100%) derived from treated CD34+ cells expressed BCR-ABL. 
These results indicate that BMP2/4 specifically affect the leukemic primitive cell 
compartment. In summary, these results indicate that changes in the expression of multiple 
BMP signaling factors correlate with a deregulated and amplified biological response in 
leukemic CD34+ cells after exposure to soluble BMP. 
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Figure 32 : Effects of BMP2 and BMP4 treatments on leukemic progenitor 
amplification. Selected CD34+ cells isolated from healthy donors (open bars) or CP-CML 
(closed bars) samples were incubated in serum-free medium (6x105/mL) for 7 days in the 
presence of BMP2 or BMP4 (50ng/mL). *p<0.05 indicate differences between healthy and 
CML samples. Cell viability (A) and proliferation (B) were evaluated using trypan blue 
staining and cell counting. Results are expressed as the % of viable cells or the proliferation 
ratio that is the ratio of cell counts to the number of input cells. The mean ± SEM of n=10 
experiments is presented. (C) Phenotypic analysis of CD34, the hematopoietic progenitor 
marker, was performed using flow cytometry on a Facscalibur® cell analyzer (Becton 
Dickinson) and gated for viable cells. Results are presented as the mean ± SEM of n=5 
experiments for healthy donors and n=8 experiments for CML patients. (D) Stem cell content 
of treated-cells was analyzed by the LTC-IC co-culture assay and results are presented as 
the mean value ± SEM for of n=12 or n=9 experiments for healthy donors and CML patients, 
respectively. Results are presented as the total LTC-IC derived colonies after 5 weeks of co-
culture per 1x104 seeded cells. (E) The progenitor content of treated-cells was analyzed by 
the clonogenic CFC assay. Results are expressed as the ratio of treated to untreated cells 
and represent the mean value ± SEM of n=12 or n=19 experiments for healthy donors and 
CML patients, respectively. (F) The number of leukemic colonies in either CFC- or LTC-IC-
derived colonies was assessed by picking individual colonies to quantify expression of ABL, 
BCR-ABL and the reference genes BGUS and TBP by qPCR. Leukemic positive colonies 
were determined by simultaneous detection of all genes while normal negative colonies were 
stated as ABL positive but BCR-ABL negative. In all cases, internal gene controls were 
positive, otherwise those samples would have been removed. Results are expressed as the 
% of positive BCR-ABL colonies out of the total assayed colonies of n=3 experiments for 
healthy donors and CML patients. 
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5. BMP2 and BMP4 induce the specific amplification of committed myeloid 
progenitors 
 
To confirm the effect of BMP2/4 on leukemic CD34+ progenitors, we analyzed their 
activities on the different categories of clonogenic cells (Figure 33).  
 
Figure 33 : Effect of the BMPs on the clonogenic potential of primary single cells. (A) 
Illustration of the different functional assays output throughout hematopoiesis differentiation 
scheme. The content of treated cells in distinct hematopoietic progenitor categories was 
determined using the clonogenic CFC assay. We scored them as early erythroid (over three 
clusters) and myeloid (over 1x103 cells/colony) as well as late erythroid (one to two clusters) 
and myeloid (below 1x103 cells/colony). (B) Sorted CD34+, CD38- stem cells from healthy 
and CML samples were plated at one cell/well and were incubated in serum-free medium for 
7 days in the presence of 50ng/mL BMP2 or BMP4. After 7 days, methylcellulose was added 
to the wells and incubated for 2 weeks prior to scoring of single cell derived CFC colonies. 
CFC categories from data obtained in each condition as erythroid (E-CFC) and mixed 
colonies (CFU-GEMM) are presented here. Values of colony subtypes are expressed as a 
percentage of the total number of colonies obtained from five experiments for normal and 
CML. 
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The most significant effects were observed in the granulo-monocytic compartment 
with a 9.6-fold increase in late leukemic CFU-GM induced by BMP4 treatment (p=0.045). 
BMP2-exposure led to a 13-fold increase in early granulo-monocytic progenitors (p=0.05, 
Figure 34A). No difference was observed in the number of erythroid or (CFU-GEMM) mixed 
colonies (data not shown). These data strongly support the notion that BMP2/4 are involved 
in the amplification of leukemic myeloid progenitors. We compared the effects of BMP2/4 in 
the same experiments on CD34+ CML cells obtained from 18 patients. The absolute number 
of colonies, obtained in each condition from the same initial number of purified CD34+ CML 
cells, was used to normalize the number of colonies obtained for the erythroid and granulo-
monocytic categories and values were plotted as the percentage of progenitor subtype. 
Compared to untreated CML cells (54%), those treated with BMP4 or BMP2 amplified more 
granulomonocytic progenitors (61% and 65%, respectively) at the expense of erythroid 
progenitors (Figure 34B). The balance between granulo-monocytic and erythroid colonies 
thus significantly shifted towards a more granulo-monocytic phenotype with either BMP2 
(p=0.01) or BMP4 (p=0.02) in a leukemic context, but remained unchanged for healthy cells. 
To evaluate if BMP2/4 induced LSC commitment towards the myeloid lineage, we sorted 
CD34+, CD38- cells from CP-CML patients at diagnosis (n=5) and from healthy donors (n=5). 
The cells were plated at one cell per well in serum free conditions with or without BMP2 or 
BMP4. After 7 days, methylcellulose was added to the wells and single cell derived colonies 
were scored 2 weeks later. Consistent with the bulk culture results, less than 2% of normal 
single cells gave rise to colonies (Figure 34C) while the CML samples exhibited a strong 
increase in cloning efficiency (10–16%). Only the leukemic CD34+, CD38- cells responded to 
BMP2/4, with a slight increase in total and CFU-GM colonies by BMP4 and no effect in the 
presence of BMP2. These data suggest that only BMP4 has a very weak effect on single cell 
proliferation and the clonogenic ability of the LSC while BMP2 is likely to contribute to the 
expansion of more differentiated myeloid progenitors. 
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Figure 34 : BMP2 and BMP4 amplify leukemic myeloid progenitors. Selected CD34+ 
cells (6x105/mL) were incubated in serum-free medium, for 7 days in the presence of either 
BMP2 or BMP4 (50ng/mL). The progenitor content of the treated-cells was analyzed using 
the CFC assay. (A) We scored them as indicated as early or late erythroid-E and granulo-
monocytic-GM. Results represent the mean value ± SEM of n=12 or n=15 experiments for 
healthy donors and CML patients respectively and are expressed as ratio of treated to 
untreated cells (none). (B) CFC values obtained from CD34+ cells treated in the same 
experiments with BMP2 or BMP4 and isolated from n=12 or n=18 different healthy or CP-
CML patients at diagnosis respectively are expressed as a % of the total number of colonies 
obtained and presented as pie charts. p<0.05 indicate differences between treated and 
untreated cells. (C) Sorted CD34+, CD38- cells from healthy and CML samples were plated at 
one cell per well in serum-free medium in the presence of 50ng/mL of BMP2 or BMP4. After 
7 days, methylcellulose was added to the wells and single cell-derived colonies were scored 
2 weeks later. We scored all colonies (total CFC) as well as for CFU-GM content. Results are 
expressed as % of wells that give rise to colonies and represent the mean value ± SEM of 
n=5 experiments for healthy donors and CML patients. 
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6. BMPRIb drives primitive leukemic myeloid progenitor amplification 
 
To characterize the direct involvement of the BMP pathway in the amplification of 
leukemic myeloid progenitors we analyzed the effect of BMP2/4 treatments on the CFC and 
LTC-IC output of primary CD34+ cells. Cells were isolated from healthy donors or CP-CML 
patients but divided into two groups on the basis of the level of BMPRIb gene expression. 
The BMPRIb-low group expressed transcript levels similar to normal samples (<10 arbitrary 
units) contrarily to the BMPRIb-high group that had transcript levels increased by 10-fold. In 
contrast to the BMPRIb-low patients, the BMPRIb-high group of samples strongly responded 
to BMP4 or BMP2 exposure, as measured by a major increase in LTCIC (107-fold; p=0.0018 
and 15-fold; p=0.003, respectively) (Figure 35A) and CFC (4-fold; p=0.05 and 4-fold; 
p=0.008, respectively) (Figure 35B). These data suggest that while BMP4 has a very weak 
effect and BMP2 has no effect at all on cell fate decisions, in the overall CP-CML analysis of 
LSC, BMP2/4 both appear to induce a very strong expansion of LSC over-expressing 
BMPRIb that correlates to CFC amplification. Using the TF1-BCR-ABL model, we 
reproduced the CFC expansion following BMP4 or BMP2 chronic exposure to a similar 
extent as measured in primary cells with a 3.5-fold and 6-fold CFC increase in the presence 
of BMP4 or BMP2, respectively (Figure 35C) and no effect with control cells (TF1-Empty 
vector). The introduction of BMPRIb was by itself sufficient to increase the CFC number by 
2.1-fold (p=0.003) while BCR-ABL alone led to only a 1.5-fold increase (p=0.05) (Figure 
35D). Introducing BMPRIb into TF1-BA cells did not further expand CFCs. Lastly, we treated 
primary CD34+ cells taken at diagnosis from CP-CML patients from BMPRIb-low or -high 
groups with soluble forms of the BMPRIa (sBMPRIa) or the BMPRIb (sBMPRIb) using 
previously determined optimal conditions399 to out compete BMP binding to endogenous 
membrane-bound receptors. The BMP2/4-mediated CFC-increase was reduced in the 
presence of sBMPRIb and inversely increased when incubated with sBMPRIa (Figure 35E). 
Similarly, a significant (p=0.042) inhibition by of BMP2-driven CFC expansion was observed 
(Figure 35F) by treating TF1 cells transduced or not with BCRABL for 48 hours with 
sBMPRIb. These data confirm that changes in BMPRIb expression are associated with an 
alteration of the BMP2/4 response involved in the amplification of the leukemic myeloid stem 
and progenitor compartment in CP-CML patients. 
? ???
 
Figure 35 : BMPRIb receptor mediates BMP2 and BMP4 effects on LSC and myeloid 
progenitors. Following qPCR analysis of BMPRIb expression, CP-CML samples were 
divided as low and high BMPRIb-expressing CML samples. CD34+ cells were then isolated 
from healthy donors (open bars) or both groups of CP-CML samples (closed bars) and 
incubated at 6x105/mL in serum-free medium, for 7 days in the presence of BMP2 or BMP4 
(50ng/mL). (A) The stem cell content of the treated cells was analyzed using the LTC-IC co-
cultured assay and results represent the mean value ± SEM of the indicated number of 
samples. Results are presented as the total LTC-IC derived week 5 colonies per 1x104 
seeded cells. (B) The progenitor content of treated cells was analyzed using the CFC assay. 
Results are expressed as ratio of treated to untreated cells and represent the mean value ± 
SEM of the indicated number of samples. (C) BCR-ABL- (closed bars) or empty vector-
transduced (open bars) TF1 cells were continuously treated for 4 weeks by 50 ng/mL BMP2 
or BMP4 then assayed by CFC assay for their progenitor content. Results are expressed as 
the ratio of treated to untreated cells and represent the mean value ± SEM of n=5 
experiments. (D) Parental TF1 cells (TF1-WT) or TF1-BCRABL (TF1-BA) cells were 
transfected with a control empty (grey bars) or a BMPRIb-encoding (dark grey bars) vector. 
The effect on CFC output was analyzed using the CFC assay. Results are expressed as the 
total CFC colonies per 1x103 seeded cells and represent the mean value ± SEM of n=7 or 
n=3 experiments for TF1-WT and TF1-BCR-ABL, respectively. (E) The progenitor content of 
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CD34+ cells isolated from healthy donors (open bars) or CP-CML (closed bars) samples. The 
cells were divided as low- and high-BMPRIb-expressing CML-samples and were treated for 7 
days in serum-free medium by BMP2 or BMP4 (50 ng/mL) in the presence or absence of 
soluble BMPRIa or BMPRIb receptor (4 µg/mL). Results are expressed as ratio of treated to 
untreated cells and represent the mean value ± SEM of the indicated number of experiments. 
(F) The progenitor content of parental TF1 cells (TF1-WT, open bars) or TF1-BCR-ABL cells 
(closed bars) was analyzed by CFC assay following 48 hours of treatment by BMP2 or BMP4 
(50ng/mL) with or without soluble BMPRIb receptor (4 µg/mL). Results are expressed as the 
total CFC colonies per 1x103 seeded cells and represent the mean value ± SEM of n=5 
experiments. *p<0.05 indicates differences between parental TF1 cells transduced with an 
empty vector and BCR-ABL-transduced TF1 cells. 
 
III. Discussion 
 
In various cancers including leukemia, the SC niche is often deregulated without 
being transformed per se85,484 but its contribution to the maintenance, survival and resistance 
of LSC has only started to be deciphered. Here, we report a significant increase in the 
availability of soluble BMP2 and BMP4 in the BM of CP-CML patients at diagnosis, combined 
with an over-sensitivity of LSC to these molecules. In line with a recent in vivo study that 
demonstrated that CML-associated changes in the microenvironment confer a selective 
growth advantage to LSC,485 we revealed for the first time the crucial role of alterations in the 
BMP pathway during the early stages of CML. By analyzing more than 70 samples from CP-
CML patients at diagnosis, we demonstrated that the expression of a multitude of elements 
in the BMP pathway are altered in almost all CML subpopulations; including the stem 
cell/progenitor compartment, indicating a pathologic deregulation of this pathway while not 
reflecting the prevalence of a specific subpopulation. Some changes become more striking 
during the course of disease progression, such as BMPRIb over-expression. Our results, 
together with the fact that we restricted our analysis to samples obtained from patients that 
only display the t(9;22) translocation without additional clonal abnormalities, suggest that the 
BMP signaling alterations represent an early event in the transformation process. We 
demonstrated that alterations in the BMP pathway do not prevent leukemic cells from 
responding to exogenous BMP2/4. These data were confirmed using a model of BCR-ABL-
positive immature CD34+ cells reproducing the main features observed in primary immature 
CP-CML cells. Using this model, we further showed that over-expression of BCR-ABL 
increased BMPRIb surface expression. The erythroid-myeloid progenitor balance changed in 
favor of the granulo-monocytic lineage when treating CML-CD34+ cells with BMP2/4. Also, 
BMP4-expanded LTC-IC were all genotypically Ph+, suggesting that the biological response 
of CD34+ cells to BMP2/4 is specifically altered in CML. It then suggests that BMP4-mediated 
amplification and maintenance of LSC and BMP2-dependent expansion of myeloid 
progenitors are related to a hypersensitivity to exogenous BMP2/4 signaling mediated by 
? ???
BMPRIb over-expression. This would further explain how LSC, in contrast to normal HSC, 
respond to soluble BMPs, thus contributing to the vast increase in the myeloid compartment 
observed in CML. In summary, we have demonstrated the existence of molecular and 
functional alterations in the BMP pathway in CML cells, as well as alterations in the quantities 
of soluble BMPs present in the tumor niche itself.486 These alterations are involved in the 
chronic phase of the disease through their role in the survival of LSCs as well as in the 
expansion of myeloid progenitors (Figure 36). The analysis of the BMP pathway may 
therefore represent an interesting prognostic tool, allowing the design of drugs directly 
targeting the reservoir of LSC. 
 
Figure 36 : Proposed model for BMP pathway alteration effects on CML LSC survival 
and myeloid progenitor expansion. 
	   144	  
Role of BMP pathway alterations and soluble BMP production in 
LSC resistance to TKI 
 
I. Introduction 
 
One of the main causes of treatment failure in cancers is the development of drug 
resistance by cancer cells.85 The persistence of cancer stem cells (CSC) might explain 
cancer relapses as they could allow reactivation of cancer cells proliferation following 
therapy, leading to disease persistence and ultimately to patients’ death.85 Clinically, it is 
crucial to develop therapeutic strategies able to target resistant CSC in order to cure the 
patients. In this context, Chronic Myelogenous Leukemia (CML) is the reference model of a 
true hematopoietic stem cell (HSC) alteration by a t(9,22) chromosomal translocation leading 
to the formation of the BCR-ABL fusion protein,487 with high tyrosine kinase activity and 
directly responsible of the leukemic transformation.92,105 Despite the success of targeted 
therapies against BCR-ABL with the development of tyrosine kinase inhibitors (TKIs),131 a 
residual disease is still detected in many CML patients, probably due to the persistence in 
vivo of CML leukemic stem cells (LSCs).81,92,144 None of the therapeutic agents available to 
date seem to eradicate these undifferentiated BCR-ABL+ cells that may serve as a reservoir 
for additional oncogenic events.92,144,181 In some cases, resistance to TKIs treatment 
appears, involving different mechanisms with 30% of unknown origin that could be due to 
LSC survival.488 LSC are controlled by a variety of biochemical and biomechanical signals 
from the leukemic niche.489 Thus, deregulation of these signals could contribute to LSC 
emergence and resistance. We demonstrated for the first time that alterations of intracellular 
BMP signaling pathway in CP-CML primary samples corrupt and amplify the response to 
exogenous BMP2 and BMP4, which are abnormally abundant in the tumor 
microenvironment.486 Considering the crucial role of BMP pathway alterations in the 
maintenance of CP-CML LSC, these alterations could also influence LSCs resistance upon 
TKIs treatment. The importance of the BMP pathway in CML LSC is also illustrated by a 
recent discovery demonstrating that Twist-1, a bHLH embryonic transcription factor often 
regulated by BMPs,446,447,490 constitutes a new predictive factor of TKI response in CML 
patients.445 Interestingly, a reciprocal regulation between Twist-1 and BMP pathway elements 
has been demonstrated,448,449 depending on the cellular context. Here we asked whether 
alterations of soluble BMP levels in the bone marrow of CML patients and/or alterations of 
BMP signaling pathway in CML LSCs could be involved in resistance to TKIs. 
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II. Results 
 
1. Increase of BMP2 and BMP4 production with the emergence of resistance in 
tumor microenvironment 
 
We first investigated if soluble BMP involved in the amplification of immature CP-CML 
cells were present in the CML tumor environment under TKIs treatment. Using an ELISA 
assay, we measured the levels of BMP4 and BMP2 present in BM plasma obtained from 
healthy donors, CP-CML patients at diagnosis, CML patients in complete cytogenetic 
remission (CCyR) and CML patients resistant to TKIs treatment. We previously observed an 
increase of BMP2 and BMP4 production in the CP-CML bone marrow environment.486 
Interestingly, we detected lower levels of BMP2 and BMP4 in patients that attained CCyR 
under TKIs treatment compared to CP-CML patients at diagnosis (Figures 37A and B). 
However, BMPs levels remained slightly higher compared to those observed in healthy 
donors bone marrow environment. In addition, the results observed for CML patients who 
developed a resistance to TKIs treatment are even more striking. Indeed, we observed an 
increase of both BMP2 and BMP4 levels in the bone marrow of resistant CML patients as 
compared to patients with an optimal response to TKIs treatment (CCyR). 
 
Figure 37 : Levels of BMP2 and BMP4 produced in the CML bone marrow 
microenvironment. (A) ELISA quantification of BMP4 and (B) BMP2 in BM plasma obtained 
from healthy donors, CP-CML patients at diagnosis, patients in complete cytogenetic 
remission (CCyR) or patients resistant to TKIs treatment. Results expressed in pg/mL 
represent the mean value ± SEM of the indicated number of analyzed samples. 
 
2. Molecular alterations in BMP signaling elements in resistant CML cells 
 
To evaluate whether the endogenous BMP pathway is specifically deregulated in 
CML patients resistant to TKI treatment, we compared the gene expression profiles of the 
main elements of the BMP pathway in CML cells at diagnosis prior to any treatment, using 
quantitative PCR (qPCR). After clinical follow-up of at least 2 years, the samples analysed at 
diagnosis were separated between sensitive and resistant to TKI treatment (Figure 38A). We 
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found that the expression of several components of the BMP pathway was deregulated in 
mature CD34- cells from resistant CML patients (Figure 38B). When compared to sensitive 
CD34- CML cells, BMP2, BMPRIa, BMPRII, Bambi and Smad4 were significantly down-
regulated while Twist-1, BMP4 and Foll were significantly up-regulated. We then investigated 
if these changes could also affect immature CD34+ CML cells. While BMPRIa and Smad4 
were significantly down-regulated, Twist-1, BMP2, BMP4, FLRG, Smad1 and Smad6 were 
up-regulated (Figure 38C). While this needs to be confirmed at protein level, the increase of 
both BMP2 and BMP4 expression in immature resistant CML cells could sign the activation 
of an autocrine loop for BMP production in these cells. These results indicate that the BMP 
pathway is altered in immature CD34+ CML cells at all levels of the pathway.
 
Figure 38 : Expression of BMP signaling elements in primary CML cells. (A) Gene 
expression (by qPCR) of Twist-1 and BMP signaling elements in sensitive CML samples at 
diagnosis (blue bars, n=50) and resistant CML samples at diagnosis (red bars, n=24) for (B) 
CD34- cells or (C) CD34+ immuno-selected hematopoietic cells. Results are expressed as 
fold change versus the reference value obtained for each gene using the same CD34- 
healthy donor sample. 
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Moreover, although the BMP signaling pathway seems to be profoundly altered with 
the resistance, in some cases these alterations are radically opposed between immature 
(CD34+) and mature (CD34-) compartments. For example, it is the case for Smad6 gene, a 
specific inhibitor of the BMP signaling pathway.491 Indeed, we observed a 10-fold increase of 
Smad6 expression in CD34+ cells from resistant patients compared to CD34+ cells from 
sensitive patients (Figure 38), while almost a slight decrease was observed for Smad6 
expression in CD34- cells. 
However, deregulation of Smad6 in CD34+ cells appeared more complex than we first 
realized. Indeed, when comparing its expression for each single patient, we observed an 
increased heterogeneity in Smad6 gene expression levels in resistant patients (Figure 39A). 
We discriminated two groups of patients based on Smad6 mean expression in CD34+ cells 
isolated from healthy donors (Figure 39B). We then found that among 31 resistant patients 
samples, 7 over-express Smad6 while 24 display a decrease of Smad6 expression as 
compared to sensitive samples, suggesting the possibility of two different mechanisms 
involved in CD34+ cells resistance to TKIs. Thus, a minority of resistant patients displayed a 
strong over-expression of Smad6, while most samples showed a significant decrease in 
expression of Smad6 compared to the values observed in CD34+ donors or patients sensitive 
to treatment (0.4 versus 1.6 and 1.3 respectively). Nevertheless, in all resistant patients, we 
observed an over-expression of Twist1 in both mature and immature compartments, 
consistent with a previous report of our group. 445 
 
 
 
 
 
 
 
 
 
 
 
? ???
 
Figure 39 : Expression of Smad6 in CD34+ cells from healthy donors and CML patients. 
Smad6 gene expression (by qPCR) in CD34+ cells from healthy donors (white dots, n=14), 
sensitive CML samples at diagnosis (blue dots, n=36) and resistant CML samples at 
diagnosis (red dots, n=31). Each dot represents the value obtained for each individual 
sample. (A) The line and the associated value represent the mean of all the values obtained 
for a cell category. (B) For resistant CML patients at diagnosis only, the values were 
separated into two distinct sub-groups: a sub-group containing the samples with Smad6 
expression higher than the mean of sensitive CML samples, and a sub-group with the 
samples displaying Smad6 expression smaller than the mean of sensitive CML samples. The 
lines and the associated values represent the mean of all the values obtained for each sub-
group. Results are expressed as fold change versus the reference value obtained for the 
same CD34- healthy donor sample. 
 
3. Smad6 expression controls Imatinib sensitivity in KCL22 cells 
 
We then evaluated the potential role of Smad6 expression on resistance of CML cells 
to Imatinib treatment. To this aim, we used the KCL22 CML cell line for which we dispose of 
sensitive (KCL22S) and resistant (KCL22R) clones to TKI treatment.457 Each cell line was 
transduced with an empty vector (pCT) or a vector containing Smad6 expressing sequence 
(pS6) and with a scramble vector (shCT) or a vector containing short hairpin RNA sequence 
directed against Smad6 (shS6). After 2 days of culture, Smad6 expression was controlled by 
qPCR and cells were incubated in the presence of different doses of Imatinib. After 3 days of 
culture, cell proliferation was determined by trypan blue staining. We then observed that 
Smad6 over-expression was associated with a decrease of cell proliferation in response to 
increasing doses of Imatinib in both sensitive and resistant cell lines (Figure 40A). 
Conversely, Smad6 inhibition led to a decrease of KCL22 cells resistance to Imatinib 
treatment in sensitive and resistant clones (Figure 40B). Thus, the decrease of Smad6 
expression observed in CD34+ cells of most resistant patients compared to sensitive ones 
could be involved in their resistance to TKI treatment. 
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Figure 40 : Involvement of Smad6 in KCL22 CML cells response to TKIs. KCL22-
sensitive (KCL22S) or KCL22-resistant (KCL22R) cells were transduced with (A) an empty 
vector (pCT) or a vector containing Smad6 expressing sequence (pS6) and with (B) a 
scramble vector (shCT) or a vector containing short hairpin RNA sequence directed against 
Smad6 (shS6). After 2 days of culture, cells were incubated in the presence of Imatinib at the 
indicated dose. After 3 days of culture, cell proliferation and viability were determined by 
trypan blue staining. The percentage of proliferation was determined by reference to the non-
treated number of viable cells. Results represent the mean value ± SEM of n=5 experiments. 
 
As we previously observed increased quantities of BMP2 and BMP4 in the BM of 
resistant CML patients, we then assessed the impact of BMP treatment on resistance of 
KCL22 cells to Imatinib treatment. After 3 days of culture in presence or not of BMP2 and 
BMP4, we observed a decrease in sensitive KCL22 cell proliferation in an Imatinib dose-
dependent manner. However, no difference was observed between BMP-treated and 
untreated KCL22S cells (Figure 41A). Conversely, resistant KCL22 cells became even more 
resistant to increasing doses of Imatinib in presence of BMP2 and BMP4 (Figure 41B). Thus, 
these differences in the functional response to the same combination of soluble BMPs 
probably sign an altered molecular signaling between sensitive and resistant KCL22 cells. 
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Figure 41 : Soluble BMP impact on KCL22 CML cells resistance to Imatinib. Sensitive 
(A) or resistant (B) KCL22 cells were incubated in the presence of BMP2 and BMP4 (50 
ng/mL each). After 3 days of culture in presence of different concentrations of Imatinib, cell 
proliferation and viability were determined by trypan blue staining. The percentage of 
proliferation was determined by reference to the non-treated number of viable cells. Results 
represent the mean value ± SEM of n=6 experiments. 
 
Our group previously identified Twist-1 gene for his involvement in the resistance of 
immature cells CML.445 Interestingly, depending on cell context, Twist1 is either considered 
as a BMP pathway target gene or as a regulator of this pathway.446–449,490 To investigate 
whether the over-expression of Twist-1 and deregulation of the BMP pathway elements are 
inter-dependent or independent of each other, we started to analyze the consequences of 
the expression of one of these elements on the expression of the other at the transcriptional 
level. We first modulated Twist1 and Smad6 genes expression and assessed their reciprocal 
impact in KCL22 cells by qPCR. After modulation of Smad6 expression, we found that the 
expression of Twist-1 was inversely correlated (Figure 42A). However, Twist-1 modulation 
had no impact on Smad6 expression (Figure 42B). These results suggest that Smad6 is able 
to control Twist-1 expression in the CML context while the opposite is not true. Thus, the 
decrease of Smad6 expression observed in most immature CML samples from resistant 
patients could be responsible of an increase in Twist-1 expression also observed in resistant 
CML patients,445 thus leading to an increased survival potential under TKI treatment. No 
significant effect was observed on Bcr-Abl expression after modulation of Smad6 or Twist1 
expression (data not shown). However, these results need to be confirmed at the protein 
level and to be reproduced in more immature cell models. 
? ???
 
Figure 42 : Smad6 controls Twist-1 expression in KCL22 CML cells. (A) KCL22 cells 
were transduced with a vector containing Smad6 expressing sequence (pSmad6) or with a 
vector containing short hairpin RNA sequence directed against Smad6 (shSmad6) as well as 
with the corresponding control vectors. After 2 days of culture, Twist-1 gene expression was 
assessed by qPCR. Results are expressed as fold change versus the control vector-
transduced cells and represent the mean value ± SEM of n=3 experiments. (B) KCL22 cells 
were transduced with a vector containing Twist-1 expressing sequence (pTwist-1) or with a 
vector containing short hairpin RNA sequence directed against Twist-1 (shTwist-1) as well as 
with the corresponding control vectors. After 2 days of culture, Smad6 gene expression was 
assessed by qPCR. Results are expressed as fold change versus the control vector-
transduced cells and represent the mean value ± SEM of n=4 experiments. (C) Sensitive 
(KCL22S) and resistant (KCL22R) KCL22 cells were cultured in presence or absence of 50 
ng/mL BMP4 for 2 days. Smad6 gene expression was then assessed by qPCR. Results are 
expressed as fold change versus the untreated cells and represent the mean value ± SEM of 
n=4 experiments. 
 
Furthermore, BMP signaling pathway regulation is a very complex process that 
includes negative feedback loops such as the increase of Smad6 inhibitor expression in 
response to soluble BMPs signaling.491 We then analyzed the status of this mechanism in 
sensitive and resistant KCL22 cell lines in response to BMP4 treatment. We observed an 
increase in the expression of Smad6 inhibitor in response to a BMP4 treatment in sensitive 
KCL22 cells, while this is not the case for resistant KCL22 cells (Figure 42C). These 
preliminary results suggest the existence of a failure of the BMP pathway feedback 
mechanism to control Smad6 expression in resistant KCL22 cells. Thus, Smad6 inhibitor 
expression is not induced by BMP4 treatment, potentially leading to increased survival of 
resistant KCL22 cells to Imatinib treatment compared to sensitive KCL22 cells. However, 
these results have to be confirmed at the protein level, in primary samples from CML patients 
resistant to TKIs and will be completed by the analysis of the expression of Smad6 in 
response to BMP2 treatment. 
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III. Discussion 
 
Here, we report a significant increase in the availability of soluble BMP2 and BMP4 in 
the BM of resistant CML patients compared to CML patients in remission under TKI 
treatment. We also demonstrated that the BMP pathway is altered in cells from resistant 
CML patients compared to sensitive patients, and that some alterations seems to be specific 
of immature CD34+ compartment. Indeed, we found that most of resistant CML patients 
display a decreased expression of Smad6, the expression of which seems to be involved in 
CML cells resistance to Imatinib treatment. Preliminary results suggest that loss of Smad6 
expression could lead to the increased Twist1 expression observed in immature cells from 
resistant CML patients,445 thus leading to Imatinib resistance. Finally, we also demonstrated 
that resistant KCL22 cells were unable to increase their Smad6 expression level in response 
to soluble BMP4, like it is the case for sensitive KCL22 cells. This mechanism could 
potentially explain the differences observed in sensitive and resistant KCL22 cells when 
treated by soluble BMPs. Indeed, while BMP2 and BMP4 treatment had no effect on KCL22S 
cells resistance to Imatinib, they slightly increased KCL22R cells resistance upon Imatinib 
treatment. Our previous results demonstrated that alterations of intracellular BMP signaling 
pathway in CP-CML primary samples corrupt and amplify the response to exogenous high-
levels of BMP2 and BMP4 thus participating to the amplification and maintenance of CML 
LSC in the chronic phase of the disease.486 In line with this work, these preliminary results 
suggest that BMP pathway alterations could also be involved in the maintenance and 
resistance of CML LSC under TKI treatment. 
In summary, we have demonstrated the existence of molecular alterations of the BMP 
pathway in immature resistant CML cells, as well as alterations in the quantities of soluble 
BMPs present in the tumoral niche of resistant patients. Finally, preliminary results suggest 
that loss of Smad6 expression, observed in most resistant immature CML cells, combined 
with an increase of soluble BMPs in the BM niche could be involved in the resistance to 
Imatinib treatment. The analysis of the BMP pathway may therefore represent an interesting 
prognostic tool to assess the potential effectiveness of TKI treatment at diagnosis, allowing 
the design of drugs directly targeting the reservoir of LSC. 
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BCR-ABL increases cell stiffness in primitive CD34+ CML cells 
 
I. Introduction 
 
Recent advances in micro- and nanotechnologies have enabled the capture of single 
cell mechanical properties and their modeling.492–494 Atomic force microscopy (AFM) has 
proved to be a powerful, versatile tool to measure the mechanical properties of single living 
cells.495,496 Cell mechanics are recognized to control critical cellular functions including 
migration and division,496 and to be altered in some human diseases such as malaria,497 
diabetes498 and cancer.499 Indeed, several studies have suggested that tumor cells exhibit 
different mechanical properties compared to healthy cells.286,287,289,290,294,500,501 As such, 
single cell mechanics may help to unravel the role of mechanical alterations in cell 
transformation processes and to quantify how malignant cells differ from healthy ones.286 
However, in most studies, experiments were carried out for different unrelated cell lines or 
few primary samples with often absence of normal counterpart.499 Thus, the differences 
observed might only reflect a physiological heterogeneity in cell mechanical properties, as 
further confirmed by molecular analysis. Indeed, lack of a unique and reliable mechanical 
probing method is a severe hindrance to the comparison of these different studies. Chronic 
myelogenous leukemia (CML) arises from an hematopoietic stem cell transformation induced 
by a single reciprocal chromosomal translocation t(9;22) leading to the formation of the BCR-
ABL oncogene.487 CML represents a unique model to study Leukemic Stem Cell (LSCs) 
biology and to elucidate some of the mechanisms of cell transformation. As a 
myeloproliferative disorder, bone marrow cell density considerably increases during this 
disease,502 and better knowledge of biophysical changes such as deformability, especially in 
LSCs, will improve our general understanding of this disease. However, unlike adherent 
cells, suspended hematopoietic cells pose a challenge for AFM because these cells tend to 
slip from under the cantilever tip when performing the nano-indentation.298 In this study, we 
combined two different techniques to mechanically immobilize hematopoietic cells and to 
probe them. This also allowed us to study the effect of the microenvironment on cell stiffness. 
Finally, we performed a time-frequency analysis of force indentation curves to capture local 
variations of the cell stiffness between normal and CP-CML bone marrow purified CD34+ 
cells. 
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II. Results 
 
1. Atomic force microscopy and shear modulus extraction 
 
Initially developed as a surface-imaging tool, AFM was further applied to stiffness 
measurements from nano- to micro-scales on adherent cells.496,503 However, hematopoietic 
cells are usually suspended cells that tend to slip away from under the cantilever tip when 
performing the nano-indentation.298 To avoid this phenomenon, we immobilized these cells 
using fibronectin-coated cover slips504,505 or micro-fabricated wells298. Single living cells were 
then probed using an AFM cantilever controlled by a piezoelectric scanner and a laser 
tracking system (Methods). A sharp tip is moved back and forth towards the sample until a 
set point is reached and a force curve is generated (Figure 43A). The parameterization of 
force curves is most often performed assuming a linear elastic response of the sample as 
described by Hertz506 or Sneddon461 equations, depending on the shape of the cantilever tip 
(respectively spherical or pyramidal). Generalizing AFM force measurements to non-
adherent cells was previously performed on hematopoietic cells, but the possible changes of 
the cells mechanical response during their deformation was not considered.298 In this study, 
we revisited this assumption, considering that the elastic modulus was no longer a time-
invariant quantity and that it may also include a viscous component. To capture changes in 
cell mechanical visco-elasticity during indentation, we developed an original analysis method 
inspired from previous studies in material sciences for pyramidal indentation of visco-elastic 
solids.462 Given that the stress field is axially symmetric for a pyramidal indentation, the force-
displacement curve is written as an integral equation that straightforwardly leads to the 
temporal shear modulus G(t) via a double derivation in time (Methods). The evolution of G, 
representative of cell stiffness, during cell indentation (I) was computed locally on the second 
derivative of the force using a wavelet-based analysis (Figure 43B).  
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Figure 43 : Experimental setup and shear modulus extraction. (A) AFM force curves 
generation. The cells were allowed to settle into micro-fabricated wells, or to adhere on 
fibronectin-coated coverslips (Sigma) in culture treated plates (Fluorodish, Dutscher). 
Indentation was carried out at the center of each cell within 2 hours after removing cells from 
the incubator. (B) Shear modulus extraction from AFM force curves. The evolution of the 
shear modulus G during cell indentation is computed locally on the second derivative of the 
force F using a wavelet-based analysis. Each force curve was analyzed separately by a 
custom-written Matlab script. 
 
We recorded 2 force curves from a suspended (Figure 44A) and an adherent TF1 cell 
(Figure 44B), displaying approach in red and retract in green. We used the Sneddon model 
to parameterize the approach force curves with a parabolic function with constant G (blue 
dashed line) within a 3 μm indentation range. We estimated the local curvature of the force 
curves using a second derivative of a Gaussian (width 400 nm) as analyzing wavelet. For the 
suspended TF1 cell, the transition to contact is smooth and the variation of G(I) is very 
progressive, reaching a plateau around 120 Pa that lasts about 2 μm, before an ultimate 
sharp increase (Figure 44A). For the adherent TF1 cell, the slope of the approach curve 
presents a discontinuity (from nearly zero to a finite value) when the cantilever tip comes in 
contact with the cell (Figure 44B). This discontinuity of the derivative of F appears as a hump 
in G of size given by the width of the analyzing wavelet. At larger indentation I, the G(I) curve 
reaches a plateau around 160 Pa that lasts over 2 μm before increasing again. The last part 
of the G(I) curves probably corresponds to the interaction of the cantilever tip with the 
nucleus, that appears to be stiffer than the surrounding cytoplasm. Even though the values of 
G(I) are not very different on the plateaus before the nucleus deformation, the way the 
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suspended and adherent cells respond to the mechanical stress is very different. The former 
responds as a volume body with a visco-elasticity that increases progressively with the 
deformation while the later responds as a stiffer cortex impeding the penetration of the 
cantilever tip. These robust observations of change in local shear modulus put into light the 
need of revisiting the analysis of immature hematopoietic cell mechanical response. 
 
Figure 44 : Shear modulus extraction from AFM force curves on immature 
hematopoietic TF1 cells. (A) Approach (red) and retract (green) curves on a suspended 
TF1 cell. The blue dashed line corresponds to a parameterization of F(Z) with a parabolic 
function. G(I) curve was computed from the second derivative of the force curve, obtained 
with a fixed size (width 400 nm) second-order analyzing wavelet. (B) The same curves were 
obtained for a TF1 cell in adhesion to fibronectin. 
 
2. Statistical analysis of the dynamical response of hematopoietic cells 
 
To perform a statistical analysis of the dynamical response of soft hematopoietic cells 
under mechanical stress, we considered both the shear modulus G and the indentation I. 
Indeed, if we take the mean of G computed with a parabolic parameterization of the force 
curve, we may over- or under-estimate drastically G depending on the interval we use for this 
parameterization. Thanks to our wavelet-based analysis of G evolution during cell 
indentation, we computed histograms of G values on different intervals of I for a set of 30 
force curves recorded on an adherent TF1 cell (Figure 45A). The wide distribution of the 
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histogram displaying all the G values did not allow to obtain a single G value that could be 
characteristic of cell stiffness. We then divided I range into 4 intervals to obtain 4 different 
histograms (Figure 45A). The histograms obtained for intervals II [1 μm, 2 μm] and III [2 μm, 
3 μm] display a marked peak, meaning that within these ranges of indentation, the G curves 
cross a plateau, where the mechanical properties of the cell are invariant. Conversely, the 
histograms obtained for intervals I [0 μm, 1 μm] and IV [3 μm, 4 μm] display a wide range of 
G values. The differences observed at specific intervals, but not for all of them, support the 
idea to consider not only a mean value or a specific indentation, but the shear modulus 
evolution for all indentations inside the cell. As heterogeneity in cell size distribution could 
bias cell stiffness comparisons, we normalized I, dividing it by the diameter (D) of each 
individual cell. Finally, cell mechanical profiles were obtained by constructing histograms with 
two entries, respectively the shear modulus G, the indentation to cell diameter (I/D) ratio and 
the frequency (F) of shear modulus signal for each considered I/D ratio (Figure 45B). The 
histograms were normalized by the total number of points in the G(I) curves. We observed an 
increase of G during AFM indentation. 
 
 
Figure 45 : Cell mechanical profiles construction. (A) Histogram reconstruction from 30 
G(I) curves reconstructed from AFM forces curves recorded on an adherent TF1 cell. G(I) 
curves are displayed with the four intervals used for the histogram computation. Histogram of 
G values were computed over different indentation intervals:  all [0μm, 5μm], I [0 μm, 1 μm], 
II [1 μm, 2 μm], III [2 μm, 3 μm] and IV [3 μm, 4 μm]. (B) Cell mechanical profiles were 
obtained by constructing normalized histograms with three entries, respectively the shear 
modulus G, the indentation to cell diameter (I/D) ratio and the frequency (F) of shear 
modulus signal for each considered I/D ratio. 
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3. BCR-ABL expression leads to an increased cell stiffness in primitive CD34+ CP-
CML cells 
 
Using this strategy, we compared the mechanical properties of bone marrow CD34+ 
cells immunoselected from 4 allogeneic donor samples and 4 chronic phase (CP) CML 
samples of patients at diagnosis and prior to any treatment (Figure 46A). While the 
mechanical profiles of the 4 allogeneic donor or the 4 CP-CML samples are heterogeneous, 
the differences between healthy and CP-CML CD34+ cells are striking. Indeed, G values 
appear to be more dispersed and generally more elevated for CP-CML samples than for 
healthy counterparts (Figures 46B and C). 
 
 
 
Figure 46 : Comparative analysis of cell stiffness. (A) Bone marrow samples were 
obtained from CML patients at diagnosis and from healthy allogeneic donors. Mononuclear 
cells were separated using a Pancoll gradient and were then subjected to CD34 
immunomagnetic separation. CD34+ cells were then allowed to adhere on fibronectin-coated 
coverslips before being probed by AFM. Cell mechanical profiles were computed for (B) 
healthy (n=48 cells from 4 different healthy samples) and (C) CP-CML (n=29 cells from 4 
different CP-CML samples) bone marrow CD34+ cells. 
 
To visualize these differences, we computed a single mechanical profile by pooling 
together the 4 different samples for each condition, and observed an alteration of the 
mechanical properties of CD34+ bone marrow CP-CML cells as compared to normal 
counterparts, visualized in Figure E by the shift of the peak toward the left (Figure 47). 
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Indeed, while G reaches a plateau around 500 Pa for indentations up to 10% in normal 
CD34+ cells, G values increase up to 1500 Pa in CP-CML CD34+ cells for the same 
indentations. This reflects a higher resistance of leukemic cells in response to cantilever 
applied force at a similar depth. 
 
 
Figure 47 : Cell stiffness is increased in primary CP-CML cells. Cell mechanical profiles 
were computed for healthy (n=48 cells from 4 different healthy samples) and CP-CML (n=29 
cells from 4 different CP-CML samples) bone marrow CD34+ cells. 
 
To evaluate if these differences are related to cell transformation, we used a relevant 
CML model reproducing early steps of leukemic transformation, based on the retroviral 
transduction of BCR-ABL in the human CD34+ TF1 cell line.486 Using this model, we 
assessed the impact of BCR-ABL expression on TF1 cell stiffness by performing AFM on 
cells immobilized in micro-fabricated wells (Figure 48A) or by adhesion to fibronectin (Figure 
48B). While no differences were found between the mechanical profiles of wild type (TF1wt) 
and GFP-transduced (TF1-GFP) TF1 cells, BCR-ABL-transduced (TF1-BCR-ABL) TF1 cells 
became stiffer compared to TF1wt or TF1-GFP cells in both suspended or adherent 
conditions. Indeed, the shear modulus observed for suspended TF1-BCR-ABL cells spreads 
to larger values with the emergence of a lateral shift around 300 Pa for indentation 
comprised between 10% and 20%. The original frequency peak of these distributions around 
100 Pa is not shifted but its amplitude is decreased by 70% (Figure 48A). However, the 
differences observed in adherent conditions are even more striking. These results, visualized 
by the shift of the frequency toward the left from 150 Pa up to 200 Pa for indentations 
comprised between 10% and 20%, indicates that BCR-ABL expression alone is sufficient to 
increase immature TF1 cells stiffness, particularly when these cells are cultured in adhesion 
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to fibronectin (Figure 48B). We also observed that the G values of TF1-BCR-ABL cells are 
more broadly distributed than for TF1-GFP cells in suspended and adherent conditions, 
reflecting a higher heterogeneity in the transformed cells’ mechanical properties. 
 
Figure 48 : BCR-ABL expression increases TF1 cell stiffness in adhesion to 
fibronectin. Cell mechanical profiles were computed for wild type, GFP-transduced and 
BCR-ABL-transduced TF1 cells (A) immobilized in micro-fabricated wells and (B) in adhesion 
to fibronectin (n=150 cells each from 6 independent experiments). 
 
4. The microenvironment controls cell stiffness 
 
The differences observed after BCR-ABL transduction in TF1 cells, particularly in 
adhesion to fibronectin, support a crucial role for cell microenvironment in the control of their 
mechanical properties. Interestingly, we also observed an increase of cell stiffness in 
adhesion to fibronectin for TF1wt and TF1-GFP cells, but not as important as for TF1-BCR-
ABL cells (Figure 48A and B). Whereas G reaches a plateau around 100 Pa for indentations 
up to 20% in suspended TF1 cells, in adherent TF1 cells G do not saturate but rather keep 
increasing, as illustrated by the bend toward the left observed at larger indentations. This 
shows that the adherent cells are stiffer on average than suspended cells and that this 
stiffness increases with the indentation (Figures 48A and B). Thus, cell mechanical 
properties are probably also dependent on their interactions within a defined 
microenvironment and on their geographical location. In CML particularly, immature CD34+ 
cells are able to detach from their bone marrow microenvironment to circulate through the 
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blood vessels,507 another environment with different interactions and no adhesion. This 
suggests that the mechanical properties of these cells extracted from different locations 
could be different. To test this hypothesis, we compared the mechanical properties of CD34+ 
cells extracted either from the peripheral blood or from the bone marrow of a single CP-CML 
patient. We then observed an increased stiffness in CD34+ cells isolated from bone marrow 
as compared to those located in peripheral blood of the same CP-CML patient (Figure 49). 
While G do not exceed 700 Pa for indentations up to 10% in peripheral blood CD34+ cells, its 
value increase up to 1500 Pa for bone marrow CD34+ cells at similar indentations. These 
results demonstrate that both intrinsic (BCR-ABL expression) and extrinsic (adhesion to 
fibronectin) parameters are involved in cell stiffness control. 
 
 
Figure 49 : Cell stiffness is controlled by their environment. Cell mechanical profiles 
were computed for CD34+ cells extracted from the peripheral blood (n=15 cells) or the bone 
marrow (n=12 cells) of a unique CP-CML patient. 
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5. Alterations of cell mechanical properties are correlated with modifications of F-
actin cytoskeleton organisation 
 
Interestingly, in transformed cells, BCR-ABL has been demonstrated to bind actin 
filaments (F-actin),508 one of the major determinants of cell mechanical behavior,509 and to 
induce its redistribution into punctate, juxtanuclear aggregates.108 In addition, the binding to 
F-actin seems to be involved in the transforming ability of BCR-ABL.108 To investigate the 
impact of BCR-ABL transduction on actin cytoskeletal network of TF1 cells, the localization of 
GFP-BCR-ABL or control GFP proteins was examined by immunofluorescence after 
phalloidin-rhodamine treatment to detect F-actin in suspended and adherent cells. In 
suspended parental or TF1-GFP cells, F-actin was localized in the cortical cytoskeleton. 
However, in TF1-BCR-ABL cells, juxtanuclear F-actin aggregates were found in almost 30% 
of the cells in addition to the cortical F-actin staining (Figure 50). These structures were 
induced by BCR-ABL as they were rarely observed in the parental or TF1-GFP cell lines. No 
co-localization was observed between cortical F-actin and GFP or GFP-BCR-ABL proteins, 
mainly detected in the cell nucleus with a diffuse cytoplasm staining. 
 
 
Figure 50 : BCR-ABL alters F-actin distribution in TF1 cells. Filamentous actin (F-actin) 
was labeled with phalloidin-rhodamin (red), GFP signal was amplified using a rabbit 
polyclonal anti-GFP antibody-Alexa Fluor 488 conjugate (green) and the nuclei were labeled 
with DAPI (blue). Immunofluorescence images representative of 6 different experiments were 
taken using a confocal microscope on TF1wt, TF1-GFP and TF1-GFP-BCR-ABL cells either 
in a suspended state (A) or in adhesion to fibronectin (B). Scale bar 20 μm. Magnification 
examples are presented in lower left panels for each condition. Scale bar 5 μm. 
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When cells were allowed to adhere to fibronectin, the formation of actin stress fibers 
was observed in their cytoplasm (Figure 50B). This indicates that actin polymerization is 
correlated with increased cell stiffness in adherent cells when compared to non-adherent 
cells. While all cell types displayed rounded shapes in suspension, adherent cells appeared 
more spread and flattened, except for TF1-BCR-ABL cells that predominantly kept a rounded 
morphology even in adhesion (Figures 50A and B). Consistent with those data, TF1-BCR-
ABL cells contained fewer actin stress fibers compared to parental or TF1-GFP cells in 
adhesion. As expected, GFP proteins did not co-localize with F-actin in TF1 cells. They 
exhibited a diffuse localization in both the nucleus and the cytoplasm. In contrast, GFP-BCR-
ABL proteins were localized in both the nucleus and the cytoplasm and a small fraction of the 
total protein co-localized with actin stress fibers as well as juxtanuclear F-actin aggregates, 
still present in adherent conditions. Altogether, these results demonstrate that BCR-ABL 
oncoprotein leads to the alteration of actin cytoskeletal network and consequently of the 
mechanical properties of TF1 cells. 
The adhesion was also accompanied by a flattening of the cells. We use a 
quantitative phase microscopy (QPM) device recently developed in our laboratory472 to 
compare the shape and index of these cells in suspended and adhesive conditions. We 
observed TF1 cells with a very regular rounded shape with small protrusions on their 
surfaces (Figure 51A). QPM provides a quantitative and non-intrusive estimation of the cell 
flattening during their adhesion. The cross-sections show that this flattening is limited to 
about half the original cell diameter, probably because these cells have a nucleus that 
occupies a large part of the cell volume that limits their deformation. This is consistent with 
the observation on the force curves at large indentation of a steep increase of the shear 
modulus when the tip of the cantilever comes in interaction with the nucleus. In the TF1 cell 
line, BCR-ABL transduction leads to a profound modification of the cell internal organization 
since TF1-BCR-ABL cell sizes can reach twice the size of TF1wt or TF1-GFP cells (Figure 
51B). This is illustrated in the QPM images of TF1-BCR-ABL cells as compared to TF1-GFP 
cells. Despite the drastic increase of the diameter (from 14.6 µm ± 1.5 to 19 µm ± 3, 
computed from a sample of 25 QPM images) of these cells, their optical path length (OPL) 
does not change much (from 0.52 µm ± 0.05 to 0.53 µm ± 0.1), meaning that the volumic 
ratio nucleus/cell is likely decreasing, leaving more space for the cytoplasm. However, no 
differences in cell sizes were observed between primary CD34+ cells obtained from healthy 
donors and CP-CML patients. 
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Figure 51 : Quantitative phase microscopy (QPM) characterization of TF1 cells. (A) 
Image of the phase derivative ∂φ/∂x of suspended and adherent TF1-GFP cells. The optical 
path length (OPL) was computed from the phase derivative on the sections marked by the 
black and blue lines. (B) Image of the optical phase derivative ∂φ/∂x of suspended and 
adherent TF1-BCR-ABL cells. The optical path length (OPL) was computed from the phase 
derivative on the sections marked by the black and blue lines. Scale bar 20 μm. 
 
III. Discussion 
 
Hematopoietic cells have been identified as the softest cells of the human body.278 
We noticed a great variety of mechanical responses of TF1 cells. This variability led us to 
repeat the force curves on a large set of cells for each cell type. When comparing the 
different cell types mechanical properties, we also observed that primary CD34+ cells are 
much more stiffer as compared to CD34+ TF1 cells. 
Culturing immature hematopoietic cells on fibronectin-coated surface may also 
preferentially select cells with higher adhesion capabilities. In CML particularly, BCR-ABL is 
known for its ability to decrease progenitor cell adhesion to the BM stroma.510 By performing 
adhesion assays, we demonstrate that BCR-ABL transduction has no effect on the 
percentage of adhesion of TF1 cells on fibronectin-coated surfaces (Figure 52A). However, 
combining immunofluorescence and AFM, we show that adhesion changes qualitatively 
since TF1-BCR-ABL cells loose their ability to mature adhesion by the formation of actin 
stress fibers, in link with the presence of F-actin aggregates in 30% of the cells (Figure 52B). 
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Figure 52 : Effects of BCR-ABL transduction on adhesion and F-actin aggregates 
formation in TF1 cells. (A) 5.104 cells/well of each type TF1wt, TF1-GFP and TF1-GFP-
BCR-ABL labeled with 5 μM calcein-AM were allowed to adhere for 1 hour to fibronectin-
coated 96-well plates. Fluorescence was quantified before and after the removal of non-
adherent cells. The mean percentages of adhesion: %adhesion = 100.(Fluorescence of 
adherent fraction/fluorescence of whole cells) and their standard errors (SEM) are computed 
from a set of n = 8 experiments. (B) Suspended TF1wt, TF1-GFP and TF1-BCR-ABL cells 
were either cytospined onto untreated glass slides or allowed to adhere on glass cover slips 
coated with fibronectin for one hour before being labeled for F-actin with phalloidin-rhodamin. 
F-actin aggregates were then scored using a confocal microscope on suspended and 
adherent cells. The mean percentage of cells containing aggregates and their standard 
errors ± SEM are computed for a set of n=6 experiments. 
 
By analyzing more than 27000 AFM force curves out of 900 cells, we reveal for the 
first time the alteration of the mechanical properties of immature CML cells upon BCR-ABL 
oncogene expression. The wavelet-based extraction method of the shear modulus 
introduced here encompasses other parametrization methods, allowing a direct scale 
matching of the analyzing wavelet with the local force-indentation response curvature. We 
demonstrate that cancer cells not only become stiffer but that their mechanical response to 
stress changes, reinforcing their cortical tension and decreasing their ability to form actin 
stress fibers. We further reveal an increase of the stiffness of suspended hematopoietic 
progenitors when adhered to fibronectin. These results are consistent with the appearance of 
actin stress fibers, confirming the central role of F-actin in cell mechanical properties. As 
immature CML cells resistant to TKIs are likely to reside in bone marrow, our data open new 
perspectives in the understanding of how leukemic cells can withstand constraints exerted by 
their microenvironment to promote their survival and drug escape. Such a mechanical 
approach could be used to develop new diagnosis or prognosis tools for the early detection 
of cancer. 
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Cell confinement modulates the growth of BCR-ABL+ CD34+ cells 
through up-regulation of Twist-1 expression 	  
I. Introduction 
 
Over the past few years, there has been increasing interest in understanding SC 
biology,489 particularly as it relates to tumor initiation and progression.84,511 
Microenvironmental signals, including biochemical and biomechanical factors, are known to 
control SC fate.512 Even though most studies in the literature place an emphasis on growth 
factors and cytokines, it has been evidenced that mechanical signals also significantly 
influence cell fate.513 Recent advances in micro- and nano-technologies have opened a new 
field of research devoted to cell mechano-biology.514,515 It has now been established that 
cells can sense their physical surroundings through mechano-transduction,516 by translating 
mechanical forces and deformations into biochemical signals such as changes in genes 
expression or by activating diverse signaling pathways.517 In turn, these signals can adjust 
cellular and extracellular structure.518 This mechano-sensitive feedback modulates many 
critical cellular functions, ranging from differentiation,519 proliferation,281 quiescence,280 self-
renewal277 or apoptosis, and is crucial for organ development and homeostasis.279,520 
However, cell mechanics can also be altered in some human diseases such as cancer.499 
Consequently, defects in cellular mechano-transduction processes could contribute to the 
tumor phenotype. Indeed, recent studies have demonstrated that mechanical stress can 
cooperate with genetic lesions to promote cancer progression.315 This could be particularly 
relevant in the bone marrow (BM), a viscous tissue located in the bones that contains 
hematopoietic stem cells (HSCs). Due to its confinement by bones, the BM has a unique 
mechanical environment that can be affected by external factors452, such as blood flow, 
physiological activity, aging or disease. Thus, changes in the bone marrow mechanical 
environment may also affect the fate of resident HSCs. This could prove especially important 
in the tumor context, where uncontrolled proliferation of cancer cells entails their compaction 
within their microenvironment,322 resulting in constant mechanical stress. However, little is 
known about how this mechanical stress influences tumor cell behavior. Chronic 
myelogenous leukemia (CML) arises from a HSC transformation following the formation of 
the BCR-ABL oncogene by a reciprocal chromosomal translocation (t9;22).487 Therefore, 
CML represents a unique model to study leukemic stem cells biology and to elucidate some 
of the mechanisms of cell transformation. We demonstrated that immature CML cells 
possess a stiffer cortex as compared to healthy cells. Thus, the alteration of the cells intrinsic 
mechanical properties could lead to the alteration of their functional response to external 
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mechanical stress. Recently, investigators have attempted to elucidate these mechano-
transduction pathways through controlled biomechanical experiments.459,460 Different studies 
have demonstrated that cells submitted to mechanical stress will express specific « 
mechano-sensitives » genes, like Twist-1274,315,521 or BMP pathway elements.243,366–368,376 
Numerous systems have been designed by physicists to dynamically measure and control 
forces on single cells, such as atomic force microscopes,503 micro-plates522 or 
micromanipulators.523 While the aforementioned studies have provided great insight into cell 
biomechanical properties, functional and molecular biology protocols allowing advanced 
analysis of confined cells are challenging at single cell level. Here, we use a method based 
on the gentle application of a confining slide on the cultured cells using a modified multi-well 
plate (in collaboration with M. Piel, Institut Curie Paris).273,458–460 Because the confinement is 
applied on a population of cells, statistical data are easy to obtain, and because confinement 
can be released, the cell material is available for further biological analysis. In this study, we 
subjected normal and leukemic immature cells to defined compression using this unique cell-
confining device. 
 
II. Results 
 
1. Hematopoietic cells confinement 
 
To apply a controlled force on a population of hematopoietic cells, we adapted a 
system recently developed for adherent cells confinement.273 Briefly, the cells were allowed 
to adhere onto fibronectin-coated wells before being compressed by a gentle application of a 
confinement glass slide (Figure 53A). The diameter of the confinement slides was chosen to 
fit inside 24-wells plates, allowing the testing of different conditions simultaneously (Figure 
53B). The distance between the slide and the culture substrate is controlled by 
polydimethylsiloxane (PDMS) (relatively stiff biocompatible silicone rubber) microspacers 
molded under the confinement slide. Thus, the cells’ height is precisely imposed by defining 
the height of the microspacers, ensuring a geometric confinement (Figure 53C).458 The rigid 
glass slide provides homogeneous confinement with no long-range deformation and the soft 
material (PDMS) ensures the robustness of the confinement by absorbing the local substrate 
inhomogeneities. To evaluate the impact of BCR-ABL expression on cell response to an 
external mechanical stress, we confined GFP-transduced and BCR-ABL-transduced human 
CD34+ TF1 cells (Figure 53D). As previously described, this model reproduces the main 
features observed in primary immature chronic phase (CP) CML cells.486 Microspacers high 
enough to avoid cell confinement (30 µm) were used as control. Un-confined suspended and 
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fibronectin-adherent cells were also tested. The cells were confined for 3 days before being 
collected for further analysis. We first evaluated their viability and proliferation using trypan 
blue staining and cell counting. We observed a slight decrease of cell viability (5%) in 
presence of confining slides, consistent with the surface occupied by PDMS microspacers, 
suggesting that 5% of the cells were crushed under microspacers. While cell confinement 
had no impact on TF1-GFP cell viability, 10 μm confinement slightly increased TF1-BCR-ABL 
cell viability, that was then decreased upon increased confinement (Figure 53E). 
 
Figure 53 : Experimental setup for hematopoietic cells confinement. (A) Confinement 
slides are glass cover-slips covered by polydimethylsiloxane (PDMS) microspacers. They 
can be applied reversibly on the cell culture to provide a homogeneous confinement. (B) The 
lid of a multiwell plate is modified by introducing large PDMS pillars to hold the confinement 
slides. These pillars have the height of the plate, which can be slightly increased with a thin 
PDMS layer. When the multiwell plate containing adherent cells and culture medium is 
closed with the modified lid, the confinement slides are applied on the cells adhering to the 
bottom of the wells. Large pillars that are slightly higher than the well depth deform and apply 
pressure on the confinement slides. (C) To prevent hematopoietic cells to slip away when 
applying the confinement slides, we immobilized them using fibronectin-coated wells. By 
defining the height of the microspacers, respectively 10μm, 5μm and 2.5μm, we ensure a 
precise geometric confinement of hematopoietic cells. Microspacers high enough to avoid 
cell confinement (30μm) are used as control. (D) Images of control and confined TF1 cells. 
(E) Cell viability was evaluated in TF1-GFP (open bars) and TF1-BCR-ABL (closed bars) 
confined cells using trypan blue staining and cell counting. Results are expressed as the % 
of viable cells. Results are presented as the mean ± SEM of n=10 experiments. *p<0.05; 
**p<0.005 indicate differences between two conditions. 
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2. BCR-ABL expression modulates TF1 cells proliferation in response to 
mechanical signals 
 
 Strikingly, these differences of cell viability seem to reflect differences of cell 
proliferation. Indeed, while cell confinement had no impact on TF1-GFP cell proliferation, 10 
μm confinement led to an increase of TF1-BCR-ABL cell proliferation that was then lost upon 
increased mechanical confinement (Figure 54A). These results were confirmed using KCL22 
CML cell line (data not shown) and were also correlated with the expression of Ki67 
proliferation marker determined by flow cytometry (Figure 54B). We then performed cell-
cycle analysis to assess the potential impact of mechanical stress on cell division. Although 
cell confinement had no effect on TF1-GFP cells repartition between G0/G1, S and G2/M 
phases (Figure 54C), it significantly impacted TF1-BCR-ABL cells. Indeed, TF1-BCR-ABL 
cells displayed a shift from G0/G1 phase to S and G2/M phases upon 10 μm confinement. 
Conversely, stronger confinements reversed this effect, as illustrated by an increase of the 
percentage of cells in G0/G1 phase at the expense of S and G2/M phases at 2.5 μm 
confinement (Figure 54D). Together, these results demonstrate that BCR-ABL expression 
increased the sensitivity of TF1 cells to mechanical compression by affecting cell-cycle 
distribution thus leading to a force-dependent altered proliferation. 
 
 
 
Figure 54 : Effect of mechanical stress on cell proliferation. (A) Cell proliferation was 
evaluated in wild-type (open bars) and BCR-ABL-transduced (closed bars) confined TF1 
cells using trypan blue staining and cell counting. Results are expressed as the proliferation 
ratio that is the ratio of cell counts to the number of input cells. (B) Phenotypic analysis of the 
proliferation marker Ki67 was performed using flow cytometry on a Facscalibur® cell 
analyzer (Becton Dickinson) and gated for viable cells. Cell-cycle profiles of (C) TF1-GFP 
? ???
and (D) TF1-BCR-ABL confined cells were determined using the Watson model on Flowjo 
after propidium iodide staining. Cell repartition between G0/G1, S and G2/M cell-cycle phases 
was determined for 10 μm and 2.5 μm confinement compared to 30 μm control. Results are 
presented as the mean ± SEM of n=10 experiments. *p<0.05; **p<0.005; ***p<0.0001 
indicate differences between two conditions. 
 
 We then assessed the impact of cell confinement on bone marrow stromal cells using 
HS27A cell line. To do so, we used the same conditions as for TF1 cells confinement, except 
that we did not need to perform fibronectin coating to induce stromal cells adhesion. After 3 
days of confinement, cells were collected to evaluate their viability and proliferation using 
trypan blue staining and cell counting. While cell confinement had no impact on cell viability 
(Figure 55A), it led to a strong and force-dependent reduction in cell proliferation (from 50% 
at 5 μm confinement to 30% at 2.5 μm confinement) (Figure 55B). The same results were 
also observed using HS5 stromal and BMEC-1 micro-vascular cell lines (data not shown). 
Thus, these results demonstrate that stromal cells are much more sensitive to mechanical 
signals as compared to hematopoietic cells. 
 
Figure 55 : Effect of mechanical stress on stromal cell proliferation. Cell viability (A) and 
proliferation (B) were evaluated in confined HS27A cells using trypan blue staining and cell 
counting. Results are expressed as the % of viable cells or as the proliferation ratio that is 
the ratio of cell counts to the number of input cells. Results are presented as the mean ± 
SEM of n=6 experiments. 
 
 We next evaluated the impact of cell confinement on immature properties of TF1 
cells. We first demonstrated that cell confinement had no impact on immature CD34 marker 
expression at the membrane of both TF1-GFP and TF1-BCR-ABL cells using flow cytometry 
(Figure 56A). We further used the CFC assay to determine the impact of cell confinement on 
progenitor cell content. While BCR-ABL transduction led to a significant increase in colony 
numbers, no significant differences were observed after cell confinement (Figure 56B). We 
then scored the colonies as erythroid or myeloid (Figure 56C) and late or early (Figure 56D), 
? ???
and observed an increase in the number of late myeloid colonies after BCR-ABL-
transduction, but no impact of cell confinement. 
 
Figure 56 : Effect of mechanical stress on progenitor content. TF1-GFP (open bars) and 
TF1-BCR-ABL (closed bars) cells were confined for 3 days. (A) Phenotypic analysis of the 
immature hematopoietic cell marker CD34 was then performed using flow cytometry on a 
Facscalibur® cell analyzer (Becton Dickinson) and gated for viable cells. (B) The progenitor 
content of confined cells was analyzed by the clonogenic CFC assay. Results are expressed 
as the total CFC colonies per 1x103 seeded cells and represent the mean ± SEM of n=10 
experiments. The content of treated cells in distinct hematopoietic progenitor categories was 
determined by scoring the colonies as (C) erythroid or myeloid, and (D) late (one to two 
clusters for erythroid colonies, below 1x103 cells/colony for myeloid colonies) or early. Values 
of colony subtypes are expressed as the percentage of the total number of colonies. 
 
3. Cell confinement induces Twist-1 expression in TF1-BCR-ABL cells
 
We further analyzed by qPCR the expression of a set of genes (BMP pathway and 
Twist-1 gene) involved in the transduction of mechanical signals in different cell types, and 
previously identified for their crucial role in immature CML cells functions. While cell 
confinement had no impact on BMP2, BMP4, BMP receptors and Smad6 expression (data 
not shown), we observed a differential expression of Twist-1, a bHLH embryonic transcription 
factor also described as an oncogene,524 under cell confinement. Interestingly, Twist-1 
expression in CD34+ cells has been described as a new predictive factor of the response of 
CML patients to TKI treatment.445 Here, we found that Bcr-Abl expression alone was able to 
induce a 12-fold increase of Twist-1 expression in TF1 cells (Figure 57A). Whereas cell 
? ???
confinement had no effect on Twist-1 expression in TF1-GFP cells, 10 μm confinement led to 
a additional 2-fold increase of Twist-1 expression in TF1-BCR-ABL cells compared to non 
confined cells. However, only a small and non-significant increase of Twist-1 expression was 
observed for higher confinements (5 μm and 2.5 μm confinement). As BCR-ABL transduction 
was directly able to induce Twist-1 expression in TF1 cells, we then measured the levels of 
BCR-ABL expression after cell confinement, and demonstrated that mechanical stress had 
no impact on BCR-ABL expression in TF1 cells (Figure 57B). In addition, Twist-1 modulation 
under cell confinement was confirmed at the protein level by western-blot analysis (Figure 
57C). 
 
Figure 57 : Effect of mechanical stress on Twist-1 and BCR-ABL expression. (A) Twist-
1 and (B) Bcr-Abl genes expression was assessed by qPCR in wild-type (open bars) and 
BCR-ABL-transduced (closed bars) confined cells. Results are presented as the mean value 
± SEM of n=10 experiments. (C) Twist-1 and GAPDH (used as loading control) protein 
analysis by Western blot in TF1-GFP and TF1-BCR-ABL cell extracts. Results are presented 
as the mean value ± SEM of n=4 experiments. *p<0.05; **p<0.005 indicate differences 
between two conditions. 
 
4. Cell confinement impact on TF1-BCR-ABL cells proliferation is maintained 
upon Imatinib treatment 
 
 Twist-1 expression has previously been described by our group for its involvement in 
CML cells resistance to Imatinib treatment.445 Thus, we asked whether Twist-1 induction by 
mechanical signals could alter the response of TF1-BCR-ABL cells to Imatinib treatment. We 
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then confined TF1-BCR-ABL cells in presence of 1µM Imatinib. After 3 days, cell proliferation 
was assessed using trypan blue staining and cell counting, demonstrating a strong inhibition 
of cell proliferation in response to Imatinib treatment (Figure 58A). While adhesion to 
fibronectin and 30 µm control slide had no significant impact on cell proliferation under 
Imatinib treatment, cell confinement impact on TF1-BCR-ABL cells was maintained under 
Imatinib treatment. Indeed, 10 µm confinement increased TF1-BCR-ABL cells proliferation, 
while 5 µm and 2.5 µm confinement induced a decrease in cell proliferation in a force-
dependent manner. Thus, whereas cell confinement has no specific effect on Imatinib 
resistance despite an increased Twist-1 expression, it is still able to control cell proliferation 
under Imatinib treatment. Force-dependent modulation of TF1-BCR-ABL cells proliferation 
under Imatinib treatment was further correlated by a decrease in the percentage of Ki67-
expressing cells (Figure 58B). The impact of cell confinement on CML cells proliferation 
under Imatinib treatment was also confirmed in KCL22 CML cells (data not shown). To 
assess the impact of mechanical stress on resistant CD34+ CML cells, we cultured TF1-BCR-
ABL cells for 2 weeks in presence of 1µM Imatinib to select resistant cells. These cells were 
then confined for 3 days in presence or not of 1µM Imatinib before evaluation of cell 
proliferation (Figure 58C). We observed similar effects of mechanical stress on proliferation 
of Imatinib-treated or untreated TF1-BCR-ABL cells. Indeed, in both cases, a slight 
confinement (10 µm) led to an increase of cell proliferation that was then lost after increasing 
the confinement (5 µm and 2.5 µm). 
 
? ???
 
Figure 58 : Effect of mechanical stress on CML response to Imatinib. (A) Cell 
proliferation was evaluated in BCR-ABL-transduced confined TF1 cells after treatment with 
1μM Imatinib using trypan blue staining and cell counting. Results are expressed as the 
proliferation ratio that is the ratio of cell counts to the number of input cells. (B) Phenotypic 
analysis of the proliferation marker Ki67 was then performed using flow cytometry on a 
Facscalibur® cell analyzer (Becton Dickinson) and gated for viable cells. (C) TF1-BCR-ABL 
cells were cultured 2 weeks in presence of 1μM Imatinib to select resistant cells and were 
then confined for 3 days ± 1μM Imatinib. Cell proliferation was then evaluated using trypan 
blue staining and cell counting. Results are expressed as the proliferation ratio that is the 
ratio of cell counts to the number of input cells and are presented as the mean value ± SEM 
of n=4 experiments. *p<0.05; **p<0.005 indicate differences between two conditions. 
 
III. Discussion 
 
The ability of cells to respond to changes in their physical environments is crucial in 
the development and maintenance of tissues that are exposed to varying mechanical 
stress.279 Changes in tissue stiffness,306 cell stiffness286 and tumor growth due to proliferating 
cells316 combine to affect the physical environment of both normal and tumor cells.418 This 
altered physical environment can in turn modulate the fate of cancer cells through mechano-
transduction signaling. Indeed, for a tumor to grow in a confined space defined by the 
surrounding tissue, it must overcome the resulting compressive forces.316 However, very few 
studies have directly investigated the influence of mechanical stress on cancer cells biology. 
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Here we have reported that a mechanical stimulus applied to immature leukemic cells 
adhered to a fibronectin matrix control the proliferation of these cells. This ability appears to 
be unique to leukemic cells, as mechanical stimulus did not affect normal cells. Indeed, BCR-
ABL transduction was sufficient to trigger an altered proliferative response of CD34+ TF1 
cells under mechanical stress. However, mechanical forces displayed a dual role in TF1-
BCR-ABL cells proliferation control, as cell proliferation was increased under slight 
confinement and decreased under higher confinements. Finally, we demonstrated that Twist-
1 expression was specifically increased in response to mechanical stress in BCR-ABL+ cells. 
Interestingly, Twist-1 is involved in cell-cycle regulation525 and was recently demonstrated to 
control quiescence526 and self-renewal526 capabilities of hematopoietic stem cells. Thus, 
Twist-1 modulation could be involved in the control of CD34+ TF1-BCR-ABL cells proliferation 
under mechanical stress. These preliminary results demonstrate that BCR-ABL expression is 
required for TF1 cells to respond to mechanical signals. Strikingly, these results are in line 
with a recent study demonstrating that Twist-1 is expressed in response to transient 
compression in APC deficient colon tissue explants, but not in wild-type colon explants.315 
This suggests a potential role for Twist-1 as a common mediator of mechanical signals 
transduction in tumor cells. Thus, physical factors could be involved in existing cancer cells 
expansion and may potentiate cancer progression. This work provides unique insight into 
how physical determinants can influence immature leukemic cell fate that could help to 
explain how dividing cancer cells can take advantage of the constraints exerted by their 
microenvironment to promote tumor growth. These results emphasize the importance of a 
multidisciplinary approach in the study of immature cancer cells involving the coalescence of 
many disciplines, including cell and molecular biology and biomechanical engineering. 
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Cancer, cancer stem cells and microenvironment 
 
Cancer remains one of the leading causes of mortality worldwide. Clinically, the CSC 
discovery predicts that if the destruction of tumor bulk induces remission, only the eradication 
of CSC can lead to a cure.85 Just like normal SCs,50 CSCs are located in a peculiar 
microenvironment. However, the response of CSCs to the signals provided by their 
microenvironment can be totally altered, as CSCs are able to subvert the tumor niche to 
survive to promote their expansion and/or survival upon treatment.527 Thus, it is necessary to 
understand the key processes occurring within the CSC niche to identify potential therapeutic 
targets that can serve as the basis for development of more effective treatments, targeting 
CSC within their microenvironment. What is more, targeting CSCs in their microenvironment 
must be done without damaging normal SC. Thus, it is essential to understand the specific 
alterations that occur in the formation of both CSCs and their altered microenvironment.  
The actual dogma for cancer formation is that it is due to the accumulation of genetic 
alterations in a more or less immature cell. This is strongly supported by the CML model, 
where BCR-ABL is generally accepted as the first and sufficient alteration to promote 
leukemic formation, without any (or few) identified risk factors. The tumor formation can then 
lead to the alteration of the CSCs’ microenvironment, which will in turn participate to the 
tumor phenotype.486 In the course of the disease, cancer cells can then acquire more and 
more secondary alterations, making them even more difficult to eliminate. This is particularly 
important in the CML context where BCR-ABL induces genomic instability by inhibiting 
effective DNA repair. Thus, it is essential to detect and to understand early phase of cancer 
initiation (chronic phase of the disease for CML) where we still have a chance to overtake the 
disease. 
However, alteration of the stem cell microenvironment has also been demonstrated 
as the first initiating event leading to tumor formation. The best example is referred as donor 
cell leukemia (DCL).528 Relapse of acute leukemia following hematopoietic stem cell 
transplantation usually represents return of an original disease clone, having evaded 
eradication by pretransplant chemotherapy or radiotherapy. However, in almost 5% of all 
post-transplant leukemia relapses, acute leukemia can develop de novo in engrafted cells of 
donor origin without actual development of leukemia in the donor. While mechanisms of 
donor cell transformation are still unclear, it has been suggested that alterations of the bone 
marrow microenvironment due to myeloablative treatment could be responsible of donor cells 
leukemic transformation. In addition, recent work in our group suggests that the environment 
could be the first initiating event leading to tumor formation.425 Indeed, it was demonstrated 
that alteration of the tumor microenvironment by environmental pollutants leads to tumor 
initiation in breast cancer. If we look further into this, it means that the first event in cancer 
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formation could be the alteration of SCs microenvironment, thus favoring the transformation 
of SCs into CSCs and leading to cancer formation. Coming back to CML, such alteration of 
the BM microenvironment could possibly be needed to induce BCR-ABL formation in a HSC. 
The existence of such a mechanism could explain why BCR-ABL oncoprotein is sometimes 
detected in human blood cells, without the development of CML all along the lifetime of these 
individuals.529  While no proof of such mechanism has been found so far, the formation of a 
permissive microenvironment could then lead to CML appearance upon BCR-ABL formation, 
or could even favor t(9;22) chromosomal translocation.	  
Actually, more and more evidences demonstrate that incorrect signals from the 
microenvironment can lead to destabilization of tissue homeostasis and initiation and 
promotion of normal cells to malignancy.84,485,511,530–532 However, in some cases, the 
microenvironment could also contribute to restrain cancer progression. Indeed, it has been 
demonstrated that the microenvironment can provide crucial signals to maintain tissue 
architecture inhibit cell growth and suppress or revert the malignant phenotype.533 
CML : a model for stem cell transformation and leukemic stem cell 
resistance 
 
In this context, CML was demonstrated to be a clonal disease87,89 that origins from to 
the formation of the BCR-ABL oncogene in a single multipotent HSC.86 This unique genetic 
abnormality allowed the researchers to develop targeted therapies blocking BCR-ABL 
tyrosine kinase activity. Imatinib, the first tyrosine kinase inhibitor (TKI) developed, has 
proved to be very efficient to induce the remission of a majority of CML patients.131 However, 
none of TKIs available to date seem to eradicate undifferentiated BCR-ABL+ cells that may 
serve as a reservoir for additional oncogenic events leading to disease progression and 
requiring continued treatment.92,144,181 Therefore, CML represents a unique model to study 
LSC biology and to elucidate some of the mechanisms of therapeutic resistance. In CML, 
different mechanisms involved in resistance to TKIs have already been identified.488 
However, in some cases, the resistance mechanisms are still unknown, and could be 
explained by the existence of LSCs, that could survive to drug treatment due to their intrinsic 
specific properties and to their interactions within their microenvironment. Indeed, recent 
studies have demonstrated that LSC are particularly resistant to TKI treatments because of 
specific intrinsic properties, but also due to their protection by the leukemic niche.154 Despite 
the success of TKIs, the wide range of resistance mechanisms observed in CML cells 
(detailed in chapter 2) is striking. Thus, different alterations (of LSCs but also of their 
microenvironment) are responsible of TKIs resistance mechanisms, in line with our results 
demonstrating that the decrease of Smad6 expression is not present in all resistant CML 
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patients. Hence, it is necessary to understand the different mechanisms involved in CML 
resistance, but also to develop markers and new treatments to detect and overcome 
resistance. In particular, understanding BCR-ABL-independent resistance mechanisms could 
be useful as a model to understand resistance mechanisms in other types of cancer. At this 
time, more and more molecules are developed to target specific alterations in cancers. From 
here, the concept of personalized medicine will probably allow to develop targeted therapies 
adapted to the molecular alterations specific of each cancer, in each patient. For example, in 
breast cancer, treatment decision is based on the detection of specific alterations such as 
estrogen receptors over-expression or Her2 expression. 
BMP pathway, CML and resistance 
 
We demonstrated the existence of molecular and functional alterations in the BMP 
pathway in CML cells, as well as a significant increase in the availability of soluble BMP2 and 
BMP4 in the BM of CP-CML patients at diagnosis.486 These alterations, and particularly the 
increased expression of BMPRIb in immature CML cells, are involved in the chronic phase of 
the disease through their role in the survival of LSCs as well as in the expansion of myeloid 
progenitors (Figure 59).486 Soluble BMPs, naturally provided by the BM niche,482 have been 
implicated in myelofibrotic processes.420 In CML, changes in the SC niche such as secondary 
myelofibrosis are often correlated with disease progression.419 Myelofibrosis is characterized 
by an increased production in collagens, proteins known to sequester BMPs,534–536 and 
control the gradient of these molecules in the microenvironment. In addition, TKIs induce 
BMP2 expression by mesenchymal SCs.421 Furthermore, BMP4 has been demonstrated to 
increase hematopoietic progenitor adhesion to the stroma and regulate HSC 
behavior.399,412,476 Therefore, CML evolution and TKI treatment may contribute to a local 
increase in BMPs in the LSC niche, This also explains why both normal and leukemic SCs, 
as well as BM alterations observed in patients, are amplified throughout disease progression 
and may fuel a permanent and autonomous pool of leukemic progenitors. 
While we demonstrated an overall increase in BMPRIb expression in CD34+ CP-CML 
cells compared to healthy ones, not all CD34+ CP-CML cells and/or samples display an over-
expression of BMPRIb.486 With regard to low-BMPRIb expressing samples, it could simply 
mean that a small immature CML cell sub-population with a high expression of BMPRIb is 
responsible of the amplification of myeloid leukemic progenitors and LSCs. To answer that, it 
would be necessary to sort low- and high-BMPRIb expressing immature cells from a unique 
CP-CML patient and to assess their functional response to soluble BMPs. This is supported 
by our results demonstrating that BMP response is particularly strong in high-BMPRIb 
expressing samples.486 However, BCR-ABL expression alone has been demonstrated to be 
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sufficient to induce leukemic phenotype in both human cells and mice models.537,538 Thus, 
BCR-ABL-mediated BMPRIb over-expression could simply constitute an additional 
transforming element cooperating with BCR-ABL and participating to the leukemic 
phenotype. As we have no mean to know precisely when the t(9;22) translocation leading to 
BCR-ABL formation occurred in patients, we cannot discriminate BMPRIb expression 
depending on the time after transformation, that could help us to understand the differences 
observed between patients. However, when separating CP-CML patient samples based on 
their Sokal score, we found no differences in BMPRIb expression between high- and low-
Sokal CP-CML samples.486 Thus, it would be interesting to design of mouse model over-
expressing BMPRIb in HSC to observe if a CML-like disease appears. BCR-ABL inhibition in 
BMPRIb over-expressing CML cells could also be performed, but would entail more bias, 
such as BCR-ABL-induced secondary alterations, or difficulties to totally abolish its 
expression. 
Furthermore, considering the crucial role for BMP alterations observed in primary CP-
CML cells in-vitro,486 it would be very interesting to observe the functional consequences of 
such alterations in-vivo, to also consider the effects on the BM microenvironment. However, 
while mice models are currently used as a standard in cell biology, several studies have 
demonstrated that BMP molecules (and others) can have totally different effects on human or 
mice cells.389,390 This is probably one of the reasons why some molecules that have proved 
to be efficient in mice fail to reproduce their activities when tested in human.539 Thus, there 
would be no advantage of such a strategy to further assess the effects of BMPs on BM 
microenvironment. However, recent progress in sciences may allow circumventing these 
difficulties. Indeed, several groups are working on humanized mice, that is to say mice 
expressing specific human proteins, allowing them to ascertain that the signaling pathways 
studied in mice will be the same (or at least close) as in humans.540 
Another problem that is of importance to study the functional effect of biological 
molecules and that is recurrent in cell biology is the concentrations used. Indeed, it is very 
difficult to precisely determine the concentration of such molecules in the human body, 
particularly in specific microenvironments, where soluble molecules can also be trapped by 
different ECM proteins, soluble competitors, or can be produced in autocrine or paracrine 
manners thus affecting their diffusion and their effects on neighboring cells. Furthermore, 
most studies use very high concentrations of such molecules for in-vitro assays, probably to 
make sure to observe the functional effects of the molecules studied. However, it has been 
demonstrated that the biological effects of some molecules can be totally different depending 
on the concentration used, as it is the case for BMPs.388,409 Thus, it would be very interesting 
to test different concentrations of BMPs to observe possible differences in term of biological 
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impact in the CML context. 
In addition, two transcriptome studies were recently published, demonstrating 
alterations of the BMP signaling pathway in CML LSC. In a first study, a genome-wide 
analysis comparing transcriptomes of healthy and CP-CML CD34+, CD38−, ALDHhigh 
immature cells was performed. Interestingly, an alteration of both TGF-β and BMP signaling 
pathways elements was observed in immature CP-CML cells compared to healthy ones. 
Particularly, BMP2, BMP9 and TGF-β1 gene expression was found to be down-regulated in 
immature CP-CML cells, while the expression of SMAD7, an inhibitor of the TGF-β signaling 
pathway, was highly activated.541 This suggests a possible impairment of autocrine BMP2 
and BMP9 production by immature CP-CML cells, while both TGF-β signaling and TGF-β1 
autocrine production could be impaired. In line with this study, our results demonstrated a 
slight but non-significant decrease of BMP2 expression in CD34+ CP-CML cells compared to 
healthy ones.486 However, in this study, the expression of these molecules was not assessed 
in more mature compartments, as well as the functional consequences of these molecular 
alterations. In addition, no validation of the protein expression levels was performed to 
confirm these results. Finally, another transcriptome study confirmed BMP2 and BMP4 
down-regulation in CP-CML LSCs (CD90+, CD34+, CD38−, Lin−), whereas BMP7 and BMP10 
were found to be up-regulated.542 Although we focused our analysis on BMP2 and BMP4, 
these changes could sign an altered autocrine signaling in CP-CML LSCs. This study also 
confirmed BMPRIb over-expression in CP-CML LSCs and demonstrated that its expression 
was then progressively lost over the course of disease progression. This result confirms our 
description of BMPRIb increase as an early event in CML course, but is not in line with the 
result we obtained analyzing BMPRIb expression in 4 CML patients in advanced phase at 
diagnosis. Thus, while BMPRIb over-expression in CP-CML LSCs is validated, it is difficult to 
status for BMPRIb expression in advanced CML phases as the two studies were performed 
on few patient samples (4 acute phase and 2 blast crisis samples for the last study). 
We also demonstrated a significant increase in the availability of soluble BMP2 and 
BMP4 in the BM of resistant CML patients compared to CML patients in remission under TKI 
treatment in part 2 of the results. We further showed that the BMP pathway is altered in cells 
from resistant CML patients compared to sensitive patients, and that some alterations seems 
to be specific of immature CD34+ compartment. Indeed, we found that most of resistant CML 
patients display a decreased expression of Smad6, the expression of which seems to be 
involved in CML cells resistance to Imatinib treatment. Preliminary results suggest that loss 
of Smad6 expression could lead to the increased Twist-1 expression observed in immature 
cells from resistant CML patients, thus leading to Imatinib resistance (Figure 59). It would be 
interesting to see if different elements of the BMP pathway could also be involved in Twist1 
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expression control, and more interestingly, if this process is also true in more immature cells 
such as CD34+ CML cells or TF1-BCR-ABL cells. Indeed, these results were obtained with 
mature CD34- KCL22 cells (with sensitive and resistant clones to TKI treatment). However, 
during my PhD, part of our team developed Imatinib-sensitive and Imatinib-resistant clones 
from immature CD34+ TF1-BCR-ABL cells, which would constitute a much better model to 
study LSC-mediated resistance to Imatinib treatment. As described in chapter 4, BMPs 
induce Smad6 expression, thus providing a ligand-induced negative-feedback loop for Smad 
signaling. We demonstrated that BMP signaling is involved in immature leukemic cells 
expansion. Thus, an inhibition of this negative-feedback loop could be responsible of the 
decrease of Smad6 expression in immature CML cells even with high levels of soluble BMPs 
in the bone marrow microenvironment. This is supported by our results on KCL22 resistant 
cells that were unable to increase Smad6 expression under BMP4 treatment. In addition, 
BMP2/4 treatment increased KCL22-resistant cells survival upon Imatinib treatment, while 
this was not the case for KCL22-sensitive cells. It is generally thought that Smad6 
competitively interfere with the binding of Smad1/5/8 to type I receptors, thus preventing their 
phosphorylation and that it interferes with the BMP induced formation of the heteromeric 
Smad1–Smad4 complex. However, other studies demonstrated that Smad6 is also able to 
physically interact with Hoxc-8 and histone deacetylases (HDACs) in cell nucleus to repress 
BMP-induced gene transcription, such as Id1.543 While the precise mechanism of how 
Smad6 acts as a transcriptional co-repressor remains to be elucidated, it would be 
interesting to perform immunofluorescence staining of immature CML cells to understand the 
localization and the possible action of Smad6 in BMP pathway control. In addition, Smad6 
expression has been reported to be decreased upon mechanical stretch in rat mesangial 
cells.375 We observed that loss of Smad6 expression induced Imatinib resistance in KCL22 
cells. Thus, mechanical signals could lead to Imatinib resistance upon mechanical stress by 
inhibiting Smad6 expression. However, we found no difference in Smad6 expression in both 
TF1-GFP and TF1-BCR-ABL cells upon mechanical stress to support this hypothesis.  
The mechanism by which IFN-α mediates its anti-leukemic effects in CML cells is still 
debated. Interestingly, the p38/MAPK pathway is activated by IFN-α in BCR-ABL-expressing 
cells and appears to play a key role in the generation of the growth inhibitory effects of IFN-α 
in CML cells.544 However, IFN-α resistant CML cells failed to activate p38/MAPK signaling in 
response to IFN-α treatment. In addition, p38/MAPK axis has been identified as a key 
element in the non-canonical BMP signaling pathway.343 Thus, an alteration of the BMP 
signaling pathway in CML cells could impair p38/MAPK activation eventually leading to cell 
resistance upon drug treatment. 
While BMP signaling pathway is part of the TGF-β super-family signaling pathway, it 
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appears that these pathways bear different functional consequences in immature CP-CML 
cells. Indeed, while we demonstrated that alterations of the BMP pathway are involved in the 
expansion of immature CP-CML cells,486 it has been shown that BCR-ABL transduction in 
TF1 cell line enhances their responsiveness to the TGF-β growth inhibitory activity.443 Hence, 
while BMP signaling pathway seems to be involved in CP-CML phenotype, TGF-β signaling 
pathway could be involved in the quiescence and persistence of immature CML cells, maybe 
affecting their survival under TKIs treatment. These results illustrate the dual activity of BMP 
and TGF-β signaling and confirm the interest for recent mathematical models of CML that 
propose to combine Imatinib to a cell-cycle stimulant to eliminate quiescent and resistant 
CML cells.545 
Osteoblastic niche, vascular niche and CML 
 
Recent studies have put into light the existence and structurally and functionally 
different hematopoietic niches, called osteoblastic and vascular niches.546 The composition of 
these two niches is different, and so are the interactions between HSCs and 
microenvironmental cells. However, while different functional consequences have been 
observed, the causes explaining them are not fully understood. For example, while this has 
not been illustrated yet, the mechanical properties of these niches may be different because 
of the different cell types constituting them. Thus, this could lead to the transduction of 
different mechanical signals inside HSCs possibly involved in the control of their fate. 
Moreover, the different cell types present in the niches probably produce different types or 
different quantities of soluble molecules. Interestingly, we demonstrated that BMP4 is mainly 
produced by sinusoid endothelial cells in CP-CML BM environments,486 highlighting the 
crucial role of the vascular niche in CP-CML immature cells expansion. So far, the respective 
roles of osteoblastic and vascular niches in CML have not been particularly studied. Thus, 
the different components of the BM microenvironment could have different functional effects 
on immature LSCs, as this is the case for healthy HSCs. As the BMP pathway has been 
described as mechano-sensitive,243 the differences in term of BMP production or signaling 
could be further induced by differences of mechanical signals. Indeed, as part of the bone 
marrow microvasculature, endothelial cells are subject to important mechanical stress 
induced by blood circulation. However, we did not observe any difference in BMP2 or BMP4 
expression by confining BMEC-1 microvascular endothelial cells (data not shown). 
BCR-ABL alters cell stiffness and cell response to mechanical signals 
 
We demonstrated that BCR-ABL expression alone is sufficient to induce an increase 
of cell stiffness in CD34+ CP-CML cells (Figure 59). Interestingly, differences in cell stiffness 
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have also been observed in many types of cancers including leukemia. While most solid 
tumor cells studied so far seem to be softer compared to healthy cells,286,287,293,294 our results 
are in line with the differences of stiffness observed in other hematologic malignancies. 
Indeed, results from ALL and CLL cells analysis also found an increase of leukemic cell 
stiffness.296,299,300 However, no common molecular mechanism has been identified so far that 
could explain the similarities between hematologic malignancies or the discrepancies with 
solid tumor cell stiffness alterations. Nevertheless, mechanical alterations were almost 
always correlated with alterations of cell cytoskeleton, often involving different degrees of F-
actin polymerization. Interestingly, in transformed cells, BCR-ABL has been demonstrated to 
bind actin filaments (F-actin),508 one of the major determinants of cell mechanical behavior,509 
and to induce its redistribution into punctate, juxtanuclear aggregates.108 By performing 
immunofluorescence experiments, we were able to confirm these results in immature TF1 
cells after BCR-ABL transduction. Considering the crucial role of F-actin in cell stiffness, the 
reorganization of actin cytoskeleton induced by BCR-ABL is probably involved in the 
differences of cell stiffness observed by AFM. Moreover, we also demonstrated that 
adhesion to fibronectin led to the stiffening of TF1 cells as a consequence of F-actin 
polymerization. Interestingly, adhesion to fibronectin increased the impact of BCR-ABL 
expression on TF1 cell stiffness and was correlated with a strong co-localization between F-
actin and BCR-ABL as observed by immunofluorescence experiments. Furthermore, 
understanding the biological impact of these intrinsic cell mechanical alterations on cell 
functional properties has proved quite challenging. While we can easily assess gene and 
protein function by modulating their expression with modern molecular biology techniques, 
modulating cell stiffness is more difficult. Indeed, while we know how to modulate cell 
stiffness by acting on many components of the cytoskeleton, we cannot exclude that these 
alterations will also affect other cellular mechanisms such as cell division or vesicles 
transport since cytoskeleton is involved in many critical cellular processes. For example, a 
combination of different molecules, such as inhibitors of actin polymerization can be used to 
impair F-actin formation and to soften the cells. Actin over-expression by viral vector could 
then be used to perform the reverse experiment in order to stiffen the cells. However, F-actin 
is also involved in the regulation of numerous cell functions, probably not involving cell 
stiffness. 
Changes in tissue stiffness,306 cell stiffness286,296,298 and tumor growth due to 
proliferating cells316 combine to affect the physical environment of both normal and tumor 
cells. For example, the stroma surrounding a tumor is generally enriched in both type I 
collagen and fibronectin,307 creating a denser and mechanically rigid tissue compared to 
normal tissue.306 Moreover, uncontrolled growth in a confined space generates mechanical 
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compressive stress within tumors (Figure 59).316 In addition, an increasing amount of studies 
demonstrate that cancer cells possess altered intrinsic mechanical properties compared to 
healthy cells.286,296,298 Thus, tumor tissue displays different mechanical properties and will 
produce altered mechanical signals compared to healthy tissue. Considering the crucial role 
of mechanical signals on cell and stem cell fate control,276,547 altered mechanical signals 
and/or cell mechanical properties could also impact the biology of cancer stem cells. To 
confirm the occurrence of compressive stress in-vivo, it could be interesting to compare cell 
deformation in bone marrow biopsies (keeping the bone marrow architecture) from healthy 
donors and CML patients, by measuring cell size and shape. 
Our preliminary results also demonstrate that BCR-ABL expression is required for 
TF1 cells to respond to mechanical signals. This could sign BCR-ABL’s ability to alter 
mechano-transduction signaling pathways in these cells. As BCR-ABL lead to an alteration of 
F-actin cytoskeleton in CML cells,108 alterations in the tensional force generated by the 
actin/myosin apparatus may play a pivotal role in tumor cells functions. To analyze the role of 
BCR-ABL/F-actin binding in mechanical signals transduction, it would be necessary to design 
Bcr-Abl mutants with impaired binding ability to F-actin cytoskeleton. This strategy could also 
be combined to AFM to assess the role of BCR-ABL/F-actin binding in alteration of immature 
cell stiffness. 
Only a few clues on hematopoiesis control by mechanical signals have been 
identified so far.46,453,455,548,549 However, the crucial role for mechanical forces in 
hematopoiesis is perfectly illustrated by the growth of colonies in the CFC assay performed 
in semi-solid culture conditions using methylcellulose. Indeed, such terminal differentiation of 
hematopoietic progenitor cells seems to depend on physical signals provided by culture in a 
three-dimensional gel. This crucial influence of mechanical stress on cell functional 
properties put into light the need to develop and to use three-dimensional assays 
reproducing tissue organization and mechanical interactions to understand cell fate in a more 
physiological environment. In this study, using a unique system allowing us to confine a 
population of hematopoietic cells,273,458–460 we report that a mechanical stimulus applied to 
immature leukemic cells adhered to a fibronectin matrix control the proliferation of these 
cells. This ability appears to be unique to leukemic cells, as mechanical stimulus did not 
affect normal cells. Indeed, BCR-ABL transduction was sufficient to trigger an altered 
proliferative response of CD34+ TF1 cells under mechanical stress. However, mechanical 
forces displayed a dual role in TF1-BCR-ABL cells proliferation control, as cell proliferation 
was increased under slight confinement and decreased under higher confinements. Finally, 
we demonstrated that Twist-1 expression was specifically increased in response to 
mechanical stress in BCR-ABL+ cells. Interestingly, Twist-1 is involved in cell-cycle 
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regulation525 and was recently demonstrated to control quiescence526 and self-renewal526 
capabilities of hematopoietic stem cells. Thus, Twist-1 modulation could be involved in the 
control of CD34+ TF1-BCR-ABL cells proliferation under mechanical stress. To assess this 
hypothesis, it would be interesting to modulate Twist-1 expression (plasmid vectors and 
shRNA) in TF1-BCR-ABL cells and evaluate the impact on cell proliferation. It would also be 
necessary to inhibit Twist-1 expression in TF1-BCR-ABL cells during cell-confinement to 
observe if cell confinement is still able to control TF1-BCR-ABL proliferative capabilities in 
these conditions. In addition, it would be interesting to perform LTC-IC assays after primary 
CD34+ CML cells confinement to test the impact of mechanical stress on CML LSCs self-
renewal capabilities, that have been linked to Twist-1 expression. Strikingly, these results are 
in line with a recent study demonstrating that Twist-1 is expressed in response to transient 
compression in APC deficient colon tissue explants, but not in wild-type colon explants.315 
This suggests a potential role for Twist-1 as a common mediator of mechanical signals 
transduction in tumor cells. Thus, physical factors could be involved in existing cancer cells 
expansion and may potentiate cancer progression. Interestingly, the impact of mechanical 
signals on TF1-BCR-ABL cell proliferation was conserved under Imatinib treatment, but with 
lower rates of proliferation. Twist-1 expression has been involved in TKIs resistance, and is 
increased in TF1-BCR-ABL cells under confinement. Yet, Twist-1 induction by mechanical 
signals was not sufficient to increase the resistance of TF1-BCR-ABL cells to TKI treatment 
in our experiments. 
While we observed no impact on BMP pathway elements gene expression in CD34+ 
TF1-BCR-ABL cells, preliminary results demonstrate that mechanical signals could be 
involved in BMP pathway regulation through activation of Smad1/5/8 effectors 
phosphorylation (data not shown). Indeed, such mechanism has already been described to 
either activate or inhibit cell response to soluble BMPs.243 In addition, it would be interesting 
to assess BMP inhibitor genes expression, also controlled by mechanical stress. Thus, while 
mechanical stress had no impact on BMP2 or BMP4 gene expression (in TF1-GFP, TF1-
BCR-ABL as well as in stromal cells, data not shown), it could still be involved in cell 
response to soluble BMPs present in the BM microenvironment. Interestingly, Twist-1 is able 
to bind to the Runx1 Runt domain and decrease Runx1 transactivation activity.526 Runx1 
plays important roles in hematopoiesis, particularly during embryogenesis,550 and is 
described as a downstream target of BMP signaling pathway. Thus, Twist-1 could act as a 
mediator to control BMP pathway signaling through regulation of BMP target genes under 
mechanical stress. Moreover, even if the system we used allows us to reproduce mechanical 
signals in-vitro,458 it is not sufficient to reproduce 3-dimensional mechanical parameters such 
as capture and release of soluble molecules by ECM under mechanical stress. 
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Probing hematopoietic cells stiffness 
 
So far, only a few groups have tried to measure hematopoietic cells mechanical 
properties. While micro-fluidic devices, micropipette aspiration or optical stretcher were 
sometime used, most studies were performed using AFM technology.296,298–300 Moreover, 
because hematopoietic cells tend to slip from under the cantilever when performing AFM 
indentation, we have to immobilize these cells. Up to now, these different groups designed 
micro-fabricated wells or pillars to mechanically immobilize hematopoietic cells and to probe 
them. In our study, we combined the design of micro-fabricated wells to hematopoietic cell 
adhesion on fibronectin-coated cover-slips to immobilize them. This also allowed us to study 
the impact of cell adhesion to ECM on their stiffness. 
We and others demonstrated that hematopoietic cells are very soft cells.298 This is 
probably due, at least in part, to the low level of F-actin polymerization (compared to 
adherent cells), which is involved in cell stiffness control. Moreover, due to the size of their 
nucleus and to their low F-actin content, hematopoietic cells are generally round cells. 
Interestingly, as in liquid droplets, a round morphology tends to minimize the mechanical 
constraints at the cell surface.551 Thus, such a round morphology could also be involved in 
hematopoietic cell softness. However, this is not true when hematopoietic cells become 
adherent to ECM proteins, such as fibronectin. Indeed, in that case, we observed different 
cell morphologies together with an increased F-actin polymerization consistent with the 
increased stiffness observed in adherent hematopoietic cells. 
Finally, we also observed that primary CD34+ cells are much more stiffer as 
compared to CD34+ TF1 cells. Thus, we have to be careful when interpreting AFM studies, 
some of which comparing stiffness results obtained from both primary cells and cell lines. 
Comparing healthy and leukemic cells’ mechanical properties can prove very difficult 
for different reasons. First, and particularly for leukemic cells, it is difficult to assess the ratio 
of healthy to leukemic cells that are both present in blood samples of patients. That is why 
the CML model is very interesting, because it is easy to control the percentage of BCR-ABL+ 
cells, that is to say the leukemic cells content. The other advantage of this model is that the 
first transforming event being identified, it can be reproduced in in-vitro studies to confirm the 
role of BCR-ABL in cell stiffness differences. 
Moreover, hematopoietic cells are not a homogeneous population, as many cell types 
with different properties co-exist in this tissue. Thus, these cells can display different intrinsic 
structures leading to different mechanical properties. Indeed, a recent study demonstrated 
that myeloid cells were 18 times stiffer than lymphoid cells and six times stiffer than 
neutrophils on average.298 However, these results have to be confirmed as they were 
obtained comparing cell lines to primary cells (HL60 cell line, Jurkat cell line and primary 
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neutrophils respectively). Indeed, we demonstrated that primary cells were much more stiffer 
as compared to the TF1 cell line. To circumvent this difficulty, we selected CD34+ cells from 
both healthy donors and CP-CML patients, allowing us to compare a more homogeneous cell 
population. This is very important as up to now, mechanical analysis on hematopoietic cells 
were performed on heterogeneous leukocytes populations.296,299–301 But, CML being 
characterized by an expansion of myeloid progenitors, we cannot exclude that the results we 
observed are due to an increased proportion of myeloid progenitors among CP-CML CD34+ 
cells. This would be in line with the increased stiffness observed in myeloid cells in the 
aforementioned study. Despite that, we were able to demonstrate that BCR-ABL expression 
alone was able to increase the cell stiffness of TF1 cells. Thus, this demonstrates that BCR-
ABL is at least partly involved in the increased cell stiffness that we observed in primary 
CD34+ CP-CML cells. 
Pitfalls in cell mechanics studies 
 
Interestingly, a recent study demonstrated the progressive alteration of cell 
mechanical properties after culture in a two-dimensional stiff environment. By combining 
AFM and optical stretching, it was evidenced that mesenchymal SC stiffness dramatically 
increased during extended passaging on stiff substrata.552 This cell stiffening was correlated 
with an increased polymerization of actin stress fibers, and was only observable when the 
cells were adherent. Indeed, this effect was lost with cell detachment at each passage, and 
was anew observed after each cell reattachment to the substrata. This study further supports 
the impact of environment on cell stiffness, and demonstrates that substrata stiffness can 
have a durable impact on cell stiffness and/or select a population of stiffer cells probably 
more suited to persist in these conditions. Thus, when comparing cell mechanical properties, 
it is important to consider the potential impact of cell culture and to minimize it by culturing 
the cells for a same and short amount of time. What is more, a study recently evidenced that 
cell confluence could impact their stiffness, single adherent cells being stiffer as compared to 
confluent cells cultured in monolayer.553 Interestingly, other factors such as cell apoptosis,301 
aging554 and nutrients consumption555 were also demonstrated to affect cell stiffness. In 
addition, while it is not physiological for mesenchymal cells to be in a suspended state, this 
study also demonstrated the stiffening of an adherent cell over tens of minutes after being 
released from substratum contact.552 This was correlated with changes of cell surface 
topography as well as with a reduction of actin stress fibers. These results seem surprising at 
first, as reduction of F-actin is usually associated with decrease of cell stiffness. However, F-
actin cortical reinforcement was also observed as membrane-cortex connections developed 
and strengthened. Thus, the shift from a stress fiber to a cortical mechanical response could 
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then explain the differences observed. Finally, lack of a unique and reliable analysis method 
is a severe hindrance to the comparison of these different AFM studies. The wavelet-based 
extraction method of the shear modulus introduced in our study encompasses other 
parameterization methods, allowing a direct scale matching of the analyzing wavelet with the 
local force-indentation response curvature. 
In part 4 of the results, we used the cell-confining device developed by M. Piel 
(Institut Curie Paris) to apply mechanical forces on hematopoietic cells. Just as for AFM 
experiments, we had to immobilize hematopoietic cells to confine them, by allowing the cells 
to adhere onto fibronectin-coated wells. To allow the testing of multiple conditions in the 
same experiments, we designed modified standard polystyrene 24-well plates in which 
PDMS pillars fixed on the plate lid held the micro-structured slides (Figure 27). We used 14 
mm diameter confinement glass slides (slightly smaller than the 15 mm wells) bearing PDMS 
micro-structures to confine adherent hematopoietic cells. However, about 15% of cells are 
found in the zone between the cover-slip and the side of the well, and are not confined during 
the experiments. Thus, this probably dampens the consequences of mechanical signals that 
we observe, as some of the cells are actually not confined. Another method that could be 
used to confine hematopoietic cells would be to perform CFC assays with different 
concentrations in methycellulose, thus creating a range of meshing that will confine cells 
during their expansion. This would be interesting to maintain cell confinement during the CFC 
assay (2 weeks), since the cell-confining system cannot be used in semi-solid medium. 
Indeed, in our experimental setup, the confinement was released after 3 days and the cells 
were then plated in methylcellulose (without additional confinement for 2 weeks). 
Cell stiffness and leukostasis 
 
In CML, BCR-ABL+ cells of the myeloid lineage proliferate uncontrollably. 
Leukostasis, a poorly understood condition in which cells aggregate in the vasculature, is 
commonly observed in patients with myeloid hematologic malignancies such as AML, but is 
also observed during CML blast crisis.556 Indeed, during CML blast crisis, decreased cell 
deformability is thought to influence vascular flow and contribute to vascular complications 
such as leukostasis.557,558 As myeloid cells are stiffer compared to other hematopoietic 
cells,298 the amplification of the myeloid compartment in CML could lead to an increase of 
stiff cell content, thus potentially leading to leukostasis. Moreover, we evidenced that BCR-
ABL expression alone is sufficient to increase immature cell stiffness, and could thus 
potentially reduce the capability for these cells to circulate through blood vessels, thus 
leading to leukostasis. In addition, such a mechanism has already been identified in pediatric 
ALL, where cells extracted from ALL patients with leukostasis were stiffer compared to cells 
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obtained from ALL patients without leukostasis.299 This condition often results in intracranial 
hemorrhage and respiratory failure that rapidly leads to death. Thus, better knowledge of 
biophysical changes in leukemic cells such as deformability is necessary to improve 
understanding of the disease. 
Cell stiffness, microenvironment stiffness and BMP production in CML 
 
Unlike most tissues, hematopoietic tissue is mainly composed of non-adherent cells 
that are organized differently compared to adherent cells. However, this doesn’t mean that 
these cells have no physical interactions with each other. This is particularly true for 
immature hematopoietic cells that are adherent to their bone marrow stroma, composed of 
ECM but also of stromal cells and other hematopoietic cells. In CML, we demonstrated that 
BCR-ABL expression alone is sufficient to induce a stiffening of immature CD34+ cells. 
Interestingly, an emerging concept that has been recently described hypothesizes that the 
cells stiffness will be dependent on their microenvironment stiffness. This concept, known as 
mechano-reciprocity imply that stiff cells will preferentially grow in stiff environments and 
vice-versa.241,418 Indeed, it has been demonstrated that cells are capable to adapt their 
stiffness to fit with the rigidity of their environment.552 However, this concept is still debated in 
cancer cells as most of the studies have demonstrated that cancer cells are softer compared 
to their normal counterparts,286,290,294 while cancer microenvironment (and particularly the 
ECM) seems to acquire stiffer characteristics306 over the course of the disease. So far, we 
cannot really conclude about the relevance of such concept in cancer processes, as most 
cancer cells stiffness studies were in fact metastatic cancer cell studies. Interestingly, the 
metastatic potential of cancer cells was correlated with a decrease of cell stiffness in several 
studies. Thus, cell softening could be necessary for metastatic processes, in which cells 
have to break through several tissues, to migrate through blood circulation and to colonize 
different (mechanical) environments. Furthermore, the observed differences between tissue 
stiffness (increased) and cell stiffness (decreased) in tumor context seem contradictory, 
probably because of the crucial role of the ECM that appear stiffer in different tumor 
types.306,310,312 But, in CML, this concept could also means that the stiffening of immature 
cells induced by BCR-ABL could lead to a reciprocal alteration of their microenvironment’s 
stiffness. However, the mechanisms controlling mechano-reciprocity between cells and their 
environment are still unknown. 
Such mechanism could for example involve the over-production of BMPs molecules. 
Indeed, BMPs have been well described to control mesenchymal SC differentiation.414 Thus, 
the increase amount of BMP2 and BMP4 that we observed in the bone marrow of CP-CML 
patients486 could lead to mesenchymal SC differentiation into specific lineages, leading to the 
	   192	  
alteration of the BM microenvironment due to the presence of a particular set of cells 
producing specific factors such as ECM proteins. This could eventually lead to the alteration 
of the BM microenvironment stiffness, with possible induction of myelofibrosis, a 
phenomenon often observed with disease progression. 
This idea brings us back to the production of soluble BMPs in the bone marrow of CP-
CML patients. While we demonstrated that BMPs are synthesized in abnormally high 
quantities by the BM microenvironment of CP-CML patients, we still don’t know the exact 
mechanism that triggered this over-production.486 One of the hypothesis that could explain 
this production is the increase of the mechanical stress in the tumor microenvironment. 
Indeed, BMPs are well-known mechano-sensors whose production can be controlled by 
mechanical forces applied to the cells.243 In CML particularly, BCR-ABL formation leads to an 
uncontrolled proliferation of hematopoietic cells in their BM microenvironment, potentially 
leading to cell compaction within this defined environment. This increased cell confinement 
could lead to differential expression of mechano-sensitive genes such as BMPs, or Twist-1 
as demonstrated in part 4 of the results. Moreover, this abnormal cell compaction will 
probably confine hematopoietic cells, leukemic cells, but also stromal cells present in this 
environment, potentially also affecting their production of soluble BMPs. Another interesting 
question is the possible impact of BMPs production on cell stiffness. 
While no proof of such a mechanism has been evidenced yet, cell stiffness control by 
soluble molecules cannot be excluded. For example, BMP2 is able to induce rapid actin 
cytoskeleton reorganization in mesenchymal SC,559 thus probably leading to the alteration of 
their mechanical properties. In addition, BMPs are known controllers of SC differentiation 
both in mesenchymal414 and hematopoietic399,404 systems. Thus, BMP over-production in CP-
CML BM niche could lead to the amplification of specific lineages with specific intrinsic 
mechanical properties, as it is the case for myeloid progenitors in CML.298 
? ???
 
Figure 59 : Proposed model for BMP pathway and cell confinement effects on CD34+ 
CML cells maintenance and resistance to TKIs. In the normal context, hematopoiesis is 
tightly controlled. However, in CML, BCR-ABL induces an increase of BMPRIb expression at 
the surface of immature CP-CML cells as well as the stiffening of these cells. Together with 
an increase in BMP2 and BMP4 levels in the bone marrow microenvironment, BMPRIb over-
expression leads to the expansion of myeloid progenitors and LSCs. This potentially induces 
cell compression in the bone marrow, producing mechanical signals that promote Twist-1 
expression. In CML patients resistant to TKIs treatment, Smad6 expression is lost, and could 
be responsible of the increased Twist-1 expression involved in TKI resistance. Finally, BMP2 
and BMP4 levels seem even more elevated in the bone marrow of TKIs-resistant CML 
patients compared to TKIs-sensitive ones, and could also be involved in cell resistance to 
TKIs. 
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Oligonucleotide primers for human gene expression analysis by qRT-PCR 
 
Gene Sense primer Antisense primer 
TBP CAC GAA CCA CGG CAC TGA TT TTT TCT TGC TGC CAG TCT GGA C 
BGUS CGC CCT GCC TAT CTG TAT TC TCC CCA CAG GGA GTG TGT AG 
HPRT TGA CCT TGA TTT ATT TTG CAT ACC CGA GCA  AGA CGT TCA GTC CT 
BMP2 AGA CCT GTA TCG CAG GCA CT CCT CCG TGG GGA TAG AAC TT 
BMP4 CTT TAC CGG CTT CAG TCT GG GGG ATG CTG CTG AGG TTA AA 
BMPRIa GAA AAA GTG GCG GTG AAA GT TAG AGC TGA GTC CAG GAA CC 
BMPRIb GCC AGC TGG TTC AGA GAG AC CAG GAC CCT GTC CCT TTG AT 
BMPRII TAG CAC CTG CTA TGG CCT TT CTG AAT TGA GGG AGG AGT GG 
Smad1 CGC GTT CCT TCT GAA AAT TG TGC AAA AGG ACA GCA GAA GA 
Smad4 TTT CCT TGC AAC GTT AGC TG ATG CAC AAT GCT CAG ACA GG 
Smad5 TCT GCT TGG GTT TGT TGT CA GCA GCT GCT GGG AAT CTT AC 
Smad6 CTG CAA CCC CTA CCA CTT CA AGA ATT CAC CCG GAG CAG T 
Smad7 TCC TGC TGT GCA AAG TGT TC AAA TCC ATC GGG TAT CTG GA 
Smad8 AAG TGT GCA TTA ACC CTT ACC A AGG CTG AGC TGG GGG TTA T 
Bambi ATC GCC ACT CCA GCT ACA TC GCA TCG AAT TTC ACC TTT GG 
Foll TCT GCC AGT TCA TGG AGG AC CCC GTT GAA AAT CAT CCA CT 
FLRG GGG CTT CGT GAG CTC CAT ACC AGG CGG TGT CAA TGT 
Id1 GGT GCG CTG TCT GTC TGA G TGT CGT AGA GCA GCA CGT TT 
Id2 TAT TGT CAG CCT GCA TCA CC AAT TCA GAA GCC TGC AAG GA 
Id3 AAA TCC TAC AGC GCG TCA TC AAG CTC CTT TTG TCG TTG GA 
Runx1 TGG AGG AGG GAA AAG CTT CA CCG ATG TCT CTT CGA GGT TCT C 
Runx2 GTG GAC GAG GCA AGA GTT TC  TTC CCG AGG TCC ATC TAC TG 
Runx3 CTT CAA GGT GGT GGC ATT G GCT CAG CGG AGT TCT CG 
Abl TGG AGA TAA CAC TCT AAG CAT AAC TAA AGG T GAT GTA GTT GCT TGG GAC CCA 
Bcr-Abl TCC GCT GAC CAT CAA TAA GGA CAC TCA GAC CCT GAG GCT CAA 
BMI GAT ACT TAC GAT GCC CAG CA GGA CCA TTC CTT CTC CAG GT 
Twist-1 GGC TCA GCT ACG CCT TCT C CCT TCT CTG GAA ACA ATG ACA TCT 
 
BMP, Bone Morphogenetic Protein; BMPR, BMP receptor; Foll, Follistatine; TBP, Tata Box 
binding Protein; Id, Inhibitor of differentiation; Runx, Runt-related; Abl, Abelson; Bcr-Abl, 
Breakpoint cluster region-Abelson; Bambi, Bmp and activin membrane-bound inhibitor; 
BGUS, beta-glucuronidase; Smad, Small body size mothers against decapentaplegic; Twist-
1, twist-related protein 1; FLRG, follistatin-related gene. 
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Oral communications 
 
Journée de recherche LMC (Bordeaux, 2012) : La voie des BMPs est altérée au niveau fonctionnel et 
moléculaire dans la LMC en phase chronique. 
 
Journée des doctorants en physique de l’ENS (Lyon, 2013) : Rôle du microenvironnement dans le 
maintien et la résistance des Cellules Souches Leucémiques. 
 
Journées du département immunologie du CRCL (Aussois, 2013) : BMP signaling alterations in stem 
cells and their niche fuel tumor emergence and expansion. 
 
Congrès du Club Hématopoïèse et Oncogenèse (Giens, 2013) : Primitive CML cell expansion relies 
on abnormal levels of BMPs provided by the niche and BMPRIb over-expression. 
 
Journées de l’école doctorale BMIC (Lyon, 2013) : Primitive CML cell expansion relies on abnormal 
levels of BMPs provided by the niche and BMPRIb over-expression. 
 
Société Française d’Hématologie (Paris, 2014) : L’altération de la voie BMP dans les cellules souches 
leucémiques et au sein de leur niche dirige l’expansion des progéniteurs myéloïdes caractéristique de 
la leucémie myéloïde chronique en phase chronique. 
Concours « votre thèse en 180s » (Lyon, 2014) : Rôle du microenvironnement dans la résistance des 
cellules souches cancéreuses. Finaliste régional. 
 
Congrès de l’ESH, 16th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and 
Therapy (Philadelphie, 2014) : Impact of BCR-ABL expression on cell stiffness in a model of immature 
hematopoietic human cells. 
 
Congrès du Club Hématopoïèse et Oncogenèse (Grasse, 2014) : Impact of BCR-ABL expression on 
cell stiffness in a model of immature hematopoietic human cells. 
 
Journées de l’école doctorale BMIC (Lyon, 2014) : Impact of BCR-ABL expression on cell stiffness in a 
model of immature hematopoietic human cells. 
 
Posters 
 
Journées scientifiques du CRCL (Lyon, 2011) : Role of BMP4 in adhesion and resistance of Leukemic 
Stem Cells. 
 
Congrès de la Science-Académie (Lyon, 2012) : Etude des propriétés mécaniques des cellules dans 
la Leucémie Myéloïde Chronique. 
 
Journées scientifiques du CRCL (Lyon, 2012) : BMP pathway alterations drive Chronic Myeloid 
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Résumé 
Une des principales causes d’échec dans le traitement des cancers est le développement de 
résistances aux drogues par les cellules tumorales. Les cellules souches cancéreuses (CSC) sont 
suspectées d’être responsables de ces rechutes, conduisant à la récurrence de la maladie et bien 
souvent au décès des patients. En clinique, il est donc nécessaire de développer des stratégies 
thérapeutiques capables de cibler ces CSC résistantes et aboutir à la guérison des patients. Les CSC 
sont régulées par un ensemble de signaux aussi bien biologiques que physiques au sein de la niche 
tumorale. Mon projet a pour objectif de déterminer l’implication du microenvironnement tumoral (voie 
de signalisation BMP et contraintes mécaniques) dans le maintien et la résistance des cellules 
souches leucémiques (CSLs) de la leucémie myéloïde chronique (LMC). Pour cela, nous avons 
combiné tests fonctionnels et moléculaires ainsi que l’analyse de la niche tumorale sur plus de 200 
échantillons de patients atteints de LMC. Nous avons ainsi démontré que l’altération de la voie BMP 
intrinsèque aux cellules immatures de la LMC corrompt et amplifie la réponse à BMP2 et BMP4, 
présents en quantités anormalement abondantes au sein de la niche tumorale. Ces résultats 
récemment publiés dans Blood nous ont amenés à évaluer le rôle de la voie BMP dans le maintien 
des CSLs sous traitement par les ITK. La microscopie à force atomique nous a permis de démontrer 
que l’expression de BCR-ABL est suffisante pour induire une augmentation de la rigidité des cellules 
immatures de LMC par rapport à des cellules saines. Enfin, l’utilisation d’un système de confinement 
cellulaire nous a permis de démontrer que le stress mécanique contrôle la prolifération des cellules 
leucémiques immatures en régulant l’expression de gènes mécano-sensibles comme Twist-1. Ces 
résultats pourraient expliquer comment des CSLs tirent profit des contraintes mécaniques issues de 
leur microenvironnement afin d’acquérir un avantage prolifératif par rapport aux cellules saines. 
Ultimement, nous espérons que cette approche transdisciplinaire permettra d’identifier les molécules 
clés de la transduction de signaux mécaniques potentiellement impliqués dans le maintien et la 
résistance des CSC et ainsi proposer de nouvelles cibles pour contrer ces effets. 
 
Mots clés : Leucémie Myéloïde Chronique, Inhibiteurs de Tyrosine Kinase,  Cellules Souches 
Leucémiques, Bone Morphogenetic Proteins, résistance, stress mécanique, rigidité cellulaire 
  
 
Abstract 
One of the main causes of treatment failure in cancers is the development of drug resistance by 
cancer cells. The persistence of cancer stem cells (CSCs) might explain cancer relapses as they could 
allow reactivation of cancer cells proliferation following therapy, leading to disease persistence and 
ultimately to patients’ death. Clinically, it is crucial to develop therapeutic strategies able to target 
resistant CSCs in order to cure the patients. CSCs are controlled by a variety of biochemical and 
biomechanical signals from the leukemic niche. My project aims to determine the involvement of the 
tumor microenvironment (BMP signaling pathway and mechanical stress) in the maintenance and 
resistance of Leukemic Stem Cells (LSCs) in Chronic Myelogenous Leukemia (CML). For this, we 
combined functional and molecular assays to the analysis of tumor microenvironment on more than 
200 CML patients’ samples. We demonstrated that alterations of intracellular BMP signaling pathway 
in CP-CML primary samples corrupt and amplify the response to exogenous BMP2 and BMP4, which 
are abnormally abundant in the tumor microenvironment. These results, recently published in Blood 
led us to evaluate the role of the BMP pathway in LSC maintenance under TKI treatment. Atomic force 
microscopy allowed us to demonstrate that BCR-ABL expression alone is sufficient to increases the 
rigidity of immature CML cells compared to healthy ones. Finally, using a unique cell confining system, 
we were able to demonstrate that mechanical stress controls the proliferation of immature leukemic 
cells by regulating the expression of mechano-sensitive genes such as Twist-1. These results could 
explain how LSCs can benefit from a mechanical stress exerted by their microenvironment to acquire 
a proliferative advantage over normal cells. Ultimately, we hope that this transdisciplinary approach 
will help to identify key molecules in the transduction of mechanical signals potentially involved in 
maintenance and resistance of CSCs and thus offer new targets to counter these effects. 
 
Key words : Chronic Myelogenous Leukemia, Tyrosine Kinase Inhibitors, Leukemic Stem Cells, Bone 
Morphogenetic Proteins, resistance, mechanical stress, cell stiffness 
  
